Target Based Design And Synthesis of Heterocycles in the Potential Treatment of Cancer and Opportunistic Infection by Choudhary, Shruti
Duquesne University
Duquesne Scholarship Collection
Electronic Theses and Dissertations
Fall 1-1-2017
Target Based Design And Synthesis of Heterocycles
in the Potential Treatment of Cancer and
Opportunistic Infection
Shruti Choudhary
Follow this and additional works at: https://dsc.duq.edu/etd
Part of the Medicinal-Pharmaceutical Chemistry Commons
This One-year Embargo is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic
Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact
phillipsg@duq.edu.
Recommended Citation
Choudhary, S. (2017). Target Based Design And Synthesis of Heterocycles in the Potential Treatment of Cancer and Opportunistic
Infection (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/233
  
TARGET BASED DESIGN AND SYNTHESIS OF HETEROCYCLES IN THE 
POTENTIAL TREATMENT OF CANCER AND OPPORTUNISTIC INFECTION 
 
 
 
 
A Dissertation 
Submitted to the Graduate School of Pharmaceutical Sciences 
 
 
 
Duquesne University 
 
In partial fulfillment of the requirements for 
the degree of Doctor of Philosophy 
 
By 
Shruti Choudhary 
 
December 2017
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Shruti Choudhary 
 
2017
 
 iii 
 
 
 
 
TARGET BASED DESIGN AND SYNTHESIS OF HETEROCYCLES IN THE  
 
POTENTIAL TREATMENT OF CANCER AND OPPORTUNISTIC INFECTION 
 
 
 
 
 
 
 
By 
 
Shruti Choudhary 
 
Approved August 30, 2017 
 
 
 
________________________________ 
Aleem Gangjee, Ph. D. (Committee Chair) 
Professor of Medicinal Chemistry Graduate 
School of Pharmaceutical Sciences 
Duquesne University, Pittsburgh, PA 
 
 
 
 
________________________________ 
Patrick T. Flaherty, Ph. D. (Committee 
member) 
Associate Professor of Medicinal Chemistry 
Graduate School of Pharmaceutical Sciences 
Duquesne University, Pittsburgh, PA 
________________________________ 
David J. Lapinsky, Ph. D. (Committee 
member) 
Associate Professor of Medicinal Chemistry 
Graduate School of Pharmaceutical Sciences 
Duquesne University, Pittsburgh, PA  
 
 
 
________________________________ 
Kevin Tidgewell, Ph. D. (Committee member) 
Assistant Professor of Medicinal Chemistry 
Graduate School of Pharmaceutical Sciences 
Duquesne University, Pittsburgh, PA 
________________________________ 
Rehana Leak, Ph. D. (Committee member) 
Associate Professor of Pharmacology 
Graduate School of Pharmaceutical Sciences 
Duquesne University, Pittsburgh, PA  
 
 
________________________________ 
J. Douglas Bricker, Ph. D.  
Dean of Mylan School of Pharmacy and 
Graduate School of Pharmaceutical Sciences,  
Duquesne University, Pittsburgh, PA  
 
 
       
 iv 
ABSTRACT 
 
TARGET BASED DESIGN AND SYNTHESIS OF HETEROCYCLES IN THE 
POTENTIAL TREATMENT OF CANCER AND OPPORTUNISTIC INFECTION 
 
 
 
By 
Shruti Choudhary 
December 2017 
 
Dissertation supervised by Professor Aleem Gangjee 
Dose limiting toxicity and development of multidrug resistance by the tumors are 
the major limitations of current cancer chemotherapy. Microtubule targeting agents 
(MTAs) are a structurally diverse set of compounds that disrupt microtubule dynamics and 
exert their anticancer effect. Among the various classes of such agents, the colchicine site 
binding agents are particularly important as they circumvent the Pgp and β-III tubulin 
mediated clinical resistance. These resistance mechanisms, when manifested, are a major 
reason for the failure of clinically used agents such as taxanes and vinca alkaloids. A series 
of monocyclic pyrimidine analogs were designed and synthesized as colchicine site binding 
agents to overcome Pgp and β-III tubulin meditaed drug resistance. 
Multitargeted single agents with dual mechanism of actions, containing both 
cytostatic and cyotoxic components are particularly relevant to cancer chemotherapy as 
 v 
they have the potential to overcome multidrug resistance and dose limiting toxicities. 
Antiangiogenic agents target tumor angiogenesis, an important phenomenon for tumor 
growth and metastasis. The angiogenic effect is mediated by receptor tyrosine kinases 
(RTKs) and therefore, RTK inhibitors are used widely in the treatment of various types of 
cancers. To overcome the limitations of current cancer chemotherapy namely, dose limiting 
toxicity and multidrug resistance, quinazolines were designed and synthesized as dual 
acting MTA and RTK inhibitors. 
Toll-like receptors (TLRs) are key mediators in regulating the inflammatory 
response. Currently, more than 50 clinical trails of TLR agonists in the treatment of cancer 
are being conducted, either alone or in combination. Multitargeted single agents with dual 
acting MTA and TLR agonist (2,5-diaminoquinolines) were designed and synthesized as 
potential anticancer agents. A major part of this project covers the Pd-catalyzed cross 
coupling reaction optimization on the 2,5-diaminoquinolines including mechanistic details 
of the coupling reaction. 
Opportunistic infection by Pneumocystis jirovecii in immunocompromised patients 
such as organ transplant, cancer and AIDS patients is associated with high mortality. The 
current treatment involving the use of a combination of trimethoprim and sulfamethoxazole 
is limited by drug resistance, treatment failures and adverse side effects. Dihydrofolate 
reductase (DHFR) is an essential enzyme that provides folate cofactor for DNA, RNA and 
methionine biosynthesis. Hence, selectively inhibiting pjDHFR is an important strategy for 
effective treatment of infection by the pathogen. Incorporating the key differences in the 
active site residues in pjDHFR and hDHFR, thieno[2,3-d]pyrimidines were designed and 
synthesized as selective pjDHFR inhibitors. 
 vi 
 In addition, molecular modeling studies were performed on a series of 
pyrimido[4,5-b]indoles and cyclopenta[d]pyrimidines to explain their observed in vitro 
biological activities. Molecular modeling studies were also performed on a series of 
furo[2,3-d]pyrimidines and pyrrolo[3,2-d]pyrimidines to explain their biological activities 
on multiple targets (colchicine site of tubulin and multiple RTKs). 
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I. BIOCHEMICAL REVIEW 
A.  Microtubule targeting agents (MTAs) 
A.1 Microtubules 
Microtubules are long, filamentous tube-like protein fibers that form the key 
components of the cytoskeleton. Cytoskeletal proteins such as intermediate filaments are 
involved in providing mechanical support and resistance against physical stress, whereas 
microtubules are associated with regulating cell polarity, morphogenesis, intracellular 
transport and cell division during mitosis.1 Due to their dynamic behavior in dividing cells, 
microtubules participate in the formation of the mitotic spindle during cell division and 
hence, inhibiting this key step forms the basis of the efficacy of MTAs in cancer 
chemotherapy.1 The clinical success of these compounds is evident from the inclusion of 
MTAs as one of the most promising drugs in the treatment of both solid tumors as well as 
haematological malignancies, often as a component of combination chemotherapy.2-4  
A.2 Microtubule structure and dynamics 
 Microtubules are composed of α- and β-tubulin subunits that form the αβ-tubulin 
heterodimers. The tubulin dimers associate longitudinally to form the protofilaments, 
which in turn associate laterally to form tube like structures (Figure 1).1, 5 Tubulin dimers 
preferentially add to the growing microtubule protofilament at the “plus end” capped by 
the β-tubulin subunit. The “minus end” of microtubules is exposed to α-tubulin subunit and 
is relatively stable. The two microtubule ends behave differently, such that the minus end 
grows more slowly and undergoes a transition from growth to shortening (catastrophe) less 
frequently.  
 2 
 
Figure 1. Microtubule structure and dynamics. Reprinted with permission from “Control 
of microtubule organization and dynamics: two ends in the limelight” by A. Akhmanova 
and M. O. Steinmetz, Nat. Rev. Mol. Cell Biol. 2015, 16, 711-726. Copyright 2015 Nature 
Publishing Group. 
 In vitro studies have shown that the polymerizing plus end of the microtubule 
exhibits curved, flattened and tapered sheet-like structure, whereas during 
depolymerization the plus end exhibits more curved, peeling protofilament like structure 
(Figure 1).5 The switching of microtubules between phases of growth and shrinkage is 
termed as dynamic instability and these transitions between the curved and straight 
conformations of tubulin are associated with factors controlling microtubule dynamics. 
 3 
 The conformation of microtubules is regulated by the binding and hydrolysis of 
guanosine 5´-triphosphate (GTP) at the αβ-tubulin heterodimer. 
 
Figure 2. A) Exchange of GDP for GTP in solution at the αβ-tubulin. B) Cryo-EM maps 
of GMPCPP (non hydrolyzable analog of GTP, 4.7 Å) and GDP (4.9 Å) bound to 
microtubules. Reprinted with permission from “High-resolution microtubule structures 
reveal the structural transitions in alphabeta-tubulin upon GTP hydrolysis” by G. M. 
Alushin, G. C. Lander, E. H. Kellogg, R. Zhang, D. Baker and E. Nogales, Cell, 2014, 157, 
1117-1129. Copyright 2014 Elsevier Inc. 
 Two GTP-binding sites are present within the αβ-tubulin dimer. The N-site 
(nonexchangeable site) is buried between the α- and β-subunits and is constitutively 
occupied by GTP (Figure 2A). The E-site (exchangeable site) is present at the terminal end 
of the microtubule plus end and is exposed to the surface.6 αβ-tubulin dimers in solution 
exchange guanosine 5´-diphosphate (GDP) for GTP so that they can undergo 
polymerization. When this GTP bound αβ-tubulin dimer adds to the plus end, the incoming 
A B 
 4 
α-subunit interacts with the E-site of the terminal β-subunit (GTP bound) of the growing 
microtubule, promotes binding and facilitates hydrolysis. The microtubule continues to 
grow as long as the GTP-cap is present at the plus end. Once the GTP-cap is lost, rapid 
depolymerization occurs due to the instability of the GDP-tubulin subunits. Through the 
cryo-EM structure analysis (Figure 2B) of GTP-like stabilized microtubule and GDP bound 
microtubule it was deduced that the GTP hydrolysis and phosphate release causes the E-
site to undergo compaction, which translates into an energetically unfavorable 
conformational strain that is released by adopting a depolymerized, bent tubulin structure.6 
 
A.3 Microtubule binding sites 
   
 
  
  
 
Figure 3. Binding sites of different classes of MTAs on αβ-tubulin dimer. Reprinted from 
“A previously undescribed tubulin binder” by J. J. Field, A. B. Waight and P. D. Senter, 
Proc. Natl. Acad. Sci. USA 2014, 111, 136874-13685. Copyright 2014 National Academy 
of Sciences. 
 MTAs are a diverse set of cytotoxic agents that are classified under two major 
categories: microtubule-stabilizers and microtubule-destabilizers.1 The microtubule 
stabilizing agents promote microtubule polymerization at high concentration and include 
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taxanes/epothilones and laulimalide/peloruside A (Figure 3). The microtubule 
depolymerizing agents include colchicine, vinca alkaloids and maytansine and induce 
microtubule depolymerization at high concentrations.1, 5, 7 At high concentrations, the 
MTAs, depending on their mechanism, promote (microtubule-stabilizer) or inhibit 
(microtubule-destabilizer) the tubulin-microtubule equilibrium by acting on unassembled 
and/or assembled tubulin. However, at low concentration, these agents primarily target the 
microtubule ends, thereby affecting microtubule dynamics.5 
 
A.3.1 Taxanes and epothilones site 
    
Figure 4. Representation of taxane binding site with taxanes. Reprinted with permission 
from “Control of microtubule organization and dynamics: two ends in the limelight” by A. 
Akhmanova and M. O. Steinmetz, Nat. Rev. Mol. Cell Biol. 2015, 16, 711-726. Copyright 
2015 Nature Publishing Group. 
 Taxanes and epothilones bind to the taxane site of β-tubulin, which is located on 
the luminal surface of the microtubules (Figure 4).5 Paclitaxel and its derivatives show a 
preferential binding to the microtubules over the soluble tubulin dimers.8 These compounds 
stabilize the microtubules by causing a conformational change that stabilizes the 
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longitudinal and/or lateral tubulin contacts via allosteric mechanisms.6, 9 At low 
concentration, taxanes are capable of causing cell cycle arrest and induce apoptosis without 
changing microtubule mass. This effect is evident from the observed IC50 for the 
antimitotic effect of paclitaxel (8 nM in HeLa cells) compared to the IC50 of 80 nM for 
increasing the microtubule polymerization.10 Taxanes are widely used in the treatment of 
breast, ovarian, non-small cell lung, prostate and head and neck cancers.11 In addition, 
ixabepilone (Ixempra®) belonging to the epothilone class of taxane-binding agents was 
approved for the treatment of drug-refractory metastatic breast cancer.12 
 
A.3.2 Laulimalide/peloruside A site 
   
Figure 5. Representation of laulimalide/peloruside A binding site with their structures. 
Reprinted with permission from “Control of microtubule organization and dynamics: two 
ends in the limelight” by A. Akhmanova and M. O. Steinmetz, Nat. Rev. Mol. Cell Biol. 
2015, 16, 711-726. Copyright 2015 Nature Publishing Group. 
 Laulimalide and peloruside A are marine derived macrocycles, which were shown 
to have microtubule stabilizing activities (Figure 5). In in vitro assays, both macrocycles 
demonstrated efficacy in cells resistant to paclitaxel and epothilones and did not compete 
with taxanes at the binding site, suggesting an alternate site of binding.13 These microtubule 
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stabilizing agents bind to the site adjacent to the taxane binding site, on β-tubulin at the 
outer surface of microtubules. Moreover, owing to their macrocyclic structure these 
compounds bind to two adjacent β-subunits mimicking a bridging interaction.14 High 
potency of peloruside A has been reported against lung and multi-drug resistant (MDR) 
breast cancer tumor xenografts in vivo, thus promising its further development.15 
Development of laulimalide, on the other hand, is hindered owing to its high toxicity and 
high mortality.13 
 
A.3.3 Colchicine site 
 The compounds binding to this site comprise a diverse set of small molecules that 
destabilize microtubules by preventing curved to straight conformational transition of 
tubulin. Some of the agents binding to this site are colchicine, combretastatin A4 (CA4), 
podophyllotoxin and 2-methoxyestradiol.16 Colchicine binds to soluble tubulin, on β- 
   
Figure 6. Representation of colchicine site with colchicine and CA4. Reprinted with 
permission from “Control of microtubule organization and dynamics: two ends in the 
limelight” by A. Akhmanova and M. O. Steinmetz, Nat. Rev. Mol. Cell Biol. 2015, 16, 711-
726. Copyright 2015 Nature Publishing Group. 
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tubulin, at the interface of α- and β-subunits (Figure 6). On binding, it promotes formation 
of curved protofilament assemblies, which are not feasible for polymerization and requires 
straight microtubular protofilament.5 Several agents belonging to this class have been 
evaluated in phase I and II clinical trials as anticancer agents, including 2-
methoxyestardiol,17 CA4,18, 19 and verubulin,20 however, none of them have been clinically 
approved so far and are currently in the mid-to-late stages of clinical trials. 
 Combretastatins are potent vascular disrupting agents (VDAs), in addition to being 
potent antimitotic agents. VDAs are cytotoxic agents that effect the existing tumor vessels 
(endothelial cells and pericytes) leading to their vascular collapse and subsequent tumor 
death mediated via necrosis at the tumor core.16 VDAs selectively target the tumor 
vasculature without affecting the normal blood vessels. This selectivity can be attributed 
to significant differences between the normal blood vessels and the vessels in the tumor 
microenvironment. The normal vasculature is more organized as compared to the uneven, 
leaky vessels in the tumor microenvironment. Moreover, the tumor vasculature is more 
fragile due to lack of pericytes and basement membrane.16 
A.3.4 Vinca site 
  
Figure 7. Representation of vinca site with vinca alkaloids. Reprinted with permission 
from “Control of microtubule organization and dynamics: two ends in the limelight” by A. 
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Akhmanova and M. O. Steinmetz, Nat. Rev. Mol. Cell Biol. 2015, 16, 711-726. Copyright 
2015 Nature Publishing Group. 
 The vinca alkaloids bind to the β-subunit of two different, longitudinally aligned 
dimers (Figure 7).5 Vinblastine binds with high affinity to the microtubule ends, in addition 
to binding to soluble tubulin. Similar to the mechanism of taxol described before, at high 
concentration (10-100 nM in HeLa cells) vinblastine acts as a depolymerizing agent and at 
low concentration (1 nM) suppresses microtubule dynamics and blocks mitosis. Other 
agents binding to the vinca site includes cryptophycins,21 halichondrins22 and dolastatins.23 
 
A.3.5 Maytansine site 
Maytansine (Figure 8) was shown to bind to a recently discovered new binding site 
on β-tubulin reported by Prota et al.24 Binding of maytansine to the plus end of the 
microtubule led to microtubule depolymerization. Maytansine is also a component of the 
antibody drug conjugate Trastuzumab emtansine that was recently approved by the FDA 
for the treatment of HER-2 positive advanced breast cancer.25 
 
 
Figure 8. Representation of maytansine site with maytansine. Reprinted with permission 
from “Control of microtubule organization and dynamics: two ends in the limelight” by A. 
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Akhmanova and M. O. Steinmetz, Nat. Rev. Mol. Cell Biol. 2015, 16, 711-726. Copyright 
2015 Nature Publishing Group. 
   
A.4 MTAs in cancer 
 The clinical efficacy of the MTAs in the treatment of cancer is attributed to their 
ability to inhibit cell proliferation by altering microtubule dynamics. The essential role of 
microtubules in dividing cells is most evident during the formation of mitotic spindle, 
where the participation of microtubules results in the separation of sister chromatids.1 
However, according to recent literature evidence it has been suggested that even though 
patient tumors appear to be highly proliferative, most of the solid tumors in patients 
demonstrate low mitotic indices. In addition, the cytotoxicity of MTAs to non-dividing 
neuronal cells indicates a mechanism other than targeting mitosis. Interphase dependent 
alteration of the neuronal transport has been proposed as one of the reason for dose-limiting 
neuropathy of these chemotherapeutic agents.26 Several functions of microtubules 
associated with the interphase stage are affected by MTAs including centrosome clustering, 
mitochondrial toxicity, mRNA delivery to polysomes, and vesicular transport.27 The exact 
mechanism by which MTAs exert their anticancer effect currently warrants further studies 
but increasing evidence suggests an involvement of interphase function disruption in 
addition to their well-established role during mitosis.26, 27 
 A.4 Mechanism of tumor resistance to MTAs 
MTAs, like other chemotherapeutic agents, are limited in their efficacy due to 
multiple-drug resistance (MDR). There are several mechanisms by which tumors develop 
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resistance to these cytotoxic agents, the clinically significant mechanisms include efflux 
by ATP-binding cassette (ABC) transporters and overexpression of the β-III isotype of 
tubulin.28, 29  
ABC transporters are transmembrane proteins that regulate the flux of hydrophobic 
compounds across the plasma membrane.29 The multi-drug resistance protein 1 (MDR1), 
also known as P-glycoprotein (Pgp), was identified as the chief transporter causing 
resistance to vinca alkaloids and taxanes in vitro.30 Pgp overexpression has been associated 
with chemotherapy failures in clinical settings in several tumor types, including breast, 
kidney, colon and liver cancers, as well as leukaemias and lymphomas.29, 31 Compounds 
that act by inhibiting Pgp have been used in combination with MTAs to reverse Pgp-
mediated drug resistance, but failed to reverse resistance in clinical trials.32 The first 
generation Pgp inhibitors, such as verapamil, tamoxifen and cyclosporine were non-
specific and failed to demonstrate overall efficacy as Pgp inhibitors. The development of 
second generation inhibitors (valspodar, biricodar) with improved potency was equally 
disappointing as they led to drug-drug interactions ultimately leading to reduced 
chemotherapeutic drug clearance and therefore increased toxicity. The third generation 
inhibitors (tariquidar, zosuquidar) are currently being evaluated for their clinical 
efficacy.32, 33 
Overexpression of β-III isotype of tubulin is another mechanism that is clinically 
observed in the development of resistance to MTAs.28 Clinical resistance to taxanes in 
multiple tumor types such as non-small cell lung,34 breast,35 ovarian36 and gastric cancers37 
has been strongly associated to the expression of β-III isotype of tubulin. Paclitaxel 
demonstrated 5-fold less activity in in vitro studies in β-III tubulin expressing HeLa cells.38 
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It was proposed that the resistance to taxanes was due to the absence of Ser275 residue on 
β-III tubulin, which undergoes H-bonding interaction with the 7-OH of paclitaxel and 
facilitates its diffusion through the pores of the microtubule wall. The loss of hydrogen 
bonding (H-bonding) interaction with Ala275 in β-III tubulin prevents the binding of 
paclitaxel in β-III expressing cell lines.39 In addition, β-III tubulin expression causes 
clinical resistance to vinca alkaloids in non-small cell lung40 and ovarian cancers,41 
mediated via a different mechanism. 
B. Angiogenesis and receptor tyrosine kinases (RTKs) 
B.1 Angiogenesis 
 Angiogenesis is a process of sprouting new blood vessels from the existing 
vasculature, a process that is indispensable for tumor growth and metastasis.42 In normal 
tissue, angiogenesis is tightly regulated by balance between proangiogencic and 
antiangiogenic factors (Figure 9). The blood vessels thus formed are structurally and 
functionally normal. On the contrary, the tumor vasculature is highly tortuous, saccular and 
chaotic in its organization, with large gaps between endothelial cells, detached pericytes, 
and abnormally thick or thin basement membranes of the vessel walls.42 The tumor 
microenvironment, which is characterized by hypoxia, low pH and elevated fluid pressure, 
initiates other pathways involved in over expression of proangiogenic factors. 
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Figure 9. Tumor angiogenesis. Reprinted with permission from “Snapshot: Tumor 
angiogenesis” by R.K. Jain and P. Carmeliet, Cell 2012, 149, 1408-1408 el. Copyright 
2012 Elsevier Inc. 
Factors such as vascular endothelial growth factor (VEGF), platelet derived 
endothelial growth factor (PDGF), and epidermal growth factor (EGF) promote endothelial 
cell proliferation/migration and lead to angiogenesis.43, 44 These proangiogenic factors lead 
to hostile tumor microenvironment to chemotherapy as they promote tumor progression 
and treatment resistance via genetic instability, immune suppression, inflammation etc. 
Thus, antiangiogenic agents have been successfully used in the treatment of cancer.45, 46 
B.2 Receptor tyrosine kinases 
RTKs belong to a family of cell surface receptors that act as key regulators of 
critical cellular processes such as proliferation and differentiation, cell survival and 
metabolism, cell migration, and cell-cycle control.47 All the RTKs have a similar structural 
organization with an extracellular ligand binding domain, a single transmembrane helix 
and a protein tyrosine kinase domain in the cytoplasm (Figure 10). In general, the growth 
factor binding at the extracellular domain induces a conformational change that leads to 
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receptor dimerization (homodimerization or heterodimerization). This activates the 
intracellular tyrosine kinase domain causing autophosphorylation mediated via transfer a 
phosphate group from adenosine 5´-triphosphate (ATP) to the hydroxyl group of tyrosine 
residue of the substrate protein and triggers a cascade of downstream cell signaling 
pathways.47 
 
     
 
 
 
 
 
 
Figure 10. General representation of RTKs, Ig (immunoglobulin-like). Reprinted with 
permission from “Cell signaling by receptor tyrosine kinases” by M. A. Lemmon and J. 
Schlessinger, Cell 2010, 141, 1117-1134. Copyright 2010 Elsevier Inc. 
 Proangiogenic growth factors such as VEGF, PDGF and EGF bind to their 
respective growth factor receptors VEGFR, PDGFR and EGFR, and initiate downstream 
signal transduction leading to regulation of cell permeability, survival, proliferation and 
migration.48 Under normal physiological conditions these signaling pathways are tightly 
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regulated and monitored, however, dysregulation of these signaling pathways has been 
linked to malignancy and contributes to the hallmarks of cancer.47 
 Several small-molecule RTK inhibitors (RTKIs) have been approved clinically for 
the treatment of various types of cancers (Figure 11).49  These RTKIs broadly fall under 
five categories.50 Type I inhibitors bind to the active form of the kinase and reversibly 
compete with ATP for its binding site (eg. sunitinib).  
 
Figure 11. Representative RTKIs in clinic 
Type II inhibitors bind to the inactive form of the kinase (eg. sorafenib) and indirectly 
compete with ATP by reversibly occupying the catalytic DFG pocket. Type III inhibitors 
bind in an allosteric fashion outside the catalytic site, whereas the type IV inhibitors bind 
reversibly to the substrate binding site. Type V inhibitors bind covalently to cysteine 
residues at specific site of the tyrosine kinase (eg. afatinib).48, 50  
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VEGFR 
The VEGF family consists of five members, VEGF-A, VEGF-B, VEGF-C, VEGF-
D, and placenta growth factor (PLGF) and constitute important growth factors that are 
involved in angiogenesis and vasculogenesis (i.e., the formation of the embryonic 
circulatory system).51 VEGFRs comprise of VEGFR-1, VEGFR-2 and VEGFR-3. Among 
these, VEGFR-1 and VEGFR-2 are expressed on the surface of endothelial cells, whereas 
VEGFR-3 is expressed on lymphatic vessels. Hypoxia mediated upregulation of VEGF-A 
results in activation of VEGFR-2, which further causes tumor development, progression 
and metastasis.48 VEGFRs are overexpressed in several tumor types with different 
expression patterns, ligand specificity and cellular/physiological effects. Thus, targeted 
inhibition of VEGFR-2 produces abrogation of angiogenesis, and decreased tumor 
growth.51, 52 Sunitinib, a mutli-RTKI (VEGFR-2, PDGFR-β and c-kit) is clinically used in 
the treatment of renal53 and pancreatic cancers.54 Sorafenib, another mukti-RTKI (VEGFR-
2, VEGFR-3, PDGFR-β and Raf kinase) is used in the treatment of renal55, 56 and thyroid 
cancers.57 
PDGFR 
 The PDGF family consists of five growth factors namely, PDGF-AA, -BB, -CC, -
DD, and -AB, which bind to two receptors, PDGFR-α and PDGFR-β. PDGFRs are 
structurally related to VEGFRs.58 These receptors are expressed on pericytes, smooth 
muscle cells that provide mechanical support to vasculature. Aberrant signaling of PDGF 
in tumor angiogenesis, either alone or in combination with VEGF, stimulates endothelial 
cell proliferation, migration, sprouting and tube formation in tumors.58 The importance of 
PDGF signaling in tumor angiogenesis is further supported by several studies 
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demonstrating that PDGFR inhibitors improve the antitumor efficacy of VEGFR 
inhibitors.59  
EGFR 
 The EGFR is one of the four members of the EGFR family comprising of EGFR-
1(EGFR), HER-2, HER-3, and HER-4. The ligand for EGFR, EGF, regulates cellular 
pathways linked to cell proliferation, migration and differentiation, such that any aberration 
in this signaling cascade results in increased tumor cell proliferation, survival and 
invasiveness.60 High expression of EGFR has been associated with primary human tumors 
and glioblastoma.61 As a result, EGFR has been extensively studied and targeted by small 
molecule inhibitors (erlotinib62) and monoclonal antibodies (cetuximab).63 
 
B.3 RTK binding site 
   
 
 
 
 
 
Figure 12. ATP-binding site of RTKs. Reprinted with permission from “Knowledge based 
prediction of ligand binding modes and rational inhibitor design for kinase drug discovery” 
by A. K. Ghose, T. Herbertz, D. A. Pippin, J. M. Salvino and J. P. Mallamo, J. Med. Chem. 
2008, 51, 5149-5171. Copyright 2008 American Chemical Society. 
front  
cleft 
back  
cleft 
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 Most protein kinases have a common structural feature consisting of two lobes, the 
N-terminus lobe consisting of five antiparallel strands and one helix, and a highly helical 
C-terminus lobe (Figure 12).64 The ATP binding site is a narrow hydrophobic pocket 
located between these two lobes linked by a flexible hinge region. The hinge region usually 
has one hydrogen donor flanked by two hydrogen acceptors that binds to the adenine ring 
of ATP.64, 65  
The catalytic cleft of RTKs is composed of the N-lobe and the C-lobe. The N-lobe 
contains the glycine-rich loop (G-loop or P-loop) formed by highly conserved GXGXXG 
motif. The G-loop forms the top (roof) of the ATP binding cleft and due to its flexibility 
adopts various conformations, depending on the presence of ligand and the conformational 
state of the kinase. The catalytic cleft consists of the front cleft, where the ATP binding 
site is located and the back cleft, which comprises of elements important for the catalytic 
activity of the kinase. These two regions share a border formed by β8-strand, an activation 
loop (A-segment) on which lies the Asp-Phe-Gly (DFG) motif and the β3-strand. A 
gatekeeper residue at the back cleft controls the access to the back cleft depending on its 
size and volume. A small amino acid like Ala or Thr make the back cleft easily accessible 
whereas, bulkier gatekeeper residues like Phe, Leu or Met prevent the entry of small 
molecules into the back cleft.64, 65 β3- Lysine is another functionally important residue that 
is conserved in all kinases and adopts various conformations in different protein kinase 
complexes. It helps anchor the α- and β-phosphates of ATP to form a Lys-ATP complex 
that is stabilized by an ion pair interaction between Lys and the catalytic Glu residue 
(Figure 12).  
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 In a fully active state, protein kinases adopt a DFG-in conformation where the side 
chain of the DFG aspartate is directed into the ATP binding site and the aromatic ring of 
the Phe is positioned in the back cleft.64 The Asp residue is required to chelate Mg2+ and 
helps to orient the γ-phosphate of the ATP for its transfer in the active DFG-in 
conformation. The aromatic side chain of Phe in the active DFG-in motif is in contact with 
αC. This contact in many active kinases facilitates the formation of a Lys-Glu ion pair for 
kinase catalysis.64  In the inactive state, the DFG motif is in either a DFG-in, DFG-out or 
DFG-out like conformation. In the DFG-out conformation, the aromatic ring of Phe is 
positioned in the ATP pocket and the Asp residue of the DFG motif is in the back cleft.64  
The front cleft includes the ATP binding site and small, non-ATP contact regions. 
The ATP site is broadly divided into the following subregions depending on the binding 
mode. 
1. Adenine region: This pocket is predominantly hydrophobic and is involved in binding 
various inhibitor scaffolds. This region is bordered by the hinge region and the gatekeeper. 
Two key hydrogen bonds are formed by the interaction of the N1 and N6 amino nitrogens 
of the adenine ring with the NH and carbonyl groups of the peptide backbone of the hinge 
region residues of the RTKs. Several RTK inhibitors use at least one of these key hydrogen 
bonds. Other backbone amide groups in the hinge region can serve as hydrogen bond 
donors or acceptors for inhibitor binding.64 
2. Ribose binding region: The ribose pocket accommodates the sugar moiety of ATP and 
is adjacent to a hydrophilic, solvent exposed region. This pocket includes includes three 
hydrophobic residues. These residues (Ile, Val and Leu) have traditionally been exploited 
in developing EGFR inhibitors.64 
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3. Phosphate binding region: This region is covered by G-loop, Asp, Lys and Asn residues 
and the DFG motif. This region is highly flexible, hydrophilic and solvent exposed, and 
therefore, this region has been explored to improve physicochemical properties of 
inhibitors.64 
4. Hydrophobic region II: This pocket is not used by ATP and serves as an entrance for 
ligand binding. Variation in the residues and conformation of this pocket have been 
reported for various kinase targets. Thus, this region has been used to gain selectivity in 
the design of kinase inhibitors.  
In addition to the ATP-binding site, the back cleft provides important binding 
regions. ATP does not bind in the pockets in the back cleft.64, 65 
1. Hydrophobic region I: The hydrophobic pocket in the back cleft adjacent to the adenine 
pocket is called Hydrophobic region I or Back pocket I (BP-I). This pocket has been 
explored in the design of inhibitors to gain selectivity for kinase targets with small 
gatekeeper residues. 
2. In addition to BP-I, additional binding pockets BP-II, BP-III, and BP-IV become 
available to inhibitors depending on the binding state of the RTKs.64 
Major progress has been made with small molecule inhibitors targeting the ATP- 
binding site of RTKs. The front catalytic cleft of all kinase enzymes is accessible to ligand 
binding. Small molecule inhibitors that target the front cleft use a core scaffold to recognize 
the adenine pocket. The core scaffold is then substituted to extend into the different pockets 
of the ATP-binding site resulting in improved binding affinity and selectivity for RTKs.66 
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C. Toll-like receptors (TLRs) 
The activation of the innate immune system is the primary cellular immune response 
that occurs within the body to defend against foreign agents, such as bacteria or viruses. 
The pattern recognition receptors (PRRs) located on the cell surface, or within the 
endosomes of the innate immune cells interact with the extracellular environment and 
modulate the immune system. The toll-like receptors (TLRs) are the key PRRs of the innate 
immune system.67 
 
Figure 13. General signaling cascade arising from TLR activation. Reprinted with 
permission from “Directing the immune system with chemical compounds” by R. J. 
Mancini, L. Stutts, K. A. Ryu J. K. Tom and A. P. Esser-Kahn ACS Chem. Biol. 2014, 9, 
1075-1085. Copyright 2014 American Chemical Society. 
 TLRs are expressed in multiple cell types including dendritic cells (DCs, key 
antigen-presenting cells in adaptive immunity), macrophages, and B-cells. On agonist 
binding, TLRs form high order constructs (homodimers, hetrodimers, and tetramers) 
initiating a downstream signaling cascade that causes maturation of immune cells and 
expression and release of immunostimulatory cytokines (Figure 13).67 The general 
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structure involves a horseshoe-shaped motif composed of leucine rich repeat (LRR) 
domain around which two TLRs form a constitutive dimer. The variability in the 
hydrophobic pocket of the LRR domain with its surrounding variable region determines 
the agonist selectivity for each TLR.67 
 TLRs are broadly classified based on their location in the cell. TLRs 1, 2, 4, 5, and 
6 are expressed on the cell surface, whereas, TLRs 3, 7, 8, and 9 signals from the 
endosomes. The binding of agonists induces a conformational change that recruits adapter 
proteins and triggers signaling. The specific modulation is thus also dependent on the type 
of adapter protein. MyD88 is the predominant adapter protein and leads to activation of 
serine/threonine kinase IRAK4 that ultimately results in induction of pro-inflammatory 
cytokines. Activation of other adapter proteins such as TIR domain-containing adaptor-
inducing interferon-β (TRIF) and TRIF-related adaptor molecule (TRAM) causes 
induction of genes encoding Type I interferons.68  
 
Figure 14. Representative TLR agonists 
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TLRs1 and 2 are activated by lipids and polysaccharides found on the surface of 
the bacterial cell wall. Their activation results in MyD88 dependent upregulation NFκB 
and increase in immune cell activation. Triacylated peptides that mimic natural agonists 
have been reported as TLR1 agonists.67 In addition, small molecule agonists including 
thioureido-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylates (1) and N-benzyl-2-(N-
phenylmethylsulfonamido)acetamide derivatives (2) have shown to activate the TLR1/2 
pathway (Figure 14).69 TLR6 acts as a compliment to TLR1/2 heterodimer and is similarly 
activated by lipids, lipidated proteins and polysaccharides. TLR4 is one of the most studied 
receptor and is activated by lipopolysaccharides (LPS). It can signal via both MyD88 and 
TRIF pathway. Recently, pyrimido[5,4-b]indoles (3) were reported as selective TLR4 
agonists (Figure 14).70 TLR5 binds to flagellin and flagellin-related peptides derived from 
bacterial species.  
TLR 9 is an endosomal TLR that is activated by bacterial oligonucleotides. It is 
particularly specific for binding to unmethylated cytosine guanine (CpG) dinucleotide 
sequences. The downstream signaling pathway proceeds via MyD88 pathway and results 
in polarized T-helper cell 1 (Th1) response in which dendritic cells interact with pre-T 
helper cells to produce interferon (IFN)-γ, interleukin (IL)-1, IL-2 , tumor necrosis factor 
(TNF)-β and activation of macrophages. Similar to TLR9, TLR3 is also located in the 
endosomal compartment of cells such as DCs and macrophages. It is activated by double-
stranded viral RNA (dsRNA) and signals exclusively through TRIF pathway. No small 
molecule TLR3 agonist has been reported so far.  
TLR7 and 8 are endosomal receptors that are activated by single-stranded RNA 
(ssRNA) and heteroaromatics. The X-ray crystal structure of TLR8 was recently published 
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that suggested that it exists as a homodimer prior to ligand binding and activation.71 The 
C-terminal domains of both TLR7 and 8 are 53 Å apart prior to ligand binding. However, 
binding of the agonists to the homodimer allows the C-terminal subunits to approach a 
distance of 23 Å, dimerizing the intracellular toll-interleukin-1 receptor (TIR) domain and 
initiating signaling cascade resulting in an immune response.71 Among the 
heteroaromatics, imidazoquinolines (imiquimod and resiquimod, Figure 14) and 
thiazolo[4,5-c]quinolones (4,5) have been shown to have TLR7 and 8 agonistic activity.67, 
72 Imiquimod works through TLR7 mediated activation of MyD88 pathway that causes 
secretion of proinflammatory cytokine INFα and induction of IL-6. Imiquimod is clinically 
approved for the treatment of basal cell carcinoma and resiquimod has shown efficacy in 
breast cancer model and is currently undergoing clinical trials for the treatment of 
melanoma.73 Other small molecule agonists for TLR7 and TLR8 are currently undergoing 
evaluation for both solid and haematological malignancies.74  
  
 
F 
Figure 15. A) X-ray crystal structure of resiquimod in TLR7 (PDB: 5GMH75). B) X-ray 
crystal structure of resiquimod in TLR8 (PDB: 3W3L71). 
A B 
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The aromatic ring of resiquimod undergoes π-stacking interaction with the Phe408 
in TLR7 and Phe405 in TLR8 (Figure 15). The Asp555 in TLR7 and Asp543 in TLR8 are 
essential for binding. A key difference in the binding site is the presence of Leu557 in 
TLR7, which undergoes hydrophobic interaction with the aromatic quinoline ring of 
resiquimod. In TLR8 an Asp545 residue is present that does not undergo hydrophobic 
interaction but provides a handle for design of TLR8 selective agonists by incorporating 
protonatable amines that can undergo ionic interaction with this residue.76  
Early studies demonstrated that the activation of TLR7 or TLR8 can reverse the 
suppressive function of the regulatory T cells. In addition, agonist binding to TLR7 and 
TLR8 led to the activation of dendritic cells and natural killer cells that directly kill tumor 
cells.77 Together these mechanisms resulted in strong antitumor response.68 On activation, 
the immature DCs engulf antigens from dying tumor cells and migrate to the draining 
lymph nodes, where they process the antigen. They mature into DCs that are capable of 
presenting antigens via major histocompatibility complex (MHC) class I and class II 
molecules on their surface. Through the MHC interaction with CD4+ T helper cells and 
CD8+ effector cells, activation of T cells ensues that engages in T cell surveillance and 
eventually result in tumor cell death.78  
No clinical benefit of TLR7 and 8 agonists, when used as single agents has been 
demonstrated so far. However, it has been suggested that combining TLR agonists with 
chemotherapy or radiotherapy can provide better results in clinic. The cytotoxic component 
of the chemotherapy can promote cancer cell death releasing antigens that can stimulate 
immune response.79 RNA-based TLR7 and TLR8 agonists when used in combination with 
chemotherapeutic agents demonstrated antitumor effect in mouse model of non-small cell 
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lung cancer, in non-human primates and in human cells in an IFN dependent manner and 
induction of Th1 response.68, 80 Evaluation of TLR7 agonist in combination with radiation 
therapy in murine T cell and B cell lymphoma model suppressed the progression of tumor 
growth and improved the survival rate in tumor-bearing mice.81 Administration of 
gardiquimod (TLR7/8 agonist) in combination therapy with NK cells stimulated with DCs 
was shown to significantly suppress the growth of human HepG2 liver carcinoma 
xenografts.82  
 
D. Dihydrofolate reductase (DHFR) 
Dihydrofolate reductase, a key enzyme in folate metabolism, is present in all living 
organisms including humans, bacteria and protozoa. DHFR plays a crucial role in 
maintaining cellular levels of reduced folates (tetrahydrofolate and its derivatives). DHFR 
catalyzes the reduction of 7,8-dihydrofolate (FH2) to the 5,6,7,8-tetrahydrofolate (FH4) in 
the presence of nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor. 
Inhibiting DHFR interferes with thymidylate biosynthesis involved in pyrimidine synthesis 
and inhibition of folate-dependent formyl transferases causing inhibition of purine 
synthesis as well. It has long been considered as an attractive target for anti-infective 
therapy because of its crucial role in the biosynthesis DNA, RNA and proteins.83 
Figure 16. Catalytic mechanism of DHFR84 
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The mechanism of DHFR is not totally understood, although it has been extensively 
studied. DHFR catalyzes a hydride transfer from NADPH to the C6 of 7,8-FH2 to form 
FH4 (Figure 16). It is known that initial protonation of N5 followed by a hydride transfer 
from the C4 of the cofactor NADPH to the adjacent FH2 reduces FH2 to FH4. The 3D-
structures of DHFR have been used in structure-based drug design and to acquire 
information on inhibitor binding, enzyme-inhibitor-cofactor complexes and in particular to 
determine differences in amino acid location between parasites and host DHFR. The DHFR 
derived from Escherichia coli (ecDHFR) has been widely studied as a model system to 
understand the role of protein dynamics in enzyme catalysis and also in investigating the 
binding selectivity of 2,4-diaminopyrimidine based inhibitor, trimethoprim (TMP).84-87 
  
Figure 17. X-ray crystal structure of methotrexate (MTX, purple) in ecDHFR complex 
with NADPH (brown) (PDB: 1RX3).88 The residues are highlighted in yellow. 
 Evidence from NMR experiments suggests that the pKa of certain inhibitors such 
as TMP at N1, is increased from 7.5 in solution to about 10 on binding to DHFR. The 
Asp27 (Figure 17) gets deprotonated and protonates N1, resulting in a bidentate interaction 
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of Asp27 with N1 and N2 of TMP. The 4-NH2 group in TMP undergoes H-bonding 
interactions with Ile5 and Ile94. Favorable van der Waals interactions between the 
trimethoxybenzene ring of TMP with Leu28, Phe31, Ser49, Ile50, Leu54 contributes to the 
strong affinity of TMP to ecDHFR.86 Other factors contributing to the binding of inhibitors 
to DHFR include NADPH induced changes in the active site. It has been shown that 
NADPH binding promotes desolvation of the pocket where TMP binds and induces a 
conformational change of side chain Met20 (~8 Å). Depending on the conformation of the 
loop, the electrostatic environment around the substrate changes and alters the pKa of N5 
of FH2 prior to hydride transfer.
84 
 
Figure 18. Ribbon structure of ecDHFR with bound NADP+ (green) and folate (blue), in 
closed (PDB: 3QL3, red) and occluded (PDB: 1RX6, blue) conformation of flexible Met20 
loop. Reprinted with permission from “Perspectives on electrostatics and conformational 
motions in enzyme catalysis” by P. Hanoian, C. T. Liu, S. Hammes-Schiffer and S. 
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Benkovic Acc. Chem. Res. 2015, 48, 482-489. Copyright 2015 American Chemical 
Society. 
 In the closed conformation, the Met20 loop interacts with the substrate (folate), 
while in the occluded conformation the loop occupies the NADPH binding site partially 
(Figure 18).84  The selectivity of TMP towards ecDHFR over eukaryotic DHFR (chicken 
liver, cl) was attributed to i) the differences in residues undergoing bidentate interaction 
with N1 and N2 of TMP (Asp27 in ecDHFR vs Glu30 in clDHFR); ii) differences in H-
bonding of 4-NH2 of the pyrimidine ring (two H-bonding in ecDHFR vs one H-bonding in 
clDHFR); iii) enzyme-inhibitor interaction at trimethoxybenzyl group; iv) side chain 
torsion angles of the inhibitor and v) conformational change of side chain residues on TMP 
binding.86, 87  
 
Figure 19. Chemical structure of folic acid and representative DHFR inhibitors 
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DHFR inhibitors are classified as classical inhibitors that mimic folic acid with its 
glutamate side chain like methotrexate (MTX) and nonclassical DHFR inhibitors that lack 
the p-aminobenzoylglutamic acid side chain like trimethoprim (TMP) and pyrimethamine 
(Figure 19). Nonclassical DHFR inhibitors show high potencies, which suggested that the 
p-aminobenzoylglutamic acid side chain was not essential for binding to DHFR. The 
discovery of TMP and pyrimethamine as potential antibacterial and antimalarial agents 
stimulated the research for new nonclassical antifolates. These agents could be used in anti-
infective therapy since bacteria and protozoa synthesize folic acid de novo but do not utilize 
preformed folate. Moreover, these analogues are hydrophobic in nature and are therefore 
taken up by passive diffusion. The main drawback of these potent antifolates is their lack 
of selectivity against DHFR derived from pathogens.  
 
Figure 20. Pyrimethamine derived inhibitors of Plasmodium falciparum DHFR (pfDHFR) 
Yuthavong et al89 recently reported pyrimethamine derived pfDHFR inhibitors 6 
and 7 (Figure 20) that were active in both wild-type and quadruple mutant DHFR. The 
carboxylic acid in 7 interacted with Arg122 in pfDHFR but did not make the same 
interaction with the corresponding Arg70 in hDHFR. 
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 Pyrimethamine derivatives were also recently reported as selective Toxoplasma 
gondii DHFR (tgDHFR) inhibitors with 8 (Figure 21) showing 89-fold selectivity for 
tgDHFR over hDHFR.90 
 
Figure 21. Pyrimethamine derived inhibitors of tgDHFR 
 
Figure 22. Triazines and dihydrotriazine based DHFR inhibitors 
Traizine 9 and dihydrotriazine 10 were also recently reported as Mycobacterium 
tuberculosis DHFR (MtbDHFR) and pfDHFR inhibitors, respectively (Figure 22).91, 92  
Pneumocystis jirovecii (pj) is one of the opportunistic pathogen that infects 
immunocompromised patients, especially those with acquired immune deficiency 
syndrome (AIDS).93 Pneumocystis pneumonia (PCP) in humans is caused by the 
opportunistic pathogen pj, while Pneumocystis carinii (pc) is the pathogen that is derived 
from and infects rats. Due to ease in purification and crystallization, structural 
characterization, catalytic properties and interaction with antifolates of pcDHFR have been 
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reported.94 Cody et al.95 were able to isolate recombinant human-derived pneumocystis 
DHFR (pjDHFR) and showed that it differs from pcDHFR by 38% in amino acid 
sequences. 
 
Figure 23. The structure of PTX and 11 and 12 
Piritrexim (PTX) is a potent inhibitor of pjDHFR (IC50 = 1.6 nM) but is devoid of 
selectivity. Gangjee et al.96 recently reported 11 and 12 (Figure 23) as PTX analogs that 
retained the potency and showed selective inhibition of pjDHFR (35-fold and 26-fold, 
respectively). 
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II. CHEMICAL REVIEW 
This section will review the synthetic chemistry approaches relevant to the 
heterocyclic ring systems described in this dissertation. 
A. Quinazolines 
B. Quinolines 
C. Thieno[2,3-d]pyrimidines 
1. Quinazolines 
Various synthetic methodologies have been employed in the synthesis of quinazolines. 
Few of them will be discussed here from substituted benzene precursors. 
Scheme 1. Synthesis of quinazoline from anilines 
  
Protection of the amino group of the aniline 13 with ethyl chloroformate (Scheme 
1) and subsequent reaction with hexamethylenetetramine (HMTA) in trifluoroacetic acid 
(TFA) resulted in the formation of cyclized dihydrobenzoquinazoline 15. Oxidation of 15 
using K3Fe(CN)6 afforded the appropriate quinazoline 16 in 15-54% yield.
97, 98 
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Scheme 2. Synthesis of quinazoline from 2-aminoarylketones and benzylamines 
 
Graphite oxide was used as a recyclable heterogenous catalyst (Scheme 2) in the 
synthesis of 2-arylquinazoline 19 (84-93%), from 2-aminoarylketones 17 and 
benzylamines 18. To ensure complete oxidation t-butyl hydroperoxide (TBHP) was used.98, 
99  
Scheme 3. Synthesis of quinazoline from 2-iodobenzaldehydes via Ullmann reaction 
 
 Ligand free Cu-catalyzed Ullmann reaction conditions (Scheme 3) were used for 
preparing substituted quinazolines 22 in 61-89%yield from 2-iodobenzaldehydes 20 and 
amidine hydrochloride 21.98, 100 
  
 35 
Scheme 4. Synthesis of 2-aryl-4-methylquinazolines 
 
 In a similar reaction, quinazolines 25 (Scheme 4) were synthesized substituted 2-
bromoacetophenone 23, aldehyde 24 and aq. ammonia in the presence of Cu catalyst 
(CuCl) and N-methylpyrrolidone (NMP) as a solvent. The reaction was proposed to occur 
via Cu(I) catalyzed amination of 23 to yield substituted 2-aminobenzophenone that further 
reacted with the aldehyde 24.98, 101 
Scheme 5. Synthesis of 1(H)-quinazolin-2-one from alkynylanilines 
 
 The synthesis of target compounds were accomplished in two steps (Scheme 5). In 
the first step urea derivative 27 was obtained by reacting o-alkylnylaniline 26 with 
potassium isocyanate. In the subsequent step acid catalyzed intramolecular cyclization of 
27 yielded 28 in 28-98% yield.98, 102 
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Scheme 6. Synthesis of quinazolin-4(3H)-one from anthranilic acid 
 
 Treatment of anthranilic acid 29 (Scheme 6) with aliphatic anhydride yielded 
corresponding benzoxazinones 30, which were used further without purification to form 
acylaminobenzamides 31. Subsequent cyclization with formamide under microwave 
irradiation conditions afforded the desired quinazolin-4-one 32 in 74-87% yield.98, 103 
In another method, 2-nitrobenzamide 33 was reacted with aromatic aldehyde 34 in 
presence of sodium dithionate to yield quinazolin-4(3H)-one 38 (Scheme 7). 
Mechanistically, the reaction proceeded via reduction of nitro by sodium dithionate to 
amine 35 that cyclized with the aldehyde to yield 2,3-dihydroquinazolin-4(1H)-one 36. The 
sulfur dioxide from sodium dithionate subsequently participated in the oxidation to yield 
desired compound 38.98, 104 
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Scheme 7. Synthesis of quinazolin-4(3H)-one from 2-nitrobenzamides 
 
  
Scheme 8. Synthesis of quinazolin-4(3H)-one from isatoic anhydride 
 
 In a one-pot three-component reaction (Scheme 8) with benzyl halides 39, amines 
40 and isatoic anhydride 41 quinazolin-4(3H)-one 42 were synthesized via in situ 
generation of aldehydes by DMSO mediated oxidation of benzyl halide in the presence of 
K2CO3 in excellent yields.
98, 105 
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2. Quinolines 
B.1 Acid catalyzed synthesis of quinolines 
 Three component Povarov reaction (Scheme 9) of arylamine 43, glyoxalates 44 and 
phenylacetylenes 4 via aza Diels-Alder cycloaddition catalyzed led to the synthesis 4-
arylquinoline-2-carboxylates 46 (78-92%). The reaction mechanism involves an initial 
formation of imine. Acid catalyzed protonation of imine nitrogen facilitates the attack by 
phenylacetylene that results in a cyclized intermediate and subsequent oxidation to give 
the desired quinolines in good yields.106, 107 
Scheme 9. Synthesis of quinoline-2-carboxylates catalyzed by formic acid 
 
Scheme 10. Synthesis of 2-(2-pyridyl)quinolines 
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 Trifluoride methyl etherate catalyzed three-component Pavorav reaction (Scheme 
10) of arylamines 47, pyridine aldehydes 48 and ethyl vinyl ether 49 afforded 2-(2-
pyridyl)quinolines 50 in moderate to good yields.107, 108 
Scheme 11. HCl-mediated synthesis of 4-methylquinolines 
 
Doebner type multicomponent reaction (Scheme 11) of arylamine 51, 
benzaldehyde 52 and acetone 53 in the presence of HCl yielded 4-methyl quinolines 54 in 
70-98% yield.107 
Scheme 12. Synthesis of substituted quinolines from substituted arylisothiocyanates 
 
 Zhao et al.109 reported a multicomponent reaction (Scheme 12) of 
arylisothiocyanates 55, alkyne 56 and alkyltriflate to yield substituted quinolines 57 in high 
yields.107  
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Scheme 13. Triflic acid catalyzed synthesis of quinolines from arylmethyl azides 
 
 Arylmethyl azides 58 were used as precursors to generate N-aryl iminum ions via 
Schmidt rearrangement reaction (Scheme 13). Ethyl 3-ethoxyacrylate 59 was added next 
to yield substituted quinolines 60 in high yields.107, 110  
B.2 Base catalyzed synthesis of quinolines 
 2-substituted-3-nitroquinolines 66 (Scheme 14) were synthesized by the attack of 
the amino group of 61 on the nitro olefin 62 to form a 1,4-addition intermediate which on 
dehydration and oxidation with DDQ yielded the desired compounds in 25-97% yield.107, 
111 
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Scheme 14. Synthesis of quinolines from nitro olefins 
  
Scheme 15. Synthesis of 2,4-disubstitutedquinolines 
  
Base catalyzed cyclization of β-(2-aminophenyl)-α,β-ynones 67 (Scheme 15) via 
tandem nucleophilic addition annulation reaction in the presence of sodium methoxide 
afforded the desired quinolines 69 in 32-98% yields.107, 112 
 A three-component reaction with cyanoacetic acid methyl ester 70, substituted 
secondary amine 71 and 2-aminobenzaldehyde 72 in the presence of sodium hydroxide 
yielded 2-aminoquinoline-3-carboxamides 73 in good yields (Scheme 16).107, 113 
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Scheme 16. Synthesis of 2-aminoquinoline-3-carboxamides 
 
Scheme 17. Synthesis of 7-hydroxyquinolines from N-tosylaminophenols 
 
 7-hydroxyquinoline 79 was prepared from condensation of 3-N-tosylaminophenol 
74 with acrolein 75 to give intermediate 76 (Scheme 17). In the presence of ethanol, acetal 
77 was formed that underwent Friedel-Craft reaction, followed by dehydration, oxidation 
and detosylation to yield 7-hydroxyquinoline in 60% yield.107, 114 
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Scheme 18. Synthesis of 2,3,4-trisubstitutedquinolines 
 
 Quinolines 81 (Scheme 18) were synthesized in good yields from o-
cinnamylanilines 80 (prepared from anilines and cinnamylalcohols) via a regioselective 6-
endo-trig intramolecular oxidative cyclization using potassium tert-butoxide and DMSO 
as an oxidant.107, 115 
B.3 Miscellaneous methods 
Scheme 19. Iodine catalyzed synthesis of 2,4-disubstitutedquinolines 
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 Using molecular iodine anilines 82 and styrenes 83 wee reacted together to form 
2,4-disubstitutedquinolines 84 in 64-83% yields (Scheme 19). Mechanistically, the 
reaction proceeds via oxidation of styrene to aldehyde, which condenses with arylamine to 
give an imine. Iminium ion is formed on coupling of imine with iodine that undergoes aza-
Diels-Alder cycloaddition reaction and subsequent oxidation to form the desired 
quinolines.107, 116 
Scheme 20. Synthesis of 2-amino-4-arylquinoline-3-carbonitriles 
 
 L-proline mediated synthesis of 2-amino4-arylquinoline-3cabonitriles 4 (Scheme 
20) was performed using a multi component reaction involving anilines 85, aldehydes 86 
and malononitrile 87 under aqueous conditions.107, 117 
Substituted quinolines 97 were synthesized from o-tosylamidobenzaldehydes 91 
and activated acetylenes 90 in a phosphine-catalyzed one-pot procedure (Scheme 21). 
Mechanistically, nucleophilic addition of phosphine to the alkyne 89 generated 
phosphonium allenoalte 90, which acts as a base to activate the pro-nucleophile 91 through 
deprotonation, causing a subsequent base-catalyzed Michael/Morita-Baylis-Hillman 
tandem reaction and aromatization to yield 97.107, 118 
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Scheme 21. Phosphine-catalyzed synthesis of quinolines 
 
 2,4,6-trisubstituted quinolines 102 were synthesized via Au-catalyzed 
intramolecular cyclization of N-propargylamines 101 in methanol at room temperature in 
good yields (Scheme 22). The N-propargylamines were prepared from anilines 98, alkynes 
99 benzaldehydes 100 using RuCl3/CuBr.
119 Under the reaction conditions, different 
substituents were tolerated at R1 position, however, aryl substitution with electron-
withdrawing group at R2 position and alkyl groups at R3 position were not tolerated. 
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Scheme 22. Au-catalyzed synthesis of quinolines from N-propargylamines 
 
3. Thieno[2,3-d]pyrimidines 
C.1 Synthesis of thieno[2,3-d]pyrimidines from thiophene precursors 
Scheme 23. Synthesis of thieno[2,3-d]pyrimidine 107 
 
2-Amino-5,6-disubstituted thieno[2,3-d]pyrimidines 107 (Scheme 23) were 
synthesized via cyclocondensation of appropriate thiophenes 103-105 with an amidine 
derivative 106, (guanidine R = NH2 or chloroformamidine hydrochloride R = Cl). The 
nature of the X substitution in thiophene 103-105 determined the substitution pattern at 4-
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position (Y at the C4-position ) in 107; when X = CN, COOR or CHO, the cyclization 
reaction afforded 107 with Y = NH2, OH or H respectively.
120, 121 
Scheme 24. Synthesis of thieno[2,3-d]pyrimidine 110 
 
A novel synthesis of 2-amino-4-phenyl substituted thieno[2,3-d]pyrimidines 110 
(Scheme 24) was reported by Ishikawa and coworkers. Urea 109 was utilized for 
condensation with aminocarbonyl thiophenes 108 to afford 110.122 
Scheme 25. Synthesis of thieno[2,3-d]pyrimidine 113 
 
The 2-substituted-4-oxo-thieno[2,3-d]pyrimidines 113 (Scheme 25) were 
synthesized by the condensation of thiophene 111 and aldehyde 112. The R group of 122 
can be an alkyl or aromatic substitution. 2-Methyl-5,6-disubstituted-thieno[2,3-
d]pyrimidines 113 were obtained when the R group is a methyl group.123 
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Scheme 26. Synthesis of thieno[2,3-d]pyrimidine 117 
 
A modified approach was reported by Corral and coworkers124 for the synthesis of 
thieno[2,3-d]pyrimidine, using acid chlorides as the cyclization reagent instead of an 
aldehyde (Scheme 26). The amino group of the thiophene 114 attacked the carbonyl group 
of acid chloride 115 to form the intermediate amide 116, which cyclized with NH3 to afford 
thieno[2,3-d]pyrimidines 117. Good leaving groups, such as OCH3, at R
3 position in 114 
resulted in OH substitutions at the 4-position in 117. When acetyl choloride was used as 
the reactant, 2-methyl-5,6-disubstituted thieno[2,3-d]pyrimidines 117 was obtained after 
cyclization. 
Scheme 27. Synthesis of thieno[2,3-d]pyrimidine 119 
 
Horiuchi and coworkers125 reported the one-pot synthesis of 119. Thiophene 118 was 
reacted with formamide to afford 119 in good yields (Scheme 27).  
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Scheme 28. Synthesis of thieno[2,3-d]pyrimidine 122 
 
Briel, D.126 reported the synthesis of 2-phenyl substituted thieno[2,3-d]pyrimidine 
122 via the condensation of thiophene 120 with benzamidine hydrochloride 121 (Scheme 
28). 
C.2 Synthesis of thieno[2,3-d]pyrimidines from pyrimidine precursors 
Scheme 29. Synthesis of thieno[2,3-d]pyrimidine 126 
 
Taylor and coworkers127 reported the synthesis of the classical TS inhibitor 126 as 
an analogue of pemetrexed (Scheme 29). Condensation of 2-substituted-4-hydroxy-6-
mercaptopyrimidine 123 with the α-chloroketone 124 gave pyrimidine sulfide 125, which 
was further cyclized in the presence of p-toluenesulfonic acid to give 126. 
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Scheme 30. Synthesis of thieno[2,3-d]pyrimidine 130 
 
A novel approach for the synthesis of thieno[2,3-d]pyrimidine 130 was reported by  
Sakamoto and coworkers128 (Scheme 30). The intermediate 129 was synthesized by 
Sonogashira coupling between iodopyrimidines 127 and ethynyltrimethylsilane 128. 
Compound 129 then cyclized to give 130 in the presence of NaSH. 
Scheme 31. Synthesis of thieno[2,3-d]pyrimidine 134 
 A novel approach for the synthesis of the thieno[2,3-d]pyrimidine 134 was reported 
via a cyclization reaction of 5-carbonitrile-6-mercaptopyrimidnes 131 and chloroacetone 
132 (Scheme 31).129 Compound 133 was the key intermediate in the reaction, which was 
further cyclized in the presence of NaSH to give 134. 
Scheme 32. Synthesis of thieno[2,3-d]pyrimidine 136 
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Similarly, chloroacetonitrile 135 was utilized instead of chloroacetone 132, with 
131 to afford 5-amino-4-methyl-2-phenyl-thieno[2,3-d]pyrimidine-6-carbonitrile 136 
(Scheme 32).130  
Scheme 33. Synthesis of thieno[2,3-d]pyrimidine 139 
 
Briel and coworkers129 reported a strategy to synthesize 139 (Scheme 33). 5-
ethylester-6-mercaptopyrimidnes 137 was cyclized with chloroacetic acid methyl ester 138 
to afford thieno[2,3-d]pyrimidine 139 with a 5-hydoxy. 
 
Scheme 34. Synthesis of thieno[2,3-d]pyrimidine 147 
 
van Straten and coworkers131 reported the synthesis of 147 by the procedure 
depicted in Scheme 34. α,β-unsaturated ketones 142, obtained by aldol condensations, were 
reacted with 2-cyanothioacetamide 143 to afford thiopyridones 144, which underwent 
nucleophilic substitution and cyclization to afford 147.  
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Scheme 35. Synthesis of thieno[2,3-d]pyrimidine 151 
 
Based on the cyclization reaction shown in Scheme 33, a modified method was 
developed by Ried and coworkers (Scheme 35).132 5-Carbonitrile-6-chloropyrimidine 148 
reacted with ethyl 2-mercaptoacetate 149 to form intermediate 150, which was further 
cyclized to afford 151. 
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III. STATEMENT OF THE PROBLEM 
1. The present work deals with the design and molecular modeling studies in the following 
three major areas: 
1.A Microtubule targeting agents: Monocyclic pyrimidine analogs as microtubule   
targeting agents binding to the colchicine site 
      1.B Single agents with combination chemotherapy potential 
1.B.1 Inhibition of multiple tyrosine kinases and microtubule targeting agents: 
Quinazoline analogs as microtubule targeting agents and multiple receptor tyrosine 
kinase inhibitors 
1.B.2 Dual acting microtubule targeting agents and toll-like receptor agonists: 
Quinoline-2,5-diamines as microtubule targeting agents and toll like receptor 
agonists 
      1.C Selective inhibition of P. jirovecii dihydrofolate reductase: Thieno[2,3-
d]pyrimidines as selective inhibitors of pjDHFR 
 
2. In addition, molecular modeling studies were performed to rationalize the observed 
biological activities for the following projects: 
2.A Microtubule targeting agents: Pyrimido[4,5-b]indoles and 
cyclopenta[d]pyrimidines in the colchicine site of tubulin 
 2.B Single agents with combination chemotherapy potential: 5-Methyl-N-
(substituted)-furo[2,3-d]pyrimidin-4-amines and 7-benzyl-N-(substituted)-pyrrolo[3,2-
d]pyrimidin-4-amines as dual acting microtubule targeting agents and multiple tyrosine 
kinase inhibitors 
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1. Microtubule targeting agents (MTAs) 
MTAs have a long history of utility in the treatment of both solid tumors and 
hematological malignancies.1, 133, 134 The tumor suppressor p53 regulates transcription of a 
wide variety of genes involved in DNA repair, metabolism, cell cycle arrest, apoptosis and 
senescence. More than half of all human tumors carry mutations in this gene making it one 
of the most frequently mutated gene.135 Recent efforts have led to development of drugs 
that could activate or restore the p53 pathway, particularly inhibitors of MDM2, a negative 
regulator of p53.136 Many of the inhibitors of MDM2 are still in early stages of clinical 
trials and therefore, in the absence of such agents the most effective drugs in p53 mutant 
cell lines are MTAs.137 Their efficacy in the treatment of a wide variety of tumors is 
attributed to the disruption of microtubule dynamics during mitosis.1, 133 Their ability to 
disrupt cellular transport and protein trafficking has also been implicated as an important 
contribution towards the anticancer effect of these agents in the interphase.26, 27  
 The clinical efficacy of the most widely used MTAs, taxanes and vinca alkaloids, 
is limited by two major mechanisms of drug resistance, namely, overexpression of Pgp and 
expression of β-III tubulin.138 Pgp overexpression is particularly observed in patients who 
have received prior chemotherapy and is also associated with poor response to taxol-based 
chemotherapy in patients with non-small cell lung cancer.139, 140 Additionally, 
circumventing Pgp-mediated resistance by using Pgp inhibitors failed to show any success 
due to intolerable side effects.141 Therefore, MTAs that are not substrates for Pgp (e.g. 
epothiolones) represents a promising alternate strategy for overcoming Pgp-mediated drug 
resistance.138 
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In addition to Pgp overexpression, clinical resistance to taxanes and vinca alkaloids 
is also observed in non-small cell lung,34, 40, 142 breast,35 ovarian36, 41 and gastric cancers37 
due to expression of β-III tubulin. Several colchicine site binding agents such as CA4P 
(Fosbretabulin®) 18, 19, 143, 144 and OXi4503145 have been evaluated in clinical trials and 
verubulin (Azixa®) has been granted orphan drug status for the treatment of glioblastoma 
multiforme.146 Development of MTAs binding to the colchicine site, therefore, offers the 
advantage of overcoming Pgp and/or β-III tubulin resistance and could result in broader 
antitumor activity and improved survival rates.  
 
1.A Monocyclic pyrimidine analogs as microtubule targeting agents binding to the 
colchicine site 
 
Figure 24. Tubulin inhibitor 152 
 Pyrrolo[2,3-d]pyrimidine 152 (Figure 24) was reported by Gangjee et al.38 as a 
potent microtubule depolymerizing agents which inhibited the growth of 51 cancer cell 
lines in the NCI 60 cell line panel assay in the submicromolar range. It was also shown to 
bind at the colchicine site of tubulin (Table 1) and was capable of overcoming Pgp and β-
III tubulin mediated drug resistance.38 
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Table 1. Effects of 152 on proliferation of MDA-MB-435 cell lines, tubulin assembly and 
[3H] colchicine binding.38 
Compd IC50 ± SD (nM) 
(MDA-MB-435) 
Inhibition of tubulin 
assembly (µM) 
Inhibition of colchicine binding 
(% inhibition ± SD) at 5 µM 
152 183 ± 3.4  2.6 ± 0.05  70 ± 2 
CA4 4.4 ± 0.5  1.0 ± 0.09  99 ± 0.2 
 
 
Figure 25. Series I (compounds 153-154) 
 In an attempt to improve activity, it was of interest to design structurally simplified 
analogs of 152 followed by optimization studies. Compounds 153 and 154 (Figure 25) 
were designed as structurally simplified derivatives of 152 to determine the minimal 
structural requirement for a compound to be a MTA binding at the colchicine site. 
Compound 153 with a 5-Me substitution was designed to mimic the pyrrole ring of the 
pyrrolo[2,3-d]pyrimidine scaffold of 152. The hydrophobicity imparted by a chloride 
group and its similarity in size to a methyl group led to the design of 154 with a 5-Cl 
substitution to evaluate the effect of an electron withdrawing group on the pyrimidine ring. 
In addition, the acidic N-7 proton in 152 was replaced by a basic 6-NH2 group in 
compounds 153 and 154. On the basis of the preliminary activities of compounds 153 (IC50 
MDA-MB-435 = 206.4 ± 8.9 nM) and 154 (IC50 MDA-MB-435 = 71.3 ± 6.1 nM), scaffold 
154 was chosen for further optimization studies. 
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Figure 26. Series II 
 Compounds 155-160 (Figure 26) were designed to optimize the substitution at the 
N4-position. N4-desmethyl compound 155 was designed to evaluate the contribution of N4-
Me group towards the antitubulin activity of 154. Additionally, the N4-Me group in 154 
can impart activity due to hydrophobic interactions and/or conformational restriction about 
‘a’ bond, which would be absent in 155. This was confirmed by performing a 
conformational search for 154 and 155 (SYBYL-X 2.1.1) by rotating bond ‘a’ by 1° within 
5 kcal/mol, which yielded 91 and 157 conformations, respectively.33 Compounds 156 with 
4´-SMe substitution and 157 with 3´-OMe substitution, were designed to determine the 
effect of H-bond strength and the position of H-bond acceptor on the phenyl ring on tubulin 
inhibitory activity, respectively. Due to the lower electronegativity of sulfur atom, the 4´-
SMe group in 156 is a weaker H-bond acceptor than 4´-OMe group in 154.147 Compounds 
158 and 159 were designed to assess the effect of conformational restriction on different 
parts of the 4-anilino substitution (bond b in 158 and bond c in 159) on the antitubulin 
activity, along with the additional hydrophobic properties of the added ring. 
Cyclopenta[d]pyrimidines with regioisomeric methoxy substituted naphthylamines were 
synthesized by Gangjee and cowokers as microtubule targeting agents in which 5-methoxy-
N-methylnaphthalen-2-amine substituted compound was most potent inhibitor of tubulin 
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polymerization.148 Therefore, compound 160 was designed to determine the steric bulk 
tolerance at the N4-position by replacing a 4´-OMe phenyl with a 5´-OMe naphthyl moiety 
for the monocyclic pyrimidine scaffold. 
  
Figure 27. Series III 
The colchicine binding site on tubulin is a large site with dimensions ∼10 A˚ ∼10 
A˚ ∼4-5 A˚.149-151 To mimic the steric effects of the pyrrole ring of the lead pyrrolo[2,3-
d]pyrimidine 152 and to improve the tubulin inhibition of the monocyclic pyrimidine 
analogs by optimizing hydrophobic interactions in the pocket, compounds 161-169 (Figure 
27) were designed. Substitution of the 6-NH2 with alkyl and benzyl groups led to the design 
of 161-167 with 4-methoxy-N-methylaniline substitution at the C4-position. Due to similar 
activity of 160 (Figure 26, IC50 MDA-MB-435 = 56.1 ± 5.0 nM) compared to 154 (Figure 
25), substituted derivatives 168 and 169 with 5-methoxy-N-methylnaphthalen-2-amine at 
the C4-position and alkylamines at the 6-position were also proposed. 
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Figure 28. Superimposition of the docked poses of 152 (green, Figure 25) and 163 
(magenta, Figure 27) in the colchicine (pink) binding site of tubulin (PDB ID: 4O2B).152  
Figure 28 shows the docked conformations of lead compound 152 (green) and 
proposed analog 163 (magenta), superimposed on the co-crystallized ligand, colchicine 
(pink). The pyrimidine ring of 163 superimposes on the pyrimidine ring of the lead 
compound 152 and interacts with residues Leuβ248, Asnβ258 and Lysβ352 in the binding 
site. The 2-Me moiety lies in a pocket lined by residues Serα178, Alaα180, Leuβ248 and 
Lysβ352. The N4-Me group mimcs the bridging interaction of C5-C6 atoms of colchicine 
and interacts with Lysβ254. The N4-phenyl group undergoes hydrophobic interactions with 
Cysβ241, Leuβ248, Leuβ255 and Alaβ316. The 4´-OMe substitution in 152 and 163 
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superimposes on the 2-OMe substitution on the A ring of colchicine. These OMe groups 
undergo a water mediated H-bond with Valβ238 and Cysβ241. This interaction has been 
described in the literature as an important interaction for compounds binding at the 
colchicine site.150 Additionally, the N-propyl substitution at the N6-position in 163 
undergoes hydrophobic interactions with Asnβ258, Metβ259, Thrβ314 and Lysβ352 and 
accesses the pocket more completely than the rigid pyrrole group in 152. The docked score 
of 152 was -7.48 kcal/mol whereas, the docked score of 163 was -8.67 kcal/mol. The 
docked scores for compounds 161-169 in Series III were -7.65 kcal/mol to -9.26 kcal/mol. 
 
Figure 29. Series IV (compounds 170-171) 
Compounds in Series IV (Figure 29) were designed as pKa mimics of the pyrrole 
ring in the scaffold pyrrolo[2,3-d]pyrimidine of compound 152 (calc. pKa = 13.5).
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Compound 170 was N-acetyl derivative of 154 with a calc. pKa of 11.5. Compound 171 
with an N-pivaloyl substitution was an intermediate in the synthesis of 158 and had a calc. 
pKa of 11.3, and was also tested for its antitubulin activity as a pKa mimic of 152. 
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1.B Single agents with combination chemotherapy potential 
 
1.B.1 Inhibition of multiple tyrosine kinases and microtubule targeting agents: 
Quinazoline analogs as microtubule targeting agents and multiple receptor tyrosine 
kinase inhibitors  
Angiogenesis is an essential process for tumor growth and metastases and involves 
the formation of new blood vessels from existing vasculature.153 Proangiogenic growth 
factors such as VEGF, PDGF, and EGF are released by the tumors under hypoxic 
conditions which bind to their respective RTKs (VEGFR, PDGFR-β and EGFR). This 
results in a cascade of events leading to angiogenesis and further tumor growth, survival 
and metastases. RTK inhibitors that circumvent angiogenesis have established a new 
paradigm in cancer chemotherapy.49, 154 Utility of multiple RTK inhibitors in cancer 
chemotherapy offers an advantage in overcoming resistance due to single RTK inhibitors 
such as point mutations in the ATP binding site and upregulation of additional RTKs.155, 
156 Subsequently, the use of multiple RTK inhibitors has emerged as an important approach 
in cancer chemotherapy and is validated by the approval of several multi-RTK inhibitors 
such as axitinib157, 158 (VEGFR, PDGFR, c-kit), pazopanib159 (PDGFR, VEGFR, c-kit, 
FGFR), vandetanib160 (VEGFR, EGFR, RET kinase), sunitinib161, 162 (VEGFR, PDGFR 
and c-kit) and sorafenib163, 164 (VEGFR-2, PDGFR β and Raf kinase). The cytostatic 
activity of RTK inhibitors does not kill cancer cells and thus, needs to be combined with 
cytotoxic chemotherapeutic or radiotherapeutic agents to provide a synergistic effect and 
improve therapy outcomes.165 
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 Microtubules are essential cytoskeletal component in eukaryotic cells which are 
involved in cellular process during both the interphase as well as the dividing phase of the 
cell.1 In the interphase stage microtubules are involved in intracellular trafficking of 
proteins and nucleic acid cargo and in dividing cells they make up the mitotic spindle and 
take part separation of daughter chromosomes.27 Microtubule targeting agents act by 
interfering with crucial processes involved in cell division in mitotic phase as well as by 
disrupting cellular transport and protein trafficking in the interphase.1, 26, 133  
 The strategy of using a combination of drugs, each acting at a different biological 
target has been successfully applied in the treatment of many diseases.166 The basic premise 
for such an approach is to overcome alternate signaling pathways which may get activated 
when only a single pathway is inhibited. In the same way, combination chemotherapy with 
antiangiogenic and cytotoxic agents acts by simultaneously inhibiting multiple pathways, 
thereby, inhibiting the growth of tumor cells dependent on alternate signaling pathways.165, 
167, 168 
 The vascular normalization theory proposes that the antiangiogenic effect of RTK 
inhibitors causes pruning of abnormal blood vessels and transiently normalizes the 
structural and functional integrity of the vasculature. This normalization restores blood 
flow to the tumors, aids in the improved delivery of co-administered cytotoxic agents and 
thus, explains, in part, the synergistic effect seen with such a combination.169, 170 Multi-
target directed ligands are rationally designed analogs which incorporate essential 
pharmacophores for inhibiting two or more biological targets.171, 172 In cancer 
chemotherapy, such agents may help in preventing cancer cells to develop resistance, lower 
 63 
the risk of drug-drug interactions, improve patient compliance and have low side effect 
profile due to efficacy of low affinity of cytotoxic component of the drug to its target.  
 Single agents with dual microtubule targeting activity and antiangiogenic activity 
are highly desirable as these agents can act synergistically and exert their cytotoxic effect 
as soon as the tumor vasculature normalization is achieved via the antiangiogenic 
component.42 Due to their mode of action, these agents need not be as potent as the 
currently used chemotherapeutic agents. The lower cytotoxic activity of these agents would 
mimic metronomic chemotherapy, which allows for low doses of cytotoxic agent to be 
administered compared to conventional chemotherapy.173 Clinical evaluation of the safety 
and efficacy of metronomically dosed cytotoxic agents in conjunction with antiangiogenic 
agents such as sunitinib and sorafenib has also been explored.168, 174, 175 The dose limiting 
cytotoxicity of conventional chemotherapeutic agents could also be avoided by using these 
single agents as these agents work by synergistic mechanisms and the cytotoxic component 
need not be as potent, thus minimizing toxicity. 
 Multi-target directed ligands with dual cytotoxic and antiangiogenic activities have 
shown to significantly reduce tumor growth, metastasis and angiogenesis in tumor 
xenograft mice models, without any significant toxicity.176, 177 Because of their crucial role 
in angiogenesis VEGFR-2, PDGFR-β and EGFR were chosen as targets in the current 
studies. Due to the clinical utility of cytotoxic tubulin inhibitors, such as paclitaxel, in 
combination with antiangiogenic agents, tubulin was chosen as the potential cytotoxic 
target.178-180 
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Figure 30. Lead compound 172 
 Compound 172 (Figure 30) was reported as a potent inducer of apoptosis, binding 
at the colchicine site and an inhibitor of tubulin polymerization (EC50 T47D = 2 ± 0.1 
nM).181 The compound was also shown to overcome resistance due to multidrug resistant 
transporters such as P-glycoprotein (Pgp), breast cancer resistance protein (BCRP1) and 
was able to cross the BBB to attain 30-fold higher concentration in the brain compared to 
the plasma. These pharmacokinetic parameters led to the evaluation of 172 in glioblastoma 
multiforme (GBM) and other cancers, and it is currently approved by FDA as an orphan 
drug in the treatment of GBM.182  
 
Figure 31. Few of the representative quinazoline based RTK inhibitors 
 The quinazoline scaffold has also been widely explored for its RTK inhibitory 
activity as exemplified by gefitinib (EGFR), erlotinib (EGFR) and vandetanib (VEGFR-2, 
VEGFR-3 and EGFR) (Figure 31). Thorough structure-activity relationships have been 
performed on the quinazoline scaffold with N4-desmethyl analogs as EGFR inhibitors 
which suggested that the quinazoline scaffold showed bulk tolerance at the 6- and 7-
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positions.183, 184 However, the corresponding N4-Me analogs were not explored for their 
RTK inhibitory activities. Separately, various scaffolds such as furo[2,3-d]pyrimidines176 
and pyrrolo[3,2-d]pyrimidines177, 185 with N4-Me substitution have been shown by Gangjee 
and coworkers to have dual acting antitubulin and multiple RTK inhibitory activities.  
Based on literature evidence and the structural similarities between 172 and the quinazoline 
based RTK inhibitors, it was predicted that 172 would have RTK inhibitory and thus 
antiangiogenic effects as well. 
 
Figure 32. Docked pose of lead compound 172 (green) superimposed on the crystallized 
ligand gefitinib (pink) in EGFR (PDB: 4WKQ)186 
 Compound 172 was docked in the binding site of EGFR (Figure 32) and had a 
docked pose similar to gefitinib. Due to the presence of a 2-Me group, the hinge region 
binding interaction with Met793 and the interaction of N3 with HOH1320 does not occur 
as seen with gefitinib but the 4-position aniline substitution is oriented in the pocket similar 
to the 3-chloro-4-fluoro substituted aniline in gefitinib and lies in a pocket lined by residues 
Lys745 and Asp855. The quinazoline scaffold of 194 is stabilized by hydrophobic 
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interactions with Leu718, Leu844 and Val726 (not shown). The 2-Me group lies in a 
hydrophobic pocket formed by residues Leu718, Met793 and Leu844. The docked score 
of 194 was -6.36 kcal/mol compared to gefitinib which had a docked score of -7.85 
kcal/mol. 
  
Figure 33. Docked pose of 172 (magenta) superimposed on the crystallized ligand axitinib 
(pink) in VEGFR-2 (PDB: 4AG8)187 
 The docked pose of 172 in the binding site of VEGFR-2 (Figure 33) shows that the 
quinazoline scaffold binds to the pocket where the thiobenzamide of axitinib binds and 
interacts with residues Lys868, Val899 and Val916. The 4-position aniline substituent of 
172 interacts with Val848, Ala866, Leu1035 and Phe1047, and binds in the pocket where 
the indazole scaffold of axitinib binds. The docked score of 172 in VEGFR-2 was -5.82 
kcal/mol compared to axitinib which had a docked score of -10.00 kcal/mol. 
As expected, preliminary evaluation of 172 in in vitro assay for inhibition of EGFR, 
VEGFR-2 and PDGFR-β resulted in potent activities against all three RTKs (Table 2). 
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Compound 172 was more potent than clinically used agent sunitinib (EGFR ~61-fold, 
VEGFR-2 ~2-fold and PDGFR-β ~15-fold). Compared to erlotinib, 172 was 2-fold less 
potent in EGFR but ~15-fold and ~2-fold more potent in inhibiting VEGFR-2 and PDGFR-
β, respectively. 
Table 2. EGFR, VEGFR-2 and PDGFR-β inhibitory activity of compound 172 
Compd EGFR 
kinase 
inhibition 
(nM) 
Flk-1 
(VEGFR-2) 
 kinase 
inhibition 
(nM) 
PDGFR 
kinase 
inhibition 
(nM) 
A431 
Cytotoxiciy 
(nM) 
U251 
cytotoxicity 
(nM) 
CAM 
angiogenesis 
inhibition 
(µM) 
172 2.8 ± 1.1 8.4 ± 2.2 5.6 ± 0.4 0.9 ± 0.2 2.8 ± 0.6 2.8 ± 1.1 
Sunitinib 172.1 ± 19.4 18.9 ± 2.7 83.1 ± 10.1 - - 1.3 ± 0.07 
Erlotinib 1.2 ± 0.2 124.7 ± 18.2 12.2 ± 1.9 - - 29.1 ± 1.9 
 
 
Figure 34. Series V (173-175), Series VI (176-178), Series VII (179-182) 
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 Compounds 173-175, Series V, (Figure 34) with a 2-Me substitution were designed 
to optimize the substitution at the 4-position for activity at multiple RTKs and at the 
colchicine site of tubulin. The clinically used quinazoline RTK inhibitors (Figure 31) all 
had a 2-H substitution and hence compounds in Series VI (176-178) were designed to 
mimic the 2-position substitution of the known RTK inhibitors and determine its effect on 
microtubule polymerization activity. Due to the loss of bulk at 2-position, compounds in 
Series VI were expected to bind at the active sites of EGFR and VEGFR-2 by mainiting 
the hinge region binding interactions as seen for gefitinib in EGFR (Figure 32) and axitinib 
in VEGFR-2 (Figure 33) while still retaining interaction at the colchicine site of tubulin. 
  
Figure 35. Superimposition of the docked poses of 172 (green) and 176 (magenta) in the 
colchicine binding site of tubulin (PDB ID: 4O2B).152  
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 The docked pose of 176 in the binding site of tubulin (Figure 35) is very similar to 
the lead compound 172. The quinazoline scaffold in 172 and 176 undergoes hydrophobic 
interactions with Alaα180, Asnβ258, Metβ259 and Lysβ352. The N4-Me in 172 is oriented 
towards and interacts with Lysβ254 and in 176 it interacts with Lysβ248 and Alaβ354. The 
N4-phenyl group hydrophobically interacts with Leuβ248, Leuβ255, Alaβ316 and Ileβ318. 
The 4´-OMe is oriented towards Valβ238 and Cysβ241 and can potentially undergo water 
mediated H-bonding interaction. The docked score of 172 in the colcicine site of tubulin 
was -7.65 kcal/mol and that of 176 was -7.16 kcal/mol. Compounds in Series V (173-175) 
had docked scores in the range of -7.62 to -8.82 kcal/mol and compounds in Series VI (176-
178) had docked scores in the range of -7.16 to 8.33 kcal/mol suggesting these compounds 
to have similar or better activity than 172 as MTAs binding to colchicine site.  
  
Figure 36. Superimposition of the docked poses of 172 (green) and 176 (magenta) in 
EGFR (PDB: 4WKQ).186  
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As mentioned above, due to the loss of bulk at 2-position compound 176 (Figure 
36) is able to undergo hinge region binding interaction with Met793 while maintain other 
interactions at the binding site of EGFR as seen with 172 (Figure 34). Compounds in Series 
V docked similar to compound 172 and had docked scores in the range of -7.06 to -7.32 
kcal/mol. Compounds in Series VI docked similar to 176 and had docked scores of -7.22 
to -7.70 kcal/mol. 
   
Figure 37. Superimposition of the docked poses of 172 (green) and 176 (magenta) in 
VEGFR-2 in two different binding modes (PDB: 4AG8).187 
Compound 176 (Figure 37) when docked in the X-ray crystal structure of VEGFR-
2 showed two modes of binding, which corroborate with the similar findings reported for 
a series of furo[2,3-d]pyrimidine analogs.176 In Figure 37A 176 binds to VEGFR-2 in a 
binding mode similar to that seen for compound 172 (Figure 33) and has a docking score 
of -7.61 kcal/mol. In addition, due to the absence of bulk at 2-position, 176 binds to 
VEGFR-2 in an alternate binding mode where the N1 of the quinazoline scaffold in 176 
undergoes H-bonding with Cys919 at the hinge region of  VEGFR-2  and has a similar 
docking score of -7.51 kcal/mol. Compounds in Series V docked similar to compound 172 
and had docked scores in the range of -5.8 to -6.51 kcal/mol. Compounds in Series VI 
docked similar to 176 and had docked scores of -4.87 to -8.40 kcal/mol. 
A B 
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The 2-Cl substituted analog of 172 was reported to be an equipotent inhibitor of 
microtubule polymerization (EC50 T47D = 2 ± 0.1 nM) as 172 and hence by varying the 
bulk and electronics at the 2-position, compounds 179-182 (Series VII, Figure 34) were 
designed to assess the inhibitory effect on multiple RTKs. These compounds docked at the 
colchicine site of tubulin (docked scores, -7.50 to -8.61 kcal/mol), EGFR (docked scores, 
-6.49 to -7.39 kcal/mol) and VEGFR-2 (docked scores, -4.34 to -7.94 kcal/mol) in a mode 
similar to that shown for lead compound 172. 
 
Figure 38. Pyrido[2,3-d]pyrimidine derivative Series VIII (183)  
 Compound 183 was designed to determine the effect of changing the electronics of 
the quinazoline scaffold on the inhibitory activities towards microtubule polymerization 
and RTKs. Introduction of nitrogen atom at 8-position of the quinazoline ring changes the 
evenly distributed electron density in a benzene ring with variable electron density in a 
pyridine ring which has a dipole moment of 2.2 D. Due to the presence of pyridine ring, 
the pyrido[2,3-d]pyrimidine scaffold is electron deficient as compared to the electron rich 
quinzoline scaffold.188 Compound 183 docks in the colchicine site of tubulin in a binding 
mode similar to that observed for 176 (Figure 35) in which the N8 atom can potentially 
interact with the NH backbone of Valα181 via H-bonding. The docked score of 183 in the 
colchicine site of tubulin was -7.24 kcal/mol. The docked scores in EGFR and VEGFR-2 
were -7.28 kcal/mol and -7.63 kcal/mol, respectively. 
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1.B.2 Dual acting microtubule targeting agents and toll-like receptor agonists: 
Quinoline-2,5-diamines as microtubule targeting agents and toll like receptor agonists 
 
Cancer and immunotherapy 
The fundamental principle underlining the use of immune therapy in the treatment 
of cancer lies in the fact that the cancer cells express a variety of proteins that can be 
recognized by the immune system and is currently a well-established component of many 
cancer treatment regimens.189 The anti-cancer effect of such therapy is attained by one of 
the following methods: 1) passive immunization by monoclonal antibodies, 2) systemic 
delivery of cytokines and, 3) introducing adjuvants to the tumor microenvironment. These 
protective anti-tumor effects are mediated by the regulation of key signaling pathways in 
the innate (early, general attack) and/or the adaptive (specific attack) immune system.189 
 Toll-like receptors (TLRs) are pattern recognition receptors which are expressed on 
the members of the innate or the adaptive immune system such as DCs, macrophages, 
granulocytes, T cells, B cells, natural killer (NK) cells and mast cells.190 They are 
responsible for recognizing conserved signature patterns, either pathogen-associated 
molecular patterns (PAMPs) or microbe-associated molecular patterns (MAMPs), and 
initiate and propagate inflammatory response.191 Ten subtypes (TLR1-10) have been 
identified in humans which are activated by various ligands.192 The role of TLRs in eliciting 
antitumor response in bone sarcomas was first reported by repeated injections of Coley’s 
toxin (mixture of lipopolysaccharides and bacterial DNA products).193 This effect was due 
to TLR4 and TLR9 mediated cytokine production, stimulation of active immunity and 
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activation of NK and cytotoxic T cells.68 Due to recent efforts in identifying the role of 
innate immunity in cancer treatment, immunotherapeutic agents such as TLR agonists are 
now considered by the National Cancer Institute (NCI) as one of the few agents with 
highest potential in the treatment of cancer.194, 195  
 In response to cellular stress signals (DNA damage, viral infection etc.), the tumor 
suppressor p53 initiates a transcriptional process that regulates transcription of genes 
involved in many biological processes.196 In cancer, in addition to the tumor suppressor 
response, p53 increases the expression of key mediators of innate immunity to improve the 
clearance of damaged cells.197 Amongst various targets many members of the TLR family 
are also regulated by p53.196 The utility of TLR agonists in cancer treatment can thus be 
exploited, depending on the TLR gene expression profile and tumor microenvironment, to 
increase the immune response to tumor antigens or as adjuvants in cancer chemotherapy.198 
Accumulating amount of evidence suggests that by activating TLRs present on monocytes, 
macrophages and DCs, the immune effector functions such as phagocytosis, antigen 
presentation and cytokine secretion, are improved which lead to efficient anticancer 
immunity. Calreticulin (CRT) is an endoplasmic reticulum (ER) protein which is 
associated with phagocytic eat-me signal. CRT expression on the surface of macrophages 
is controlled by TLR, activation of which leads to phosphorylation of CRT, cleavage from 
the ER and subsequent increased expression on the cell surface. Higher surface CRT on 
macrophages resulted in stronger phagocytic ability towards human colon cancer cells in 
vitro. Thus, enhanced immunosurveillance of tumor cells can be achieved by increasing 
TLR mediated surface expression of CRT on macrophages.199 
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Bacillus Calmette-Guérin (BCG), an attenuated form of Mycobacterium bovis, is 
currently approved by the US FDA in the treatment of non-invasive transitional cell 
carcinomas of the bladder.200 Lyophilized preparation of Streptococcus pyogenes, 
picibanil, is approved in Japan for the treatment of many carcinomas.201 Monophosphoryl 
lipid A (MPL) is a derivative of Salmonella minnesota lipopolysaccharide which is used 
as an adjuvant in the treatment of cervical carcinoma associated with human 
papillomavirus (HPV) infection.202 Imiquimod, a small molecule TLR7/8 agonist, is used 
in the treatment of basal cell carcinoma.203 More than 50 clinical trials of TLR agonists 
have been initiated to assess their safety and efficacy as immunotherapeutic agents in a 
number of cancers, as a standalone therapy as well as in combination with other 
agents/interventions.204 Gliomas are one of the most aggressive types of tumors which 
occur in the central nervous system. Since these gliomas escape the immune surveillance 
by creating immune suppressed environment, immunotherapy is one of the more promising 
strategy for their treatment.205  
The expression of different TLR subtypes has different biological responses. TLR2, 
TLR4 and TLR9 subtypes in glioma have shown to be tumor promoting as they contribute 
to tumor development.206-208 On the other hand, it has been shown that imiquimod (TLR7/8 
agonist) leads to eradication of intracranial tumor when applied to mouse glioma model.209 
Additionally, a number of clinical trials are currently underway which utilize imiquimod 
as an adjuvant in the treatment of glioblastoma multiforme (GBM), the most aggressive 
form of human glioma.205 The efficacy of TLR7 agonist in cancer is due to NF-κB mediated 
induction of proinflammatory chemokines and activation of cytotoxic activity of NK cells 
which are capable of inducing tumor apoptosis.194 
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Few studies have explored the potential of exploiting combination of TLR agonists 
as adjuvants in combination with radiation, chemotherapy and/or, cancer vaccines and it 
has been suggested that the combination has better therapeutic success over monotherapy 
with TLR agonists in the treatment of cancer. The efficacy arises due to the ability of TLR 
agonist to enhance Th1 mediated cytotoxic effect via activating immune cells involved in 
adaptive immunity.192 Conventional cytotoxic chemotherapeutic agents are capable of 
reducing the tumor burden but as such are unable to activate signaling pathways involved 
in enhancing immunogenicity of cancer cells. The improved immunogenicity of cancer 
cells can increase the chances of T-cell mediated susceptibility to tumors and higher 
remission rates. It was observed that vincristine, a microtubule destabilizer, killed chronic 
lymphocytic leukemia (CLL) cells rapidly in vitro and also had weak T cell stimulatory 
properties. The presence of protein kinase C (PKC) agonist, bryostatin, in addition to 
vincristine, increased the immunogenicity of CLL cells and had effects similar to that seen 
with of TLR agonist.210 The use of combining vascular disrupting agents (VDAs) (CA-4P) 
with one or more antibodies capable of improving immunomodulatory responses in cancer 
cells (PD-1, CTLA-4) are also being assessed.211 
 
Figure 39. Structure of lead compounds (172, 184-185) 
A series of single agents were designed that incorporate structural features to 
interact with essential pharmacophores for both MTA binding at the colchicine site and 
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TLR7/8 agonists, to explore their effect in the treatment of cancer, particularly gliomas. 
Quinazoline 172 (Figure 39) is a MTA that binds at the colchicine site of tubulin (EC50 
T47D cells = 2 ± 0.1 nM)181 and was granted orphan drug status for the treatment of 
gliomas. The efficacy was attributed due to its vascular disrupting effect. A number of 
scaffolds with varying substitutions at 2-position (pyrrolo[2,3-d]pyrimidines38, 
pyrrolo[3,2-d]pyrimidines185, furo[2,3-d]pyrimidines212, pyrimido[4,5-b]indoles213) and 
bearing the 4-methoxy-N-methylaniline substitution have been reported by Gangjee and 
coworkers, of which the aniline substitution at the C4-position is considered essential for 
the antitubulin activity. Additionally, 2-aminoquinolines (184 TLR8 EC50 = 200 nM, 185 
TLR8 EC50 = 49 nM) were recently reported as TLR8 agonists.
76, 214  
 
Figure 40. Series IX 
Maintianing the 2-aminoquinoline scaffold for TLR agonistic activity (Figure 40), 
4-methoxy-N-methyl substituted compounds (186-190) Series IX, with varying alkyl 
substitutions at the 3-position are proposed. These analogs incorporate structural 
determinants for both MTAs and TLR agonists. Compound 184 (Figure 39) with n-pentyl 
substitution at the 3-position was a selective TLR8 agonistic activity. However, by varying 
substitutions at the 3- and 4-positions of the 2-aminoquinoline scaffold dual acting TLR7/8 
agonists can be obtained.215, 216 These homologated analogs will also help in optimizing 
the 3-position substitution for binding at the colchicine site of tubulin as well as TLR7/8.  
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Figure 41. Docked pose of 190 (green) superposed on to the crystallized ligand D80 (pink) 
in TLR8 (PDB: 4QBZ).216 
Compounds 186-190 were docked in the X-ray crystal structure of TLR8 (PDB: 
4QBZ)216 using MOE 2016.08.38 Figure 41 shows the docked conformations of compound 
190 (green) superimposed on the co-crystallized ligand D80 (pink). The 2-aminoquinoline 
scaffold retains the interactions with Asp543. The n-pentyl group of 190 orients similar to 
the butyl group in D80 and interacts with Phe346, Tyr348 and Val378. The N4-Me moiety 
interacts with Tyr353 and Val 378. The N4-Ph with the 4´-OMe group lies in the solvent 
exposed region of the binding pocket. The docked score of 190 in TLR8 was -8.11 kcal/mol 
which was similar to the docked score of the crystalized ligand, -8.35 kcal/mol, indicating 
that 190 is anticipated to be active as a TLR8 agonist. 
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Figure 42. Docked pose of 190 (cyan) superposed on to colchicine (pink) in tubulin (PDB: 
4O2B).152 
Compounds 186-190 were also docked in the X-ray crystal structure of colchicine 
in tubulin (PDB: 4O2B)152 using MOE 2016.08.38 Figure 42 shows the docked 
conformations of the proposed compound 190 (green) superimposed on the co-crystallized 
ligand, colchicine (pink). The quinoline scaffold interacts with Alaα180, Leuβ248, 
Asnβ258 whereas the 2-NH2 undergoes H-bonding with Thrα179. The n-pentyl group at 
the 3-position lies in a pocket lined by residues Serα178 and Leuβ248. The conformational 
orientation of the N4-substituted aniline superimposes on to the A-ring of colchicine with 
the N4-Me group in 190 oriented towards the bridging C5 and C6 atoms of colchicine. The 
docked score of 190 was -7.05 kcal/mol compared to the score of colchicine which was -
10.73 kcal/mol, indicating that there is a reasonable probability that 190 will have 
colchicine site binding and thus antitubulin activity. 
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Figure 43. Series X 
The p-anisidine analog 191 was designed to determine the effect of conformational 
restriction provided by the N4-Me substitution of 186 with respect to the quinoline scaffold 
on the activity at both TLR8 and the colchicine site of tubulin. The conformational 
restriction provided by N4-Me group was confirmed by performing conformational search 
on C5-N bond of 186 (91 conformations) and 191 (133 confirmations) within 5 kcal/mol 
using SYBYL-X 2.1.1. 
 
C. Selective inhibition of P. jirovecii dihydrofolate reductase 
 Pneumocystis pneumonia (PCP) is an opportunistic infection caused by fungus 
Pneumocystis jirovecii (Pj). The pathogen is present in the lungs of a majority of the 
population around the world. In healthy individuals the infection is kept under check due 
to normal functioning of the immune system.93 In immunocompromised patients, such as 
those suffering from HIV/AIDS, undergoing cancer chemotherapy, and organ 
transplantation, and where the CD4 count is below 200 cells/mm3 PCP infection, without 
treatment, is fatal.217, 218 Current prophylaxis and treatment for PCP includes administration 
of co-trimoxazole, a combination of trimethoprim (TMP) (targets dihydrofolate reductase,  
DHFR) and sulfamethoxazole (SMX) (targets dihydropteroate synthase, DHPS). In several 
cases the failure of co-trimoxazole therapy occurs due to development of resistance or due 
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to allergy/toxicity caused by SMX.219-221 The potent and non-selective inhibitors, such as, 
trimetrexate (TMQ) or piritrexim (PTX), require co-administration of leucovorin which is 
associated with high treatment cost, drug interactions and lower efficacy.222, 223 Thus, 
therapeutic agents (DHFR inhibitors) that have the potential of combining the selectivity 
of TMP for pathogenic DHFR with the potency offered by TMQ or PTX are highly 
desirable and present a significant advantage of improving patient compliance and can be 
used to target multiple opportunistic infections. 
 
1.C Selective inhibition of P. jirovecii dihydrofolate reductase: Thieno[2,3-
d]pyrimidines as selective inhibitors of pjDHFR 
 
  
Figure 44. General structure of pyrrolo[2,3-d]pyrimidines, thieno[2,3-d]pyrimidines and 
TMQ 
 Gangjee et al.224, 225 reported 5-methyl-6-substituted pyrrolo[2,3-d]pyrimidines 
(Figure 44) as inhibitors of pneumocystis carinii (pc) and pjDHFR The compounds in the 
series were 3-12 fold more selective for pjDHFR and had good clogP (2.31-3.91) values.  
 81 
   
Figure 45. Superimposed poses of quinazoline ring of TMQ (teal) with pyrrolo[2,3-
d]pyrimidine (orange) and thieno[2,3-d]pyrimidine (purple) 
The larger size of sulfur as compared to nitrogen allows the thieno[2,3-
d]pyrimidines to mimic the 6,6-ring system of the potent inhibitor TMQ more closely than 
the NH in a pyrrolo[2,3-d]pyrimidine (Figure 45). The replacement of the pyrrole NH with 
S would also allow for the evaluation of the ffect of HBD to a HBA, at the 7-position, on 
the biological activity. In addition, since these compounds are non-classical antifolates 
lacking the glutamic acid chain and are taken up by the pathogen via passive diffusion, the 
thieno[2,3-d]pyrimidines were found to have higher clogP values (3.04-4.65), compared to 
the pyrrolo[2,3-d]pyrimidine analogs (2.31-3.91). The thieno[2,3-d]pyrimidine scaffold 
affords another advantage as it has already been explored for antibacterial and antimalarial 
activities120, 226-228 and thus, these compounds can also be tested as potential DHFR 
inhibitors of other pathogens. 
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Figure 46. Series XI (192-199), Series XII (200-207) 
Compounds 192-199 Series XI (Figure 46) were designed to explore the effect of 
electron donating groups in the side chain thiophenyl group at the 6-position on the potency 
and selectivity towards pjDHFR. The substitutions were varied to have mono-(193-195), 
and di-(196-199) substituted electron donating groups. Similarly, compounds 200-207 in 
Series XII were designed to assess the effect of electron withdrawing groups on activity. 
 
Figure 47. Series XIII  
Compounds 208-210 Series XIII (Figure 47) with bulkier 1-naphthyl, 2-naphthyl 
and biphenyl groups respectively, were designed to explore the bulk tolerance in the side 
pocket and its effect on pjDHFR and hDHFR inhibitory activity. 
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Figure 48. Docked pose of 209 (purple) in the homology model of pjDHFR225 (green), 
superimposed on to the X-ray crystal structure of hDHFR (PDB: 1U72229, gray) to 
emphasize the difference in residues in the binding pocket. NADPH is in black. The key 
differences in the binding site residues are highlighted in red circles. 
 The docked pose of 209 in the pjDHFR homology model (Figure 48) is a 
representative example of the mode of binding of thieno[2,3-d]pyrimidines in the active 
site. The key interaction involves the bidentate ionic interaction of the N1 and 2-NH2 of 
the thieno[2,3-d]pyrimidine scaffold with Asp32 in pjDHFR and Glu30 in hDHFR. The 4-
NH2 undergoes H-bonding with Ile10 and Ile7 in pjDHFR and hDHFR, respectively. The 
rationale for introducing bulk at the 6-position can be observed from the docked pose which 
suggests that the bulky group can be accommodated by the Met33 in pjDHFR. In hDHFR, 
the presence of a Phe31 results in a steric clash of the bulky substituent with the Phe31 and 
hence improved selectivity of binding can be achieved for pjDHFR. 
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Figure 49. Series XIV 
 Compounds 211 and 212 Series XIV (Figure 49) were designed to exploit the 
difference in the residues Ile123 in pjDHFR and the corresponding Val115 in hDHFR 
(Figure 48). The homologated analogs 211 and 212 can interact with Ile123 in pjDHFR but 
Val115 in hDHFR being shorter is unable to interact with the substitutions at 5-position of 
211 and 212. This allows for increased hydrophobic binding of 211 and 212 with pjDHFR 
compared to hDHFR. 
 
2. Molecular modeling studies  
 
2.A.1 Pyrimido[4,5-b]indoles as microtubule targeting agents 
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Figure 50. Structures of pyrimido[4,5-b]indole tubulin inhibitors (compounds 213-220) 
Compounds 213‒220 (Figure 30) were synthesized by Gangjee and coworkers to 
explore the SAR and identify key structural features of 213 responsible for microtubule 
depolymerizing activity in the colchicine site.230 
Docking studies of compounds 213-220 were carried out in the reported X-ray crystal 
structure of colchicine in tubulin (PDB: 4O2B)152 to explain the microtubule 
depolymerization activities observed for these series of compounds.230 
 
2.A.2 Cyclopenta[d]pyrimidines as microtubule targeting agents 
 
 
 Figure 51. Structures of cyclopenta[d]pyrimidine tubulin inhibitors (compounds 221-234) 
Compounds 221‒234 (Figure 51) were synthesized by Gangjee and coworkers to 
explore the SAR of cyclopenta[d]pyrimidines for microtubule depolymerizing activity in 
the colchicine site.148  
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 Docking studies of compounds 221-234 were carried out in the colchicine binding 
site in tubulin (PDB: 4O2B).152 Additionally, study of the electrostatic surfaces as well as 
conformational search were also performed for these compounds to correlate the structures 
with their in vitro activities.  
 
2.B.1 5-Methyl-N-(substituted)-furo[2,3-d]pyrimidin-4-amines as single agents with 
combination chemotherapy potential 
 
 
Figure 52. Structures of dual antitubulin and antiangiogenic compounds 236-246 
Based on lead compounds 235-238, compounds 239-246 (Figure 52) were synthesized 
by Gangjee and coworkers to determine the effect of bulky substitutions at the N4-position 
towards binding at the ATP site of multiple RTKs and at the colchicine site of tubulin.231 
Docking studies of compounds 236-246 were carried out in the reported X-ray crystal 
structure of colchicine in tubulin (PDB: 4O2B, 2.3 Å)152 to explain the microtubule 
depolymerization activities observed for these series of compounds.212 To elucidate the 
RTK inhibitory activities, these compounds were docked in in the published X-ray crystal 
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structures of EGFR (PDB: 4JQ7,232 2.73 Å) and VEGFR-2 (PDB: 4AG8,187 1.95 Å), and 
in a homology model of PDGFR-β.233 
 
2.B.2 7-Benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents 
with combination chemotherapy potential 
 
 
Figure 53. Dual acting pyrrolo[3,2-d]pyrimidines 249-256 
Based on lead compounds 247-249, compounds 250-256 (Figure 53) were synthesized 
by Gangjee and coworkers to to explore the SAR of pyrrolo[3,2-d]pyrimidines towards 
binding at the ATP site of multiple RTKs and at the colchicine site of tubulin.185  
Docking studies of compounds 249-256 were carried out in the reported X-ray crystal 
structure of colchicine in tubulin (PDB: 4O2B, 2.3 Å)152 to explain the microtubule 
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depolymerization activities observed and the RTK inhibitory activities (VEGFR-2 PDB: 
4AG8,187 1.95 Å; EGFR PDB: 4WKQ,186 1.85 Å; and PDGFR-β homology model233) of 
these series of compounds.185  
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IV. CHEMICAL DISCUSSION 
Synthesis of monocyclic pyrimidine analogs 155-171 and lead compounds 153 and 154 
 Lead compounds 155 and 154 (Scheme 36) were synthesized from the 
commercially available 6-chloro-2,5-dimethylpyrimidin-4-amine (261) and 5,6-dichloro-
2-methylpyrimidin-4-amine (257), respectively. Further synthesis of compounds 155-171 
was accomplished based on the synthesis of lead compound 154. 
Scheme 36. Synthesis of lead compounds 153 and 154 (Series I) 
 
 Compound 154 (Scheme 36) was initially synthesized over three steps starting from 
commercially available pyrimidine 257. The free amine in 257 was protected using pivalic 
anhydride to give pivaloyl protected pyrimidine 258. Nucleophilic aromatic displacement 
of the 4-chloro in 258 with 4-methoxy-N-methyl aniline 259 under microwave conditions 
in 1,4-dioxane gave intermediate 260 which was deprotected under basic conditions to give 
the final compound 154 in 74% yield. The 1H NMR of 154 showed the presence of NH2 
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peak at 6.61 ppm, 4-NCH3 peak at 3.27 ppm and 4´-OCH3 peak at  3.73 ppm, confirming 
the formation of 154. Since compound 154 was required in bulk for the synthesis of 
compounds in Series III, an alternate synthetic route utilizing benchtop conditions was 
desired which would be easily amenable to scale up conditions. Therefore, compounds 153 
and 154 were synthesized in one step via SNAr displacement of the 4-chloro of 261 and 
257 with aniline 259 under benchtop conditions to give final compounds in 27% and 85% 
yield, respectively. n-Butanol being more polar than 1,4-dioxane (ɛ 17.8 vs 2.21) was 
chosen as a solvent for the reaction on polar starting material 257 and 261 (Rf of 257 in 
10:1 CHCl3/MeOH = 0.52 compared to Rf of 258 in 10:1 CHCl3/MeOH = 0.76 ). 
 
Figure 54. 13C NMR of compound 154 
 To ensure that the SNAr reaction in Scheme 36 on 257 results in the 4-substitued 
compound 154 and not the 5-substituted compound 154a, the predicted 13C NMR values 
(ACD Labs) were compared with the values obtained experimentally (Figure 54). Clearly 
the presence of the 4C signal at 163 ppm and 5C peak at 94 ppm correlates with the 4-
substitued compound 154 and confirmed that the SNAr displacement occurs, as expected, 
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at the more electrophilic and activated 4-position of the 5,6-dichloro-2-methylpyrimidin-
4-amine 257.  
Scheme 37. Synthesis of N-methylated anilines 263, 265 and 269 
 
 To synthesize compounds 156, 159 and 160 (Series II), the respective commercially 
available primary anilines (262, 264 and 266) were first methylated (Scheme 37). For 
synthesis of N-methylated anilines 263 and 265, anilines 262 and 264 were formylated 
using paraformaldehyde in the presence of sodium methoxide in methanol. Subsequent 
reduction of the N-formyl group using NaBH4 yielded anilines 263 (39%) and 265 
(46%).234 To synthesize the aniline 269 from 6-aminonaphthalen-1-ol 266, both N- and O-
methylation was required and a different strategy was necessary. 6-Aminonaphthalen-1-ol 
266 was first boc protected to give a N-Boc protected intermediate 267, which was 
subsequently methylated (both N- and O-) with methyl iodide in the presence of sodium 
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hydride235 and deprotected using trifluoroacetic acid to give 5-methoxy-N-methylnaphthyl-
2-amine 269 (55% over 3 steps).236 
Scheme 38. Synthesis of target compounds 155, 156, 158, 159 and 171 
 
Compounds 155, 156, 158, and 159 (Scheme 38) were synthesized by SNAr 
displacement of the pivaloyl protected chloro intermediate 258 with appropriate anilines to 
give the pivaloyl protected intermediates, which were deprotected under basic conditions 
to afford the final compounds in 43%, 32%, 26% and 32% respectively. The pivaloyl 
protected intermediate 171 was also obtained in 11% yield via the SNAr displacement of 
258 with 6-methoxy-1,2,3,4-tetrahydroquinoline 271. 
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Compounds 157 and 160 (Scheme 39) were similarly synthesized by the 
nucleophilic displacement of the chloro group of 157 by 3-methoxy-N-methylaniline 272 
and 5-methoxy-N-methylnaphthalen-2-amine 269, respectively. 
 
Scheme 39. Synthesis of target compounds 157 and 160  
 
Scheme 40. Synthesis of target compounds 161-169 (Series III) 
 Compounds 161-167 (Scheme 40) were synthesized by first reacting 154 with 
sodium hydride to generate the anion which was then treated with the appropriate alkyl 
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iodide or benzyl bromide to yield compounds 161-167. The low yield of these reactions 
can be attributed to the formation of a dialkylated side product which was isolated for the 
reaction of 154 with benzyl bromide as the dibenzylated analog 167a. Similarly, 
compounds 168 and 169 were synthesized by displacing the anion obtained from 160 with 
ethyl iodide and propyl iodide, respectively. 
Scheme 41. Synthesis of compound 170 (Series IV) 
 
Compound 154 was acetylated using acetic anhydride in acetic acid to give the final 
compound 170 in 30% yield (Scheme 41).237 For biological activities of 155-171, see 
Appendix Table 12, pg 219.  
 
Synthesis of N4-anilinoquinazolines 172-182 and pyrido[2,3-d]pyrimidine 183 
 
 The synthesis of N4-anilinoquinazolines 172-182 and the pyrido[2,3-d]pyrimidine 
183 (Figure 55), was envisioned via the chloro intermediate 273(a-d) which could be 
displaced via nucleophilic reaction with appropriate anilines to give the target 
compounds.181 Since 273c was commercially available, the 4-chloro intermediate 273(a, 
b, d) were considered to be synthesized via chlorination using phosphorus oxychloride on 
the 4-oxo intermediates 274(a, b, d).177 Intermediates 274a and 274b were commercially 
available. For synthesizing the 4-oxo intermediate 274d, it was of interest to carry out a 
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condensation of 2-aminonicotinic acid 275 in the presence of formamide under microwave 
irradiation conditions. A similar method was reported for the synthesis of 2-H substituted 
quinazoline (274b), which gave the target compound in 60% yield.238 
 
Figure 55. Retrosynthesis of target compounds 172-183 
Scheme 42. Reaction optimization for synthesis of intermediate 4-chloroquinazoline 
(273b) 
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The synthesis of 4-chloroquinazoline was attempted by the reaction of 
commercially available quinazolin-4(3H)-one 274b in phosphorus oxychloride at reflux 
(Scheme 42).177 After 4 hours, monitoring the reaction using thin-layer chromatography 
(TLC) suggested completion of the reaction. The work up was carried out by evaporating 
the solvent in vacuo and adjusting the pH to 8 using ammonia solution.177 This resulted in 
the conversion of 273b back to the 4-oxo starting material 274b. In another case, after the 
reaction was completed, the neutralization was carried out under ice cold conditions using 
7N NH3 in methanol which resulted in the formation of 4-methoxyquinazoline 276 
(appearance of singlet at 4.24 ppm accounting for 3H).  
In the next set of condition, 274b was reacted with phosphorus oxychloride (1 eq) 
in toluene with pyridine (1 eq) as a base at reflux (Scheme 41).239 This resulted in the 
formation of the dimer 277 (1H NMR spectrum suggested 8 aromatic peaks between 7.68-
8.26 ppm, singlets at 8.63 and 9.46 ppm , accounting for the 2-H protons of the quinazoline 
ring).  
 
Figure 56. Mechanism for the formation of dimer 277 
The dimer formation was also documented by Arnott et al,240 who suggested that 
the formation of the dimer occurs as a result of the reaction between quinazolinone 274b 
and the phosphate intermediate 278 (Figure 56). They proposed that the side reaction could 
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be overcome by adding phosphorus oxychloride to 274b under basic conditions (pKa > 9) 
and running the reaction at room temperature for 1 hour to ensure complete conversion of 
274b to 278. Once all the starting material is converted to the phosphate intermediate 278, 
heating the reaction mixture to 95 °C for 2-3 hours results in the formation of the desired 
4-chloroquinoline 273b. 
Scheme 43. Synthesis of 4-chloroquinazoline 273b 
 
 Based on the above description, 4-chloroquinazoline 273b (Scheme 43) was 
synthesized in 80% yield using a stoichiometric concentration of phosphorus oxychloride 
and triethylamine in toluene. The initial reaction solution at room temperature underwent 
a color change from pink to orange brown, which on reflux resulted in a clear brown 
solution. During the reaction work up and at later steps, care was taken to use ethyl acetate 
and not methanol to dissolve the compound, as the presence of methanol could result in the 
formation of 276 (Scheme 41). 
Scheme 44. Synthesis of 4-chloro-2-methylquinazoline 273a 
 
 Similar to the synthesis of 273b, 4-chloro-2-methylquinazoline 273a was 
synthesized from 2-methylquinazolin-4(3H)-one 274a in 50% yield (Scheme 44). 
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Scheme 45. Synthesis of target compounds 172-180 and 182 (Series V, VI and VII) 
 
  
Compounds 172-180 and 182 were synthesized by nucleophilic displacement 
reaction of 4-chloroquinazolines (273a, 273b and 273c) by respective anilines in isopropyl 
alcohol and a drop of conc. HCl at room temperature for 12 hours (Scheme 45). 
Yields of compounds in Series V were 58% (172, reported yield 71%)181, 65% (173, 
reported yield 79%)241, 70% (174, reported yield 41%)181, 68% (175). Yields of compounds 
in Series VI were 76% (176, reported yield 79%)242, 70% (177, reported yield 69%)243, 
72% (178). Yields of compounds in Series VII were 10% (179, reported yield 87%)242, 
25% (180, reported yield 87%).241 The synthesis of 181 was unsuccessful under the 
reaction conditions mentioned above which led to the formation of dimer 279 (1H NMR 
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indicated four methyl singlets, two for SCH3 at 2.48 and 2.49 ppm and two for NCH3 at 
3.29 and 3.57 ppm). Compound 182 was synthesized over two steps. The first step involved 
the nucleophilic displacement of quinazoline 273c with 6-aminonaphthalen-1-ol 266 to 
yield 6-((2-chloroquinazolin-4-yl)amino)naphthalen-1-ol 280. N- and O-methylation of 
280 using methyl iodide and sodium hydride yielded the desired compound 182 in 47% 
yield. 
Scheme 46. Synthesis of target compound 183 (Series VII) 
 
 Synthesis of compound 183 was accomplished starting with the cyclization of 2-
aminonicotinic acid 275 with formamide to pyrido[2,3-d]pyrimidin-4(3H)-one 274d 
(70%). Chlorination of 274d in the presence of phosphorus oxychloride, as mentioned 
above, led to 4-chloropyrido[2,3-d]pyrimidine 273d in 20% yield. Subsequent nucleophilic  
displacement of 273d with 4-methoxy-N-methylanilne yielded target compound 183 in 
29% yield.238 For biological activities of 172-183, see Appendix Table 13, pg 221. 
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Synthesis of quinoline-2,5-diamines 186-191  
 
Figure 57. Retrosynthesis of target compounds 186-191. 
The synthesis of target compounds 186-191 (Figure 57) was envisioned via 
palladium-catalyzed cross coupling reactions of intermediate 5-chloro- or 5-bromo-2-
aminoquinoline 281a or 281b, which could be synthesized via a modified Friedlander 
synthesis involving condensation of 2-amino-6-chlorobenzaldehyde or 2-amino-6-
bromobenzaldehyde 282a or 282b with appropriate alkanenitriles.76 Since the palladium-
catalyzed coupling reaction of intermediate 281 with anilines has not been reported, it was 
of interest to devise an efficient synthetic strategy for the target compounds 186-191. To 
accomplish the same goal the synthesis of 190 was performed for reaction optimization 
studies. 
 2-amino-6-chlorobenzaldehyde 282a was synthesized via oxidation of (2-amino-6-
chlorophenyl)methanol 283. Oxidation using manganese dioxide afforded a better yield 
(83%)244 compared to the oxidation under PCC conditions (13%).245 Condensation of 282a 
with heptanenitrile in the presence of potassium tert-butoxide under a modified Friedlander 
synthesis yielded 2-amino-5-chloroquinoline 281a in 48% yield.76 2-Amino-5-
bromoquinoline 281b was similarly synthesized in 30% yield from 2-amino-6-
bromobenzaldehyde 282b. 
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Scheme 47. Synthesis of 2-amino-5-chloro-quinoline intermediate 281a and 2-amino-5-
bromo-quinoline intermediate 281b 
 
  Since the 2-NH2 group can interfere in the subsequent palldium-catalyzed coupling 
reactions and lead to a self-coupled product, it was envisioned to synthesize pivaloyl 
protected intermediates 284 (58%) and 285 (78%) by reacting 2-amino-6-
chlorobenzaldehyde 281a and 2-amino-6-bromobenzaldehyde 281b with pivalic anhydride 
under reflux, respectively. 
 Scheme 48. Attempted synthesis of 190 using intermediate 284 
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In an attempt to synthesize 190, palladium-catalyzed amination of pivaloyl 
protected 5-chloro-3-pentylquinolin-2-amine 284 was carried out under microwave 
irradiation conditions in the presence of catalyst bis(dibenzylideneacetone)palladium(0) 
(Pd(dba)2) and BINAP as a ligand. 
Table 3. Reaction conditions for Pd-catalyzed coupling reaction on 284 
S. No. Catalyst Ligand Base Solvent Temperature Result 
1 Pd(dba)2 
8 mol% 
BINAP 
12 mol% 
NaOtBu 
3 eq 
1,4-
dioxane 
110 °C, µW, 4 h No reaction 
 
The reaction, after 4 hours, generated no new spots. A similar reaction was 
successfully utilized for palladium catalyzed amination reaction of chloroanthracenes and 
chloroanthraquinones.246 Due to commercial availability of 2-amino-6-
bromobenzaldehyde 282b and reduction in the number of steps involved in the synthesis, 
further optimization studies were carried out using 5-bromo-3-pentylquinolin-2-amine 
281b or its pivaloyl protected intermediate 285.  
Scheme 49. Attempted synthesis of 190 using intermediate 281b 
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Table 4. Reaction conditions for Pd-catalyzed coupling reaction on 281b 
S. No. Catalyst Ligand Base Solvent Temperature Result 
1 RuPhos Pd G3 
1 mol% 
RuPhos 
1 mol% 
NaOtBu 
2.5 eq 
THF 85 °C, 24 h No reaction 
2 RuPhos Pd G3 
2 mol% 
RuPhos 
2 mol% 
NaOtBu 
2.0 eq 
1,4-
dioxane 
110 °C, 24 h No reaction 
3 SPhos Pd G1 
2 mol% 
SPhos 
2 mol% 
NaOtBu 
2.0 eq 
1,4-
dioxane 
110 °C, 24 h No reaction 
4 XPhos Pd G3 
2 mol% 
XPhos 
2 mol% 
NaOtBu 
1.5 eq 
1,4-
dioxane 
110 °C, 24 h No reaction 
5 XPhos Pd G3 
2 mol% 
XPhos 
2 mol% 
Cs2CO3 
1.5 eq 
tert-
butanol 
110 °C, 24 h No reaction 
 
 In another attempt to synthesize 190, 5-bromo-3-pentylquinolin-2-amine 281b was 
reacted with 4-methoxy-N-methylaniline 259 under a variety of reaction conditions by 
varying the precatalysts (RuPhos Pd G3/SPhos Pd G1/XPhos Pd G3), ligands 
(RuPhos/SPhos/XPhos), base (NaOtBu/Cs2CO3), solvent (THF/1,4-dioxane/tert-butanol) 
and temperature. However, none of the above mentioned reactions gave a new spot on 
TLC.247, 248  
Scheme 50. Attempted synthesis of 190 using intermediate 285 
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Table 5. Reaction conditions for Pd-catalyzed coupling reaction on 285 
S. No. Catalyst Ligand Base Solvent Temperature Result 
1 Pd2(dba)3 
2 mol% 
SPhos 
8 mol% 
LiHMDS 
3.2 eq 
toluene 80 °C, 20 h Dimer 287 
2 Pd2(dba)3 
2 mol% 
RuPhos 
8 mol% 
LiHMDS 
3.2 eq 
toluene 80 °C, 20 h Dimer 287 
3 Pd(dba)2 
4 mol% 
BINAP 
4 mol% 
Cs2CO3 
1.8 eq 
THF 75 °C, 12 h No reaction 
4 Pd(dba)2 
4 mol% 
BINAP 
4 mol% 
Cs2CO3 
1.8 eq 
THF 75 °C, µW, 3 h No reaction 
5 Pd2(dba)3 
2 mol% 
SPhos 
8 mol% 
Cs2CO3 
1.8 eq 
THF 85 °C, µW, 4 h No reaction 
6 Pd2(dba)3 
2 mol% 
SPhos 
8 mol% 
NaOtBu 
1.8 eq 
THF 85 °C, µW, 4 h Dimer 287 
7 Pd2(dba)3 
2 mol% 
SPhos 
8 mol% 
LiHMDS 
2.5 eq 
THF 65 °C, 16 h No reaction 
8 Pd2(dba)3 
2 mol% 
DavePhos 
8 mol% 
LiHMDS 
2.5 eq 
THF 65 °C, 24 h No reaction 
9 XPhos Pd G3 
1 mol% 
SPhos 
1 mol% 
NaOtBu 
1.2 eq 
1,4-
dioxane 
110 °C, 24 h Dimer 287 
 
Amination of pivaloyl protected intermediate 285 with 
tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) catalyst with ligands SPhos or 
RuPhos in the presence of strong bases such as LiHMDS (entries 1 and 2, Table 5) led to 
the formation of dimer 287 (1H NMR indicated protons at 6.48 ppm, 1H, NH and 6.59 ppm 
2H, NH2 both of which were exchangeable in D2O).
96 Using another set of reaction 
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conditions with Pd(dba)2 and BINAP as a ligand did not succeed (entries 3 and 4).
249 
Changing the catalyst back to Pd2(dba)3 and by using different bases in THF led to no 
reaction in entry 5 and formation of dimer entry 6. By using LiHMDS under low 
temperature conditions (entry 7) did not form the dimer as seen in entry1.250 Use of 
DavePhos as a ligand under similar reaction conditions failed to give any product (entry 
8).251  In addition, reaction in the presence of NaOtBu with XPhos Pd G3 catalyst led to 
the formation of dimer 287. 
Scheme 51. Synthesis of N-(5-((4-methoxyphenyl)amino)-3-pentylquinolin-2-
yl)pivalamide 288 
 
Activated palladium precatalysts (XPhos Pd G3, RuPhos Pd G3 and SPhos Pd G1) 
offer an advantage as they are air moisture stable Pd(II) sources which readily form ligated 
Pd(0) in situ when exposed to base.248 In addition, XPhos is used as a preferred ligand for 
amination of primary amines/anilines, whereas, SPhos or RuPhos are preferred ligands for 
amination of secondary amines/anilines.252 To test the precatalyst, intermediate 285 
(Scheme 51) was reacted with p-anisidine 270 (primary aniline) in the presence of XPhos 
Pd G3 precatalyst which gave a new spot on TLC (Rf = 0.61 in 10:1 CHCl3/MeOH). 
1H 
NMR of 288 confirmed the formation of the desired product as it indicated presence of 4´-
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OMe at 3.72 ppm as a singlet accounting for three protons and the aniline aromatic peaks 
at 6.87-6.89 ppm and 7.04-7.06 ppm as doublets accounting for four protons. 
Scheme 52. Attempted synthesis of target compound 286 using precatalysts 
 
Table 6. Reaction conditions for Pd-catalyzed coupling reaction on 285 
S. No. Catalyst Ligand Base Solvent Temperature Result 
1 RuPhos Pd G3 
2 mol% 
RuPhos 
2 mol% 
NaOtBu 
2.5 eq 
1,4-dioxane 110 °C, 24 h 281b 
2 SPhos Pd G1 
2 mol% 
SPhos 
2 mol% 
NaOtBu 
2.5 eq 
1,4-dioxane 110 °C, 24 h 281b 
3 RuPhos Pd G3 
2 mol% 
RuPhos 
2 mol% 
Cs2CO3 
2.0 eq 
tert-butanol 110 °C, 24 h 281b 
 
 Considering that the reaction conditions with XPhos Pd G3 in Scheme 51 worked 
for amination with p-anisidine, RuPhos Pd G3 and SPhos Pd G1 were used for amination 
of secondary aniline (Scheme 52, Table 6) which, however, gave deprotected 281b as the 
product after 24 h (entry 1-3). 
 In a final attempt intermediate 285 was reacted with 4-methoxy-N-methylaniline 
259 using XPhos Pd G3 with Cs2CO3 as a base in tert-butanol to give the aminated 
intermediate 286 in 55 % crude yield. Subsequent base hydrolysis of the pivaloyl group 
yielded the desired compound 190 in 83% yield. 
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Scheme 53. Synthesis of target compound 190 
 
 
It was of further interest to mechanistically determine the reason as to why RuPhos 
(Figure 58) and SPhos based precatalysts, which are conventionally used for aminations of 
secondary amines/anilines did not work for the 2,5-diaminoquinoline scaffold and the 
reason why XPhos Pd G3 worked in the palladium catalyzed amination reactions. 
Therefore, further mechanistic studies of the Pd-catalyzed cross coupling reactions with 
precatalysts were carried out. 
 
 
Figure 58. Structures of ligands used in Pd-catalyzed cross coupling reactions 
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Figure 59. Proposed mechanism of SPhos.Pd-catalyzed amination of chlorobenzene with 
dimethylamine (modified from ref. 150). 
 The catalytic cycle in Pd-catalyzed cross coupling reactions begins with the 
formation of an active ligand.Pd complex. The ligand.Pd complexes prior to oxidative 
addition have geometries which favors Pd-O interaction (in the case of SPhos, interaction 
of Pd with OMe group) or Pd-arene interaction (in the case of XPhos, interaction with the 
aromatic ring). These interactions provide stability to the palladium complex and increase 
the electron density at the palladium center.253 The oxidative addition of aryl halides results 
in formation of active Pd(II) complexes with the Pd center saturated with four ligands: the 
phosphorus center, the aryl group, the halide group, and a Pd-arene interaction with the 
ipso carbon of the lower aryl ring (Figure 59).254 The oxidative addition complex has the 
chloride atom trans to the phosphorus atom. For the favorable binding of the amine 
(dimethylamine), rotation of the Pd(II) complex about the C-P bond of the upper aryl ring 
occurs, which makes the subsequent deprotonation by base more facile due to a lack of 
steric bulk from the lower aryl ring. Once the deprotonation has taken place, the C-P bond 
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again rotates back to establish the Pd-arene interaction with the ipso carbon and the steric 
bulk of the lower aryl ring forces the aryl and the amido ligand in closer proximity such 
that it can more closely resemble the transition state for reductive elimination.254 
 Based on the above mentioned mechanistic pathway, two steps, namely, oxidative 
addition and reductive elimination were probed for their involvement in the failure of the 
amination of the 2,5-diaminoquinoline scaffold with secondary anilines in the presence of 
RuPhos and XPhos based precatalysts.   
 It has been suggested that the electronic properties of the lower aryl ring strongly 
influence the rate of reductive elimination.255 XPhos with its isopropyl group in the lower 
aryl ring is considered electron-deficient, as this substitution does not donate electron 
density into the π-system. On the other hand, RuPhos with isopropoxy substitution is 
considered as an electron-rich ligand as the oxygen lone pair can easily donate electron 
density into the π-system of the lower aryl ring.255 For the RuPhos.Pd complex (Figure 60), 
the Pd center in the reductive elimination complex can be stabilized by interaction with the 
ipso carbon as well as the interaction with the oxygen atom of the isopropoxy group in 
RuPhos. However, for XPhos the Pd center is stabilized by interaction with the ipso carbon 
only. The additional stabilization of the RuPhos.Pd complex could therefore prevent 
reductive elimination with the use of RuPhos precatalyst. In addition, the bulky isopropyl 
groups in XPhos can promote reductive elimination by forcing the arene and amido group 
in close proximity to each other. This could result in the formation of the desired coupled 
product with the use of XPhos precatalyst.  
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Figure 60. Reductive elimination complexes of 2,5-diaminoquinolines and 4-methoxy-N-
methylaniline with RuPhos.Pd complex and XPhos.Pd complex. PG(protecting group) 
 The use of RuPhos, however, did not yield the desired product. In addition, no 
dehalogenated side product was obtained in any of the reactions involving the use of SPhos 
or RuPhos, which suggested that the problem probably exists in the oxidative addition step 
of the catalytic cycle. 
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Figure 61. Formation of the oxidative addition complex of 285 with RuPhos precatalyst. 
To analyze the formation of the oxidative addition complex with RuPhos Pd G3 
precatalyst (Figure 61), compound 285 was reacted with stoichiometric quantities of the 
RuPhos Pd G3 precatalyst and RuPhos ligand under the same reaction conditions 
mentioned above (Cs2CO3, tert-butanol).
252 
 
 
 
 
 
 
 
Figure 62. TLC of oxidative addition reaction of compound 285 with precatalysts 
When the reaction was carried out with RuPhos precatalyst at 40 °C for 5 min, the 
TLC shows that after the reaction was stopped starting material was still present (Figure 
62, left). The same trend was observed when the reaction was carried out at 100 °C for 5 
min, with RuPhos precatalyst (Figure 62, middle). However, when the same reaction was 
40 
o
C, 5 min, RuPhos Pd G3 100 
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carried out with XPhos precatalyst (Figure 62, right), almost complete conversion of 
compound 285 to new spot was seen on the TLC at 100 °C. 
 These set of experiments suggest that the reaction of compound 285 with 4-
methoxy-N-methylaniline 259 in the presence of RuPhos precatalyst failed due to a low 
rate of oxidative addition when compared to that observed with the use of XPhos 
precatalyst. However, no characterization was carried out to determine the structural 
identity of the new spot seen on TLC. 
Scheme 54. Synthesis of target compounds 186-191 
 
 As mentioned for compound 190 above (Scheme 53), the synthesis of compounds 
186-189 was achieved via condensation of benzaldehyde 282b with alkylnitrles (289a-d) 
in the presence of potassium tert-butoxide under modified Friedlander synthesis, which 
were subsequently protected with pivalic anhydride  to yield the 5-bromo-3-alkylquinolin-
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2-amines 290a (3-Me: 50%), 290b (3-Et: 36%), 290c (3-Pr: 33%),  and 290d (3-Bu: 24%). 
Further palladium catalyzed cross coupling aminations using XPhos Pd G3 precatalyst, 
XPhos ligand in the presence of Cs2CO3 as base in tert-butanol led to aminated products 
186 (20%), 291b (60%, crude yield) 291c (59%, crude yield) and 291d (40%, crude yield). 
Due to the relatively less bulky methyl group at the 3-position in 290a, microwave 
irradiation conditions were feasible to afford deprotection of the pivaloyl group to yield 
186 directly. For the bulkier substitutions in compounds 290b-d, the amination led to the 
pivaloyl protected compounds 291b-d, which were subsequently hydrolyzed under basic 
conditions to afford target compounds 187-189.  
Scheme 55. Synthesis of target compounds 191 
 
 Similarly, target compound 191 was synthesized in 64% yield via the palladium 
catalyzed amination reaction of 290a with p-anisidine 270. 
 
Synthesis of thieno[2,3-d]pyrimidines 192-210 
 The synthesis of 192-210 were accomplished as shown in Scheme 56. Reaction of 
acetone 292 with malononitrile and sulfur in the presence of morpholine was initially 
carried out according to the general procedure of Gewald and coworkers256 which gave 
very low yield of 11%. Optimization studies were carried out to synthesize the thiophene 
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293 using different bases in DMF (imidazole, 0.1 equivalent, 10%; morpholine, 0.1 
equivalent, 15%; L-proline, 0.1 equivalent, 23%; L-lysine, 0.1 equivalent, 42%).257  
Scheme 56. Synthesis of target compounds 192-210 
 L-lysine was chosen as the base for the synthesis of thiophene aminonitrile 293, 
which was subsequently condensed with chlorformamidine hydrochloride 294 in DMSO2 
to give the key thieno[2,3-d]pyrimidine intermediate 295 in 73% yield.213 Synthesis of 
target compounds 192-210 (6-61%) was accomplished by reacting 1 equivalent of 295 with 
2 equivalents of substituted benzenethiol under oxidative thiolation conditions in the 
presence of iodine.258 The oxidative thiolation process was confirmed by disappearance of 
the C6 proton 6.51 ppm and the appearance of suitable aromatic protons for compounds 
192-210. Compounds 192, 195, 196, 199, and 203 have been synthesized previously and 
tested for pcDHFR inhibitory activity.259 They were resynthesized to determine the 
pjDHFR inhibitory activities. 
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Scheme 57. Synthesis of substituted benzenethiols from anilines 
 Benzenethiols 299a-c were not available commercially and were therefore 
synthesized from the precursor anilinies (297a-c)via diazotization and displacement of 
nitrogen using potassium ethyl xanthate to afford intermediate O-ethyl S-aryl 
carbonodithioate 298a-c, which were subsequently hydrolyzed under basic conditions to 
afford the benzenethiols 299a-c.260 
Scheme 58. Attempted synthesis of 211  
 
 An attempt to synthesize 301 (Scheme 58) using 2-butanone 300 under Gewald 
reaction as mentioned above in Scheme 56 led to formation of a mixture of 301 and 301a 
(301/301a 1:5.6 ratio as determined from 1H NMR). Since it was difficult to obtain pure 
301, further synthesis of compound 211 was not carried out. It was of interest to determine 
the mechanism of formation of thiophenes 301 and 301a. 
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Figure 63. Mechanism for the formation of 301 and 301a 
 The formation of critical intermediate ‘vi’ (Figure 63) in the base catalyzed 
mechanism for the Gewald reaction results in the formation of two products when an 
asymmetrical ketone, 2-butanone 300 is used. Abstraction of the proton in ‘vi’ by the base 
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to generate a less stable, primary anion ‘vii’ results in the formation of the desired 
thiophene 301. On the other hand, the abstraction of a proton by the base to form a more 
stable secondary carbanion in ‘x’ eventually results in the formation of thiophene 301a in 
higher proportion. 
Scheme 59 Synthesis of desired compound 212 
 3-amino-4-isopropylthiophene-2-carbonitrile 303 was obtained via Gewald 
synthesis on 3-methylbutan-2-one 302 in 52% yield (Scheme 59). Subsequent cyclization 
using chlorformamidine hydrochloride 294 gave the thieno[2,3-d]pyrimidine 304 (85%). 
Iodination of 304 with N-iodosuccinimide (NIS) was carried out in the presence of acetic 
acid to yield 6-iodo-5-isopropylthieno[2,3-d]pyrimidine-2,4-diamine 305 (75%) as 
indicated by the disappearance of the 6-H peak at 6.52 ppm in 304.261 Ullman coupling of 
the iodo derivative 305 with the naphathalene-2-thiol 306 resulted in the formation of 212 
(25%).262 Under microwave irradiation conditions, at 180 °C for 45 min resulted in 
dehalogenation (50% dehalogenated compound, 50 % desired compound, as observed on 
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TLC). However if the reaction is carried out at 150 °C for 90 min less than 10% of the 
dehalogenated product is observed on TLC. For biological activities of 192-210 see 
Appendix Table 14, pg 222. 
 
Molecular modeling studies in the colchicine site of tubulin 
Pyrimido[4,5-b]indoles 
 
Table 7. Biological activities of compounds 213-220213 
Compd 
EC50 for microtubule 
depolymerization (nM) 
MDA-MB-435 
IC50 ± SD  (nM) 
EC50/IC50 Ratio 
213a 130 14.7 ± 1.5 8.8 
214 130 33.9 ± 3.4 3.8 
215 1200 130 ± 7.8 9.2 
216 1100 89.1 ± 10 12 
217 1400 220 ± 25 6.5 
218 No effects up to 40 µM 3,900 ± 200 - 
219 150 54.4 ± 4 2.8 
220 3700 271 ± 4 15 
paclitaxelb - 4.5 ± 0.5 - 
CA-4b 9.8 4.4 ± 0.5 2.2 
aResults previously published.263 
b
Results previously published.212 
Docking studies were performed for compounds 213-220 to rationalize the 
biological activities observed for the pyrimido[4,5-b]indoles as shown above (Table 7). 
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Protein and ligand preparation and docking validation213 
 The X-ray crystal structure of colchicine in tubulin (PDB: 4O2B)152 was obtained 
from protein database (PDB) and imported into Molecular Operating Environment (MOE 
2013.0801).134 Default settings were used for the protein preparation using LigX function 
and Amber99 forcefield. After the preparation of the protein using the LigX function, 
chains C, D, E, and F were deleted along with Ca2+, Mg2+, GDP, GTP, and the active site 
was defined using colchicine as the reference ligand.  Ligands were sketched in MOE 
(MOE 2015.10) using the builder function and minimized using Amber10:EHT forcefield. 
The ligands were then docked into the colchicine binding site using Triangle Matcher 
placement method and scored using London dG. The refinement was carried out Rigid 
Receptor and scored using GBVI/WSA dG function, under default settings. 
 To validate the docking study, colchicine was redocked in the binding site using 
the same set of parameters specified above and generated a docked pose with a rmsd of 
0.34 Å.  
The pyrimido[4,5-b]indole scaffold of 213, 214 and 215 (Figure 64) overlaps with 
the C-ring of colchicine and undergoes hydrophobic interactions with residues Alaα180, 
Valα181, Leuβ248, Asnβ258, Metβ259, Thrβ314 and Lysβ352. The N4-Me group interacts 
with Leuβ248 and Alaβ354, whereas, the N4-aryl moiety undergoes hydrophobic 
interactions with Cysβ241, Alaβ250, Leuβ255, and Alaβ316 and overlaps with ring A of 
colchicine. The 4'-OMe group superimposes with the 3-OMe group in colchicine and is 
oriented towards residues Cysβ241, Leuβ242 and Leuβ255 in the binding pocket. The 2-
NH2 of 213 makes a H-bond interaction with HOH623. The 2-Me group in 214 retains 
hydrophobic interactions with Leuβ248 (3.90 Å) and Serα178 (3.99 Å), however, for 
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compound 215, the 2-H group is incapable of making a H-bond with HOH623 or 
undergoing hydrophobic interactions with the surrounding residues, which could explain a 
10fold loss in both the IC50 and EC50 compared to 213 with its 2-NH2 moiety. 
  
Figure 64. Superimposition of the docked poses of 213 (black), 214 (green) and 215 
(magenta) in the colchicine (pink) binding site of tubulin (PDB ID: 4O2B).213  
 The best docked poses of 213, 214 and 215 were scored at -7.08 kcal/mol, -7.18 
kcal/mol and -6.84 kcal/mol, respectively, which suggested slightly lower affinity of 215 
when compared to 213 and 214 in the colchicine site. 
Similar to compound 215, 217 also results in almost 10-fold loss in the EC50 value and 
almost 16-fold loss in IC50 value when compared to 213 (Table 4). To explain the observed 
activity the docked poses of 213 and 217 were superimposed (Figure 65). 
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Figure 65. Superimposition of the docked poses of 213 (black) and 217 (cyan) in the 
colchicine (pink) site of tubulin (PDB ID: 4O2B). Hydrophobic surface is in green and 
hydrophilic surface is in pink.213 
 The key binding interactions of 213 as shown above in Figure 64 were retained by 
217 and the 2-NH2 afforded H-bond interactions with HOH606. Examining the lipophilic 
surface area of the pocket (Figure 65), the lower activities of compounds 217 and 218 (not 
shown), can be rationalized, in part, on the basis of the small hydrophobic pocket where 
the 5-Me and 5-Cl groups of 217 and 218, respectively, bind in the site. This hydrophobic 
pocket is lined by residues Metβ259, Alaβ316 and Lysβ352 which could result in steric 
hindrance and hence lower the activities of 217 and 218 compared to 213. The docked 
score of 217 and 218 were -5.96 kcal/mol and -6.26 kcal/mol, respectively, which was 
worse than the best docked pose of 213 (-7.08 kcal/mol). 
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Cyclopenta[d]pyrimidines 
Docking studies were performed for compounds 221-234 to rationalize the 
biological activities observed for the cyclopenta[d]pyrimidines synthesized in the Gangjee 
lab as shown below (Table 8).  
Table 8. Biological activities of compounds 221-234148 
Compd 
EC50 for microtubule 
depolymerization (nM) 
MDA-MB-435 
IC50 ± SD (nM) 
EC50/IC50 Ratio 
221 25.9 7.0 ± 0.7 3.7 
222 5,560 667 8.3 
223 12.6 4.6 ± 0.5 3 
224 40 8.2 ± 0.62 4.9 
225 31 7.9 ± 0.49 3.9 
226 >10,000 ND - 
227 45 20 ± 1.9 2.25 
228 5,116 1,258 4.1 
229 70 12.1 ± 0.9 5.8 
230 56 18.4 ± 1.9 3.0 
231 >10,000 ND - 
232 11,300 450.0 ± 13.5 25 
233 >10,000 ND - 
234 >10,000 ND - 
CA-4 13.0 3.4 ± 0.6 3.8 
 
Protein and ligand preparation and docking validation 
The X-ray crystal structure of colchicine in tubulin (PDB: 4O2B)152 was obtained 
from protein database and imported into Molecular Operating Environment (MOE 
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2016.08).134 Default settings were used for the protein preparation using QuickPrep 
function and Amber10:EHT forcefield. After the preparation of the protein using the 
QuickPrep function, chains C, D, E, and F were deleted along with Ca2+, Mg2+, GDP, GTP, 
and the active site was defined using colchicine as the reference ligand. Ligands were 
sketched in MOE (MOE 2016.08) using the builder function and minimized using 
Amber10:EHT forcefield. The ligands were then docked into the colchicine binding site 
using Triangle Matcher placement method and scored using London dG. The refinement 
was carried out using Induced Fit, the side chain was set free, cutoff was increased to 8 Å 
and radius offset was set to 0.6. 
 To validate the docking study, colchicine was redocked in the binding site using 
the same set of parameters specified above and generated a docked pose with a rmsd of 
0.36 Å.  
  
Figure 66. Superimposition of the docked poses of 221 (green), 225 (orange) and 
colchicine (pink) in the colchicine binding site of tubulin (PDB ID: 4O2B).  
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 The docked poses of compounds 221 and 225 are shown as representative examples 
of the mode of binding mode of the cyclopenta[d]pyrimidines 221-234. The 
cyclopenta[d]pyrimidine scaffold undergoes hydrophobic interactions with Alaα180, 
Valα181, Asnβ258, Metβ259 and Lysβ352. The N4-Me group in both 221 and 225 interacts 
with Alaα180, Valα181, Asnβ258, Metβ259 and Lysβ352 and superimposes on the B-ring 
of colchicine. The N4-phenyl moiety undergoes hydrophobic interaction with Leuβ248, 
Alaβ250, Leuβ255 and Alaβ316 and superimposes on the A-ring of colchicine. The 4'-
OMe group in 221 superimposes with the 2-OMe in colchicine and  interacts with residues 
Valβ238, Cysβ241, and Ileβ378 and lies within H-bond distance with HOH728 near 
Cysβ241 (3.0 Å). In compound 225, the 4'-SOMe group undergoes H-bond interaction with 
HOH728. Compounds 221 and 225 had docked scores of -7.91 kcal/mol and -8.19 
kcal/mol, respectively. Compounds 222 and 226 failed to dock, suggesting that these 
compounds may show reduced binding at the colchicine site.  
  
A B 
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Figure 67 A. Electrostatic surface of the colchicine binding site pocket in tubulin. B. 
Electrostatic surface map of colchicine. C. Electrostatic surfaces of the compounds 221-
228. Red surface indicates electron rich surface, blue surface indicates electron deficient 
surface, and white surface represents hydrophobic surface. 
 The docking studies performed on compounds 221-234, except 222 and 226, 
suggested these compounds to be potent inhibitors of tubulin. To rationalize the low 
activities observed for compounds 222, 226, 227 and 228, an electrostatic surface map was 
generated for the colchicine site pocket, colchicine and compounds 221-228 using 
MOE2016.08. The blue surface observed for the colchicine pocket (Figure 67A) signifies 
an electron deficient surface and suggests that compounds like colchicine which have 
electron rich methoxy substituents will show surface complementarity (red surface, figure 
67B) and will bind more favorably. This was well corroborated by the activities of 
compounds 221, 223, 224 and 225 which, like colchicine, have electron rich surfaces. The 
4'-SO2Me in 226 makes the aryl ring highly electron deficient. In addition, the carbonyl 
backbone of Cysβ241, Valβ248 and Aspβ251 lead to an unfavorable interaction with the 
sulfone group and is probably the reason for the failure of this compound to dock in the 
colchicine site and reflects its inactivity. 
 The low activities of 222 (compared to 221), 227 and 228 (compared to 225) can 
also be rationalized based on the electrostatic surface complementarity (Figure 67C).  The 
presence of a H-bond donor at the 4´-position in 222, 227 and 228 (circled blue surfaces in 
Figure 67C) can result in an unfavorable interaction in an already electron deficient region 
of the binding site and may provide an explanation of the poor activity of these compounds 
compared to lead compound 221. Targeting electrostatic surface complementarity has been 
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successfully utilized in obtaining target selective compounds264 and based on the above 
discussion can also be used to explain the biological activities of compounds 221-228. 
 The above-mentioned premise, however, was not sufficient to justify the inactivity 
of conformationally flexible compounds 230-234 which had electron rich substituents at 
the 4'-position. To justify the observed activities, a conformational search for compounds 
221-234 was carried out using MOE2016.08 within 7 kcal/mol using the default settings. 
Table 9. Conformations generated for compounds 221-234 using MOE2016.08. 
Compd No. of conformations 
within 7 kcal/mol 
Compd No. of conformations 
within 7 kcal/mol 
221 4 228 2 
222 2 229 4 
223 4 230 4 
224 5 231 42 
225 4 232 34 
226 4 233 36 
227 8 234 34 
 
 Comparing the low energy conformations (within 7 kcal/mol) for 221-234, 
compounds 221-230 show very low number of conformations (2-8). However, the 
conformationally flexible compounds 231-234 had 5 to 21 -fold greater number of 
conformations. Such increased conformational flexibility can prove to be detrimental for 
these compounds to adopt the bioactive conformation and therefore could be responsible 
for in the low activities of these compounds.  
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Molecular modeling studies in the colchicine site of tubulin and multiple receptor 
tyrosine kinases (EGFR, VEGFR-2 and PDGFR-β) 
 
5-Methyl-N-(substituted)-furo[2,3-d]pyrimidin-4-amines 
Docking studies were performed for compounds 236-246 to rationalize the 
biological activities observed for the furo[2,3-d]pyrimidines as shown below (Table 10).  
Table 10. Biological activities of compounds 236-246212, 231 
Compd IC50 ± SD 
(MDA-MB-435) 
(nM) 
EC50 for MT 
depolymerization 
Inhibition of 
EGFR (nM) 
Inhibition of 
VEGFR-2 
(nM) 
Inhibition of 
PDGFR-β 
(nM) 
236 ND > 10 µM 283.1 ± 40.0 38.1 ± 4.2 57.3 ± 8.0 
237 4.3 ± 0.3 24 nM 15.5 ± 2.0 9.3 ± 0.72 12.3 ± 2.0 
238 17.1 ± 1.5 103 nM 68. 2 ± 6.2 19.1 ± 3.0 22.8 ± 4.9 
239 8.1 ± 0.5 53 nM 92.5 ± 9.9 67.3 ± 6.9 51.4 ± 7.2 
240 504 ± 28 > 10 μM 10.1 ± 0.91 23.4 ± 4.1 42.6 ± 5.6 
241 27.3 ± 4.5 306 nM 7.1 ± 0.74 12.0 ± 1.6 38.9 ± 6.6 
242 183 ± 13  750 nM 4.0 ± 0.39 7.8 ± 0.94 28.9 ± 4.0 
243 12.3  ± 0.9 45 nM 7.2 ± 0.81 13.6 ± 2.0 62.2 ± 9.6 
244 ND 240 nM 6.4 ± 0.97 12.7 ± 1.8 57.8 ± 9.9 
245 ND 140 nM 3.1 ± 0.06 15.6 ± 2.2 63.0 ± 10.7 
246 ND > 10 μM >200 >200 >200 
ND = Not Determined 
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Protein and ligand preparation and docking validation in the colchicine binding site 
on tubulin212 
The X-ray crystal structure of colchicine in tubulin (PDB: 4O2B)152 was obtained 
from protein database and imported into Molecular Operating Environment (MOE 
2013.0801).134 The protein was prepared using LigX function and Amber99 forcefield 
under default settings for protein minimization. After the preparation of the protein using 
the QuickPrep function, chains C, D, E, and F were deleted along with Ca2+, Mg2+, GDP, 
GTP, and the active site was defined using colchicine as a reference ligand. Ligands were 
sketched using the builder function in MOE and minimized using MMF94x forcefield. The 
ligands were then docked in the binding site using the Alpha triangle placement method. 
Refinement was carried out using Forcefield and scored using the Affinity dG scoring 
system. 
To validate the docking study, colchicine was redocked in the binding site using 
the same set of parameters specified above and generated a docked pose with a rmsd of 
0.53 Å.  
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Figure 68. Superimposition of the docked pose of 237 (green) in the colchicine site 
(colchicine in orange) of tubulin (PDB: 4O2B).212 
 Compounds 236-246 were docked in the colchicine binding site of tubulin and the 
docked pose of 237 in the colchicine site is shown as a representative example for this 
series (Figure 68). The furo[2,3-d]pyrimidine scaffold forms hydrophobic interactions with 
Alaα180, Asnβ258 and Lysβ352 and overlaps the C-ring of colchicine. The 5-Me group of 
237 lies in a pocket lined by residues Leuβ255, Asnβ258 and Metβ259. The N4-Me moiety 
of 237 mimics the bridged C5- and C6-positions of the B-ring of colchicine and interacts 
with Leuβ248, Alaβ250 and Lysβ254. The N4-phenyl group superposes on to the A-ring of 
colchicine and interacts with Leuβ248, Leuβ255, Alaβ316 and Alaβ354, the 4´-OMe is 
oriented towards hydrophobic pocket lined by residues Thrβ240, Cysβ241, Alaβ316, 
Ileβ318 and Ileβ378.  
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Protein and ligand preparation and docking validation in RTKs 
Compounds 236-246 were docked in the reported X-ray crystal structures of EGFR 
(PDB: 4JQ7, 2.73 Å)265, VEGFR-2 (PDB: 4AG8, 1.95 Å)187 and in the homology model 
of PDGFR-β233 using Molecular Operating Environment (MOE 2016.10). The crystal 
structures of EGFR and VEGFR-2 were obtained from the protein database and imported 
into MOE 2016.10. The proteins were prepared using the QuickPrep function and the 
Amber10:EHT forcefield for energy minimization under default settings. Ligands were 
sketched using the builder function in MOE and minimized using Amber10:EHT 
forcefield. The ligands docked in the binding site of EGFR were placed using Alpha 
Triangle and scored using Affinity dG. The refinement was carried out using Rigid 
Receptor and scored using GBVI/WSA dG. The ligands were docked in the binding site of 
VEGFR-2 using a different protocol. The placement was carried using Alpha Triangle and 
scored using Affinity dG. The refinement was carried out using Induced Fit and scored 
using GBVI/WSA dG. The side chain was set free, cutoff was increased to 8 Å and radius 
offset was set to 0.6. For docking in PDGFR- β the placement was carried out using 
Triangle Matcher and scored using London dG. The refinement was carried out using Rigid 
Receptor and scored using GBVI/WSA dG. 
To validate our docking studies, the co-crystallized ligands were re-docked into the 
binding sites of EGFR and VEGFR-2, respectively, using the same set of parameters as 
described above. The rmsd of the best docked pose of co-crystallized ligands in EGFR 
and VEGFR-2 were 0.22 Å and 0.76 Å, respectively, thus validating the docking. 
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Figure 69. Superimposition of docked pose of 237 (green) and 238 (magenta) in the ATP-
binding site of EGFR (PDB: 4JQ7). 
 The docked poses of compounds 239-246 docked at the binding site of EGFR 
similar to lead compound 237, which was compared with binding mode for another lead 
compound 238 (Figure 69). The furo[2,3-d]pyrimidine scaffold of 237 forms hydrophobic 
interactions with Leu694, Ala719 and Leu820 and binds at the hinge region of the ATP 
binding pocket via H-bonding interactions of N1 with backbone NH of Met769 and N3 
with HOH2015. The N4-phenyl substitution is oriented towards pocket lined by residues 
Phe699, Val702, Leu820, Thr830, and carbon atoms of Arg817. The docked conformation 
of 238 is slightly different due to the presence of 2-Me substitution, which prevents it from 
making the hinge region binding interaction with Met769, but otherwise retains similar 
interactions as 237 in the binding site. The docked scores for 237 and 238 were -6.08 
kcal/mom and -5.94 kcal/mol respectively. 
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Figure 70. Superimposition of docked pose of 237 (green) and 238 (magenta) in the ATP-
binding site of VEGFR-2 (PDB: 4AG8). 
Figure 62 shows the docked poses of compounds 237 and 238 in the ATP binding 
site of VEGFR-2 (PDB: 4AG8). Due to presence of steric bulk of the 2-Me group in 238, 
the scaffold binds in a flipped mode when compared to the scaffold in 237. The furo[2,3-
d]pyrimidine scaffold in 237 binds at the hinge region of ATP binding pocket in VEGFR-
2 via H-bonding of N1 with backbone NH of Cys919. Additional interactions of the 
scaffold are formed with hydrophobic residues Leu840, Ala866 and Leu1035 with the 5-
Me group oriented towards Phe1047. The N4-phenyl substitution lies in a hydrophobic 
pocket formed by residues Leu889, Val914, Val916, Cys1045 and carbon atoms of Lys868. 
For compound 238, the alternate binding mode results in formation of H-bonding 
interaction of N1 with HOH2085. The docked scores for 237 and 238 were -8.17 kcal/mom 
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and -7.84 kcal/mol respectively. The docked poses of compounds 239-246 docked at the 
binding site of VEGFR-2 were similar to lead compound 237. 
  
Figure 71. Superimposition of docked pose of 237 (green) and 238 (magenta) in PDGFR-
β homology model. 
Docking in the PDGFR- β suggests that the furo[2,3-d]pyrimidine scaffold binds at 
the hinge region via H-bonding of N1 and O7 with backbone NH of Cys684 (Figure 71). 
The scaffold is additionally stabilized by interactions with Ala632, Tyr683 and Leu833. 
The N4-phenyl substitution lies in a hydrophobic pocket lined by residues Leu606, Val614, 
Val615 and Tyr683. Compound 238 binds in a different mode where the scaffold flips to 
accommodate the bulk at the 2-position. The docked scores of 237 and 238 were -6.13 
kcal/mol and -6.55 kcal/mol respectively. Compounds 239-246 docked at the active site of 
PDGFR-β with a similar binding mode. 
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Figure 72. A) Docked pose of 246 (magenta) in the ATP-binding site of EGFR. B) Docked 
pose of 246 (orange) in the ATP-binding site of VEGFR-2. Electrostatic surface of pocket, 
blue indicates electropositive regions, red indicates electronegative regions and white 
indicates lipophilic regions.  
 The loss of activity of the 4'-NO2 analog 246 (Table 10) in EGFR and VEGFR-2 
can be rationalized using Figure 64A and 64B. The docked pose of 246 in EGFR and 
VEGFR-2 are similar to those shown for compound 237 (Figures 69 and 70). In EGFR the 
4'-NO2 group lies in a highly electronegative pocket formed by the side chain carboxylate 
group of Asp831 and the backbone carbonyls of Arg817 and Asn818. Similarly, in 
VEGFR-2 the 4'-NO2 group lies in the electronegative pocket formed by the carboxylate 
group Glu885 and backbone carbonyl of Val914. These unfavorable interactions are 
reflected in the lower activity of 246 in EGFR and VEGFR-2. 
 
  
A B 
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7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines 
Docking studies were performed for compounds 249-256 to rationalize the 
biological activities observed for the pyrrolo[3,2-d]pyrimidines as shown below (Table 
11). 
Table 11. Biological activities of compounds 249-256185 
Compd Tubulin 
assembly 
IC50 (µM) ± SD 
[3H] Colchicine binding 
 % Inhibition ± SD 
5 µM inhibitor 
Inhibition of 
EGFR (nM) 
Inhibition of 
VEGFR-2 
(nM) 
Inhibition of 
PDGFR-β 
(nM) 
249 21 ± 1 ND 23.6 ± 5.8 21.3 ± 3.2 >200 
250 > 20 ND 1.1 ± 0.2 27.3 ± 5.1 8.1 ± 0.91 
251 > 20 ND 2.6 ± 0.42 26.7 ± 4.6 7.2 ± 0.9 
252 0.48 ± 0.008 92 ± 0.2 2.3 ± 0.30 33.0 ± 5.0 10.3 ± 1.7 
253 > 20 ND 167.1 ± 27.6 >200 >200 
254 3.3 ± 0.3 43 ± 3 33.6 ± 5.6 38.7 ± 7.1 90.3 ± 18.3 
255 0.91 ± 0.03 72 ± 2 4.9 ± 0.6 32.9 ± 4.9 30.2 ± 7.2 
256 13 ± 1 ND 47.1 ±5.0 84.3 ± 3.9 >200 
CA 1.2 ± 0.01 99 ± 0.3 ND ND ND 
Semaxinib ND ND ND 12.9 ND 
Sunitinib ND ND ND 18.9 ± 2.7 83.1 ± 10.1 
Erlotinib ND ND 1.2 ± 0.2 ND ND 
ND = Not Determined 
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Protein and ligand preparation and docking validation in the colchicine binding site 
in tubulin and RTKs185 
 Docking of compounds 249‒256 were performed using Molecular Operating 
Environment (MOE 2015.10) in the published X-ray crystal structures of colchicine in 
tubulin (PDB: 4O2B, 2.3 Å), gefitinib in EGFR (PDB: 4WKQ, 1.85 Å), axitinib in 
VEGFR-2 (PDB: 4AG8, 1.95 Å), and in a homology model of PDGFR-β. For tubulin, 
EGFR and VEGFR-2, the crystal structures were obtained from the protein database and 
imported into MOE 2015.10. The proteins were then prepared using the QuickPrep 
function and the Amber10:EHT forcefield for energy minimization under default settings. 
For preparation of tubulin, prior to setting up the protein for QuickPrep, chains C, D, E and 
F were deleted to reduce the time for protein preparation. After the preparation of the 
protein, Ca2+, Mg2+, GDP, GTP and all other bound ligands except for colchicine were 
deleted. Ligands were sketched using the builder function in MOE and minimized using 
Amber10:EHT forcefield. The ligands were docked in the binding site of tubulin, EGFR 
and PDGFR-β using a docking protocol to include the key interactions with water 
molecules in the binding site (for tubulin and EGFR). The placement was carried using 
Triangle Matcher and scored using London dG. The refinement was carried out using 
Induced Fit, the side chain was set free, cutoff was increased to 8 Å and radius offset was 
set to 0.6. The ligands were docked in the binding site of VEGFR-2 using the default 
settings in the docking protocol. The placement was carried using Triangle Matcher and 
scored using London dG. The refinement was carried out using Rigid Receptor and scored 
using GBVI/WSA dG. 
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 To validate our docking studies, the native ligands colchicine, axitinib and gefitinib 
were re-docked into the binding sites of tubulin, EGFR and VEGFR-2, respectively, using 
the same set of parameters as described above. The rmsd of the best docked pose of 
colchicine in tubulin, gefitinib in EGFR and axitinib in VEGFR-2 were 0.36 Å, 0.85 Å and 
0.51 Å, respectively, thus validating the docking. 
 
Figure 73. Superimposition of the docked pose of 249 (magenta) and colchicine (pink) in 
tubulin (PDB ID: 4O2B).185 
 Compounds 249-256 were docked in the X-ray crystal structure of colchicine in 
tubulin. The pyrrolo[3,2-d]pyrimidine scaffold partially occupies the region where the C-
ring of colchicine binds and undergoes hydrophobic interactions with Alaα180, Valα181, 
Leuβ248, Asnβ258 and Lysβ352. The N4-Me interacts with Leuβ255, Asnβ258, Metβ259 
and Alaβ316 and the N4-phenyl moiety interacts with Cysβ241, Leuβ248, Alaβ250, and 
Leuβ255 and superimposes with the A-ring of colchicine. The 4´-OMe group lies within 
H-bond distance with a water molecule (3.16 Å) present in the crystal structure in the 
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vicinity of Cysβ241. The benzylic group occupies a pocket lined by residues Serα178, 
Glnβ247, Leuβ248 and Lysβ352.  
  
Figure 74. A) Superimposition of docked pose of 249 (cyan) and 252 (orange) in the 
colchicine site of tubulin (PDB ID: 4O2B). B) Space fill view of selected residues (N5-Me 
of compound 252, Leuβ248 and Alaβ354) in the colchicine site of tubulin (PDB ID: 4O2B). 
The green surface indicates hydrophobic regions and the pink surface indicates hydrophilic 
region in the pocket.185 
 To rationalize the 40-fold improvement in the inhibition of tubulin assembly 
(comparing 249 and 252), the docked poses were superimposed and compared (Figure 66A 
and 66B). The N5-Me group in 252 makes additional hydrophobic interaction with 
Leuβ248 and Alaβ354. To compare the number of low energy conformations, a 
conformational search was carried out by a 1° rotation about the C4-N bond using Sybyl-X 
2.1.133 within 5 kcal/mol. Compound 249 afforded 111 conformers whereas 252 afforded 
53 conformers. Similar improvement in activity has been attributed to a combination of 
conformational, hydrophobic and desolvation effects afforded by introducing methyl 
groups.266 Therefore, improved binding of 252 over 249 could also be attributed, in part, 
A B 
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to the conformational restriction to the C4-N bond due to the presence of the N5-Me in 252 
and is absent in 249. 
 The 2-NH2 substituted compound 250 was proposed to improve the inhibitory 
potency at RTKs by undergoing H-bond interaction at the hinge region of RTKs. The 
observed inhibitory activity of 250 improved 23-fold for EGFR and >15 -fold for PDGFR-
β over 249 (Table 11).  
  
Figure 75. Docked pose of 250 (green) in the binding site of gefitinib (pink) in EGFR 
(PDB ID: 4WKQ).185 
The docked pose of 250 shows that the 2-NH2 group makes an additional H-bond 
interaction in the hinge region with the carbonyl backbone of Gln791, as predicted in the 
statement of the problem (Figure 75). 
Similar to the docked pose of 250 in EGFR, the 2-NH2 makes an additional H-bond 
interaction with Cys684 in the hinge region of PDGFR-β while retaining the other 
interactions at the binding site (Figure 76).  
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Figure 76. Docked pose of 250 (green) in the binding site of homology model of PDGFR-
β.185  
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V. EXPERIMENTAL 
All evaporations were carried out in vacuum with a rotary evaporator. Analytical 
samples were dried in vacuo in a CHEM-DRY drying apparatus over P2O5 at 50 °C. 
Melting points were determined either using a MEL-TEMP II melting point apparatus with 
FLUKE 51 K/J electronic thermometer or using an MPA100 OptiMelt automated melting 
point system and are uncorrected. Thin-layer chromatography (TLC) was performed on 
Whatman® PE SIL G/UV254 flexible silica gel plates or Sorbetch silica g TLC plates 
w/UV254 and the spots were visualized under 254 and 365 nm ultraviolet illumination. 
Proportions of solvents used for TLC are by volume. All analytical samples were 
homogeneous on TLC in at least two different solvent systems. Flash chromatography was 
carried out on the CombiFlash® Rf 200 (Teledyne ISCO) automated flash chromatography 
system with prepacked RediSep® Rf normal-phase flash columns (230 to 400 meshes) of 
various sizes were used. The amount (weight) of silica gel for column chromatography was 
in the range of 50-100 times the amount (weight) of the crude compounds being separated. 
Nuclear magnetic resonance spectra for proton (1H NMR) were recorded on the Bruker 
Avance II 400 (400 MHz) or Bruker Avance II 500 (500 MHz) NMR systems and were 
analyzed using MestReC NMR data processing software. The chemical shift values (δ ) are 
expressed in ppm (parts per million) relative to tetramethylsilane as an internal standard: 
s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quartet; m, multiplet; br, broad 
singlet; td, triplet of doublet; dt, doublet of triplet; quin, quintet. Elemental analyses were 
performed by Atlantic Microlab, Inc., Norcross, GA. Element compositions are within ± 
0.4% of the calculated values. Fractional moles of water or organic solvents frequently 
found in some analytical samples could not be prevented despite 24 to 48 hours of drying 
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in vacuo and were confirmed where possible by their presence in the 1H NMR spectra. 
Mass spectrum data were acquired on an Advion expressionS CMS system using the ESI 
probe. All solvents and chemicals were purchased from Sigma-Aldrich or Fisher Scientific 
and were used as received. 
 
N-(5,6-Dichloro-2-methylpyrimidin-4-yl)pivalamide (258) 
5,6-dichloro-2-methylpyrimidin-4-amine 257 (1.0 g, 5.62 mmol) was refluxed in pivalic 
anhydride (10 mL) for 12 h. Pivalic anhydride was then evaporated, hexanes was added to 
give a precipitate which was then filtered, washed with hexanes and dried to give 258 as 
white colored solid (1.43 g, 97%). TLC Rf = 0.87 (CH3OH: CHCl3; 1:10); mp, 105.1.1-
106.2 °C; 1H NMR, DMSO-d6 (400 MHz): 1.23 (s, 9 H, (CH3)3), 2.58 (s, 3 H, 2-CH3), 
10.34 (s, 1 H, exch, NH). The compound was carried on directly without further 
characterization. 
 
N-(5-Chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-4-
yl)pivalamide (260) 
Compound 258 (0.478g, 1.82 mmol) and 4-methoxy-N-methyl aniline 259 (0.3g, 2.19 
mmol) were added to a 2-5 mL Biotage microwave vial. 1,4-dioxane (3 mL) was added as 
the solvent and 1 drop of HCl was added. The reaction was run in a Biotage Initiator at 120 
°C for 1 hour. Silica gel was added, solvent was removed under reduced pressure and the 
crude product was purified by column chromatography using 10% MeOH in CHCl3 to 
yield light brown colored solid (0.067 g, 10%). TLC Rf = 0.62 (CH3OH: CHCl3; 1:10); mp, 
149.1-150.4 °C; 1H NMR, DMSO-d6 (400 MHz): 1.15 (s, 9 H, (CH3)3), 2.47 (s, 3 H, 2-
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CH3), 3.38 (s, 3 H, NCH3), 3.75 (s, 3 H, OCH3), 6.90-6.92 (d, 2 H, J = 8.91, Ar), 7.04-7.06 
(d, 2 H, J = 8.90, Ar), 9.65 (s, 1 H, exch, NH). The compound was carried on directly 
without further characterization. 
 
5-Chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,6-diamine (154) 
To a solution of 260 (0.050g, 0.0138 mmol) in EtOH, 1N NaOH (1 mL) was added and 
heated at 80 °C for 4 h. EtOH was evaporated, water was added and NaOH was neutralized 
using HCl. The compound precipitated, which was filtered and dried to give 154 as a brown 
colored solid (0.028 g, 74%). TLC Rf = 0.58 (CH3OH: CHCl3; 1:5); mp, 146.8-148.0 °C; 
1H NMR, DMSO-d6 (400 MHz): 2.28 (s, 3 H, 2-CH3), 3.27 (s, 3 H, NCH3), 3.73 (s, 3 H, 
OCH3), 6.61 (s, 2 H, exch, NH2), 6.86-6.88 (d, 2 H, J = 8.36, Ar), 6.97-6.99 (d, 2 H, J = 
8.28, Ar). Anal. Calcd. for C13H15ClN4O : C, 56.02; H, 5.42; N, 20.10; Cl, 12.72. Found 
C, 56.06; H, 5.38; N, 19.99; Cl, 12.68. 
 
N4-(4-Methoxyphenyl)-N4,2,5-trimethylpyrimidine-4,6-diamine (153) 
6-chloro-2,5-dimethylpyrimidin-4-amine 261 (0.150 g, 0.951 mmol) and aniline 259 were 
dissolved in n-butanol (15 mL) and heated at reflux for 12 h, after which the solvent was 
evaporated in vacuo. Silica gel and methanol were added and the solvent was evaporated 
to afford a plug. The crude product was purified by column chromatography using 10% 
MeOH in CHCl3 to yield light brown colored solid (0.067 g, 27%). TLC Rf = 0.57 (CH3OH: 
CHCl3; 1:10); mp, 95.1-96.4 °C; 
1H NMR, DMSO-d6 (400 MHz): 1.33 (s, 3 H, 5-CH3), 
2.37 (s, 3 H, 2-CH3), 3.34 (s, 3 H, NCH3), 3.75 (s, 3 H, OCH3), 6.90 (br, 2 H, exch, NH2), 
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6.90-6.92 (d, 2 H, J = 8.97, Ar), 7.00-7.02 (d, 2 H, J = 8.91, Ar). Anal. Calcd. for C14H18N4O 
. 0.25 CHCl3 : C, 59.43; H, 6.39; N, 19.46. Found C, 59.52; H, 6.77; N, 19.12; Cl, 6.80. 
 
N-Methyl-4-(methylthio)aniline (263)  
4-(methylthio)aniline 262 (1.13 g, 8.12 mmol) was added to a suspension of sodium 
methoxide (2.193 g, 40.6 mmol) in MeOH (10 mL). This mixture was then poured to 
another suspension of paraformaldehyde (0.342 g, 11.368 mmol) in MeOH (10 mL). The 
reaction mixture was then stirred at room temperature. After 5 h, sodium borohydride 
(0.307 g, 8.12 mmol) was added and the mixture was refluxed for 2 h. After the reaction, 
solvent was evaporated and 1M KOH (10 mL) was then added. The sample was then 
extracted 3 times using ether and dried over MgSO4. Combined fractions were evaporated, 
silica plug was made and was purified by column chromatography using 10% EtOAc in 
hexanes to yield 263 as brown colored liquid (0.49 g, 39%). TLC Rf = 0.76 (Hex: EtOAc; 
1:1); 1H NMR, DMSO-d6 (400 MHz): 2.33 (s, 3 H, SCH3), 2.64-2.66 (d, 3 H, J = 5.09, 
NHCH3), 5.72-5.73 (m, 1 H, exch, NH), 6.49-6.52 (d, 2 H, J = 8.58, Ar), 7.11-7.13 (d, 2 
H, J = 8.57, Ar). 1H NMR agreed well with the literature230 reported values. 
 
N-Methyl-2,3-dihydrobenzofuran-5-amine (265) 
Using the same synthetic method described for 263, compound 265 was obtained from 2,3-
dihydrobenzofuran-5-amine 264 (2.0 g, 14.80 mmol) as brown colored semi-solid (1.0 g, 
46%). TLC Rf = 0.77 (CH3OH: CHCl3; 1:10); 
1H NMR, DMSO-d6 (400 MHz): 2.62 (s, 3 
H, NCH3), 3.04-3.08 (t, 2 H, J = 8.55, ArCH2), 4.36-4.40 (t, 2 H, J = 8.56, OCH2), 5.08 (s, 
1 H, exch, NH), 6.25-6.28 (dd, 1 H, J1 = 2.41, J2 = 8.41, 6-Ar), 6.48-6.49 (d, 1H, J = 1.77, 
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4-Ar), 6.52-6.54 (d, 1 H, J = 8.40, 7-Ar). 1H NMR agreed well with the literature148 reported 
values. 
 
5-Methoxy-N-methylnaphthalen-2-amine (269) 
Compound 269 was prepared over 3 steps. 6-aminonaphthalen-1-ol 266 (1.25 g, 7.85 
mmol) was stirred with boc anhydride (5 mL) in ethyl acetate (15 mL) at room temperature. 
After 12 h, boc anhydride was evaporated and the residue was dissolved in ethyl acetate 
and purified using flash chromatography in CHCl3/MeOH to afford 267 as a brown colored 
liquid (1.74 g, 85%). TLC Rf = 0.67 (CH3OH: CHCl3; 1:5); 
1H NMR, DMSO-d6 (400 
MHz): 1.51 (s, 9 H, (CH3)3), 6.71-6.73 (dd, 1 H, J1 = 7.13, J2 = 1.21, Ar), 7.17-7.25 (m, 2 
H, Ar), 7.43-7.46 (dd, 1 H, J1 = 1.97, J2 = 9.14, Ar), 8.00-8.01 (d, 2 H, J = 8.87, Ar), 9.54 
(s, 1 H, exch., OH), 10.00 (s, 1 H, exch., NH). Compound 267 (1.70 g, 6.79 mmol) was 
dissolved in DMF (30 mL) under argon. Sodium hydride (488 mg, 20.36 mmol) was added 
next and the mixture was stirred at 0 oC for 15 min. Methyl iodide (2.12 g, 14.93 mmol) 
was added and the reaction was stirred at room temperature for 2 h. At the end of the 
reaction, solvent was evaporated, silica gel was added with methanol to make a plug and 
the mixture was purified using flash chromatography in hexanes/ethyl acetate to afford 268 
(1.36 g, 72%) as a yellow colored liquid. TLC Rf = 0.8 (Hex: EtOAc; 1:1); 
1H NMR, 
DMSO-d6 (400 MHz): 1.41 (s, 9 H, (CH3)3), 3.28 (s, 3 H, NCH3), 3.96 (s, 3 H, OCH3), 
6.92-6.94 (m, 1 H, Ar), 7.42-7.43 (m, 2 H, Ar), 7.45-7.46 (d, 1 H, J = 2.19, Ar), 7.72-7.73 
(d, 1 H, J = 2.12, Ar), 8.07-8.09 (d, 1 H, J = 9.03, Ar). Boc deprotection of 268 (1.3 g, 4.52 
mmol) was carried out in trifluoroacetic acid (TFA, 15 ml) at room temperature for 2 h. At 
the end of the reaction, TFA was evaporated and the mixture was neutralized using aq. 
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solution of K2CO3. Extraction with ethyl acetate (20 mL × 3) was concentrated and dried 
over Na2SO4 to yield 269 (0.810 g, 95%) as a green colored solid. TLC Rf = 0.77 (Hex: 
EtOAc; 1:1); 1H NMR, DMSO-d6 (400 MHz): 2.75-2.76 (d, 3 H, NCH3), 3.89 (s, 3 H, 
OCH3), 5.98-5.99 (q, 1 H, NHCH3, exch.), 6.57-6.59 (d, 1 H, J = 7.43, Ar), 6.61-6.62 (d, 1 
H, J = 1.87, Ar), 6.88-6.90 (dd, 1 H, J1 = 1.42, J2 = 9.05, Ar), 7.15-7.23 (m, 2 H, Ar), 7.83-
7.86 (d, 1 H, J = 9.05, Ar). The compound was carried on directly without further 
purification. 
 
General procedure for the synthesis of 5-chloro-N4-(substituted)-2-
methylpyrimidine-4,6-diamines 155, 156, 158 and 159 
To a 2-5 mL Biotage microwave vial were added 258 (1 equivalent), appropriate aniline 
(1.2 equivalents), 1,4-dioxane (3 mL) and catalytic amount of conc. HCl (1 drop).The 
resulting mixture was heated in microwave at 140 °C for 3 h. The solvent was removed 
under reduced pressure to obtain a mixture that was dissolved in methanol and to which 
silica gel was added. The solvent was removed by evaporation to yield a dry plug which 
was purified by flash chromatography using chloroform/methanol. The fractions 
containing the desired product (TLC) were pooled and evaporated to obtain the desired 
compounds 155, 156, 158 and 159. 
 
5-Chloro-N4-(4-methoxyphenyl)-2-methylpyrimidine-4,6-diamine (155) 
Using the general procedure described above, compound 258 (0.750 g, 2.86 mmol), p-
anisidine 270 (0.423g, 3.43 mmol) were reacted to afford 155 as light pink-brown colored 
solid (0.325 g, 43%). Under the microwave irradiation conditions, the pivaloyl protected 
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intermediate was not obtained. TLC Rf = 0.7 (CH3OH: CHCl3; 1:10); mp, 167.6-168.8 °C; 
1H NMR, DMSO-d6 (400 MHz): 2.18 (s, 3 H, 2-CH3), 3.73 (s, 3 H, OCH3), 6.59 (s, 2 H, 
exch, NH2), 6.85-6.87 (d, 2 H, J = 8.93, Ar), 7.48-7.50 (d, 2 H, J = 8.93, Ar), 8.18 (s, 1 H, 
exch, NH). Anal. Calcd. for C12H13ClN4O : C, 54.45; H, 4.95; N, 21.16; Cl, 13.39. Found 
C, 54.54; H, 4.99; N, 21.08; Cl, 13.22. 
 
5-Chloro-N4,2-dimethyl-N4-(4-(methylthio)phenyl)pyrimidine-4,6-diamine (156) 
Using the general procedure described above, compound 258 (0.3 g, 1.14 mmol), N-
methyl-4-(methylthio)aniline 263 (0.21 g, 1.37 mmol) were reacted to afford 156 as white 
colored solid (0.11 g, 32%). Under the microwave irradiation conditions, the pivaloyl 
protected intermediate was not obtained. TLC Rf = 0.71 (CH3OH: CHCl3; 1:10); mp, 
134.8-136.9 °C; 1H NMR, DMSO-d6 (400 MHz): 2.30 (s, 3 H, 2-CH3), 2.45 (s, 3 H, SCH3), 
3.30 (s, 3 H, NCH3), 6.75 (s, 2 H, exch., NH2), 6.93-6.95 (d, 2 H, J = 8.69, Ar), 7.18-7.20 
(d, 2 H, J = 8.73, Ar). Anal. Calcd. for C13H15ClN4S. 0.06 CH3(CH2)4CH3 : C, 53.68; H, 
5.39; N, 18.56; Cl, 11.75; S, 10.62. Found C, 53.61; H, 5.16; N, 18.83; Cl, 11.63; S, 10.69. 
 
5-Chloro-6-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-4-amine 
(158) 
Using the general procedure described above, compound 258 (0.750 g, 2.86 mmol), 6-
methoxy-1,2,3,4-tetrahydroquinoline 271 (0.561 g, 3.43 mmol) were reacted to afford a 
mixture with two spots. After running the flash chromatography the pivaloyl protected 
intermediate 171 was isolated in addition to the desired compound 158. Compound 158 
was obtained as off-white colored solid (0.225 g, 26%.). TLC Rf = 0.61 (CH3OH: CHCl3; 
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1:10); mp, 192.9-194.7 °C; 1H NMR, DMSO-d6 (400 MHz): 1.85-1.91 (m, 2 H, 3´-CH2), 
2.25 (s, 3 H, 2-CH3), 2.73-2.76 (t, 2 H, 4´-CH2), 3.60-3.63 (t, 2 H, N-CH2), 3.68 (s, 3 H, 
OCH3), 6.44-6.46 (d, 1 H, J = 8.80, 8´-Ar), 6.57-6.60 (dd, 1 H, J1 = 8.75, J2 = 2.52, 7´-Ar), 
6.68-6.69 (d, 1 H, J = 2.15, 5´-Ar), 6.87 (s, 2 H, exch., NH2). Anal. Calcd. for C15H17ClN4O 
: C, 59.11; H, 5.62; N, 18.38; Cl, 11.63. Found C, 59.41; H, 5.61; N, 18.41; Cl, 11.33. 
 
N-(5-Chloro-6-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-4-
yl)pivalamide (171) 
As mentioned above 171 was obtained as buff colored solid (0.125 g, 11%). TLC Rf = 0.80 
(CH3OH: CHCl3; 1:10); mp, 111.5-114.1 °C; 
1H NMR, DMSO-d6 (400 MHz): 1.20 (s, 9 
H, CH3), 1.89-1.97 (m, 2 H, 3´-CH2), 2.45 (s, 3 H, 2-CH3), 2.75-2.78 (t, 2 H, 4´-CH2), 3.72 
(s, 3 H, OCH3), 3.77-3.80 (t, 2 H, N-CH2), 6.62-6.63 (m, 2 H, Ar), 6.75-6.76 (d, 1 H, Ar), 
9.89 (s, 1 H, exch., NH).  Anal. Calcd. for C20H25ClN4O2 : C, 61.77; H, 6.48; N, 14.41; Cl, 
9.12. Found C, 61.95; H, 6.40; N, 14.22; Cl, 8.85. 
 
5-Chloro-N4-(2,3-dihydrobenzofuran-5-yl)-N4,2-dimethylpyrimidine-4,6-diamine 
(159) 
Using the general procedure described above, compound 258 (0.5 g, 1.91 mmol), N-
methyl-2,3-dihydrobenzofuran-5-amine 265 (0.341 g, 2.29 mmol) were reacted to afford 
159 as buff colored solid (0.22 g, 32%). Under the microwave irradiation conditions, the 
pivaloyl protected intermediate was not obtained. TLC Rf = 0.63 (CH3OH: CHCl3; 1:10); 
mp, 192.8-194.1 °C; 1H NMR, DMSO-d6 (400 MHz): 2.28 (s, 3 H, CH3), 3.12-3.16 (t, 2 
H, 3´-CH2), 3.25 (s, 3 H, NCH3), 4.49-4.54 (t, 2 H, O-CH2), 6.57 (s, 2 H, exch., NH2), 6.66-
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6.68 (d, 1 H, J = 8.40, 7´-Ar), 6.75-6.77 (dd, 1 H, J1 = 8.40, J2 = 2.34, 6´-Ar), 6.98-6.99 (d, 
1 H, J = 1.36, 4´-Ar). Anal. Calcd. for C14H15ClN4O 0.07 C4H8O2 : C, 57.76; H, 5.28; N, 
18.84; Cl, 11.92. Found C, 58.15; H, 5.27; N, 18.81; Cl, 11.83. 
 
5-Chloro-N4-(3-methoxyphenyl)-N4,2-dimethylpyrimidine-4,6-diamine (157) 
To a 100 mL round-bottomed flask were added 257 (0.2 g, 1.12 mmol), 3-methoxy-N-
methylaniline 272 (1.2 equivalents), n-butanol (15 mL) and catalytic amount of conc. HCl 
(1 drop).The resulting mixture was refluxed for 12 h. The solvent was removed under 
reduced pressure to obtain a mixture that was dissolved in methanol and to which silica gel 
was added. The solvent was removed by evaporation to yield a dry plug which was purified 
by flash chromatography using chloroform/methanol. The fractions containing the desired 
product (TLC) were pooled and evaporated to afford 157 as light brown colored solid 
(0.101 g, 32%). TLC Rf = 0.68 (CH3OH: CHCl3; 1:10); mp, 150.8-151.9 °C; 
1H NMR, 
DMSO-d6 (400 MHz): 2.30 (s, 3 H, 2-CH3), 3.32 (s, 3 H, NCH3), 3.71 (s, 3 H, OCH3), 
6.51-6.53 (d, 2 H, Ar), 6.60-6.63 (m, 1 H, Ar), 6.80 (s, 2 H, exch., NH2), 7.15-7.19 (t, 1 H, 
J = 8.05, Ar). Anal. Calcd. for C13H15ClN4O: C, 56.01; H, 5.42; N, 20.10; Cl, 12.72. Found 
C, 56.40; H, 5.75; N, 19.80; Cl, 12.37. 
 
5-Chloro-N4-(5-methoxynaphthalen-2-yl)-N4,2-dimethylpyrimidine-4,6-diamine 
(160) 
To a 100 mL round-bottomed flask were added 257 (0.25 g, 1.40 mmol), 5-methoxy-N-
methylnaphthalen-2-amine 269 (0.315 g, 1.69 mmol), n-butanol (15 mL) and catalytic 
amount of conc. HCl (1 drop).The resulting mixture was refluxed for 12 h. The solvent was 
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removed under reduced pressure to obtain a mixture that was dissolved in methanol and to 
which silica gel was added. The solvent was removed by evaporation to yield a dry plug 
which was purified by flash chromatography using hexanes/ethyl acetate. The fractions 
containing the desired product (TLC) were pooled and evaporated to afford 160 as light 
pink colored solid (0.06 g, 13%). TLC Rf = 0.78 (CH3OH: CHCl3; 1:10); mp, 138.3-140.1 
°C; 1H NMR, DMSO-d6 (400 MHz): 2.39 (s, 3 H, CH3), 3.43 (s, 3 H, NCH3), 3.95 (s, 3 H, 
OCH3), 6.84-6.86 (m, 3 H, Ar, NH2, exch.), 7.15-7.18 (dd, 1 H, J1 = 2.33, J2 = 9.07, Ar), 
7.35-7.36 (m, 3 H, Ar), 8.02-8.04 (d, 1 H, J = 9.07, Ar). Anal. Calcd. for C17H17ClN4O . 
0.33CH3CO2C2H5: C, 61.48; H, 5.54; N, 15.64; Cl, 9.89. Found C, 61.52; H, 5.34; N, 15.69; 
Cl, 9.70. 
 
General procedure for the synthesis of 5-chloro-N4-substituted-N6-(4-
methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-diamines 161-167a 
Compound 154 (1 equivalent) was dissolved in anhydrous DMF in a three necked round-
bottomed flask and was stirred at 0 °C under argon. Sodium hydride (2 equivalents) was 
added the above mixture and stirred at 0 °C for additional 15 min followed by addition of 
suitable alkyl halide (1.1 equivalents) while maintaining the reaction at room temperature 
for 4 h. Methanol was added at the end of the reaction, solvent was evaporated and the 
reaction mixture was then extracted with water and ethyl acetate (25 mL × 3) which were 
dried over Na2SO4. Silica gel was added next to the combined fractions, the solvent was 
removed by evaporation to yield a dry plug and column was the run using hexanes/ethyl 
acetate. The fractions containing the desired product (TLC) were pooled and evaporated to 
obtain the desired compounds 161-167a. 
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5-Chloro-N4-(4-methoxyphenyl)-N4,N6,2-trimethylpyrimidine-4,6-diamine (161) 
Using the general procedure described above, compound 154 (0.113 g, 0.405 mmol) was 
dissolved in DMF (10 mL), to which sodium hydride (0.019 g, 0.810 mmol) was added at 
0 °C. Methyl iodide (0.064 g, 0.446 mmol) was added next and after following the work 
up procedure mentioned above afforded 161 as off-white colored (0.036 g, 30%). TLC Rf 
= 0.89 (CH3OH: CHCl3; 1:10); mp, 104-105 °C; 
1H NMR, DMSO-d6 (400 MHz): 2.34 (s, 
3 H, CH3), 2.81-2.82 (d, 3 H, J = 4.61, NH-CH3), 3.27 (s, 3 H, NCH3), 3.73 (s, 3 H, OCH3), 
6.71-6.75 (q, 1 H, J = 4.30, exch., NH), 6.85-6.87 (d, 2 H, J = 8.99, Ar), 6.95-6.97 (d, 2 H, 
J = 8.98, Ar). Anal. Calcd. for C14H17ClN4O: C, 57.43; H, 5.85; N, 19.14; Cl, 12.11. Found 
C, 57.58; H, 6.02; N, 18.92; Cl, 11.88. 
 
5-Chloro-N4-ethyl-N6-(4-methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-diamine 
(162) 
Using the general procedure described above, compound 154 (0.150 g, 0.538 mmol) was 
dissolved in DMF (10 mL), to which sodium hydride (0.026 g, 1.08 mmol) was added at 0 
°C. Iodoethane (0.092 g, 0.591 mmol) was added next and after following the work up 
procedure mentioned above afforded 162 as pink colored crystalline solid (0.060 g, 36%). 
TLC Rf = 0.92 (CH3OH: CHCl3; 1:10); mp, 105.4-106.5 °C; 
1H NMR, DMSO-d6 (400 
MHz): 1.07-1.11 (t, 3 H, CH2CH3), 2.33 (s, 3 H, 2-CH3), 3.27 (s, 3 H, NCH3), 3.36-3.40 
(m, 2 H, NH-CH2), 3.73 (s, 3 H, OCH3), 6.69-6.72 (t, 1 H, exch., NH), 6.85-6.87 (d, 2 H, 
J = 8.96, Ar), 6.95-6.98 (d, 2 H, J = 8.92, Ar). Anal. Calcd. for C15H19ClN4O: C, 58.72; H, 
6.24; N, 18.26; Cl, 11.56. Found C, 58.79; H, 6.25; N, 18.09; Cl, 11.42. 
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5-Chloro-N4-(4-methoxyphenyl)-N4,2-dimethyl-N6-propylpyrimidine-4,6-diamine 
(163) 
Using the general procedure described above, compound 154 (0.2 g, 0.717 mmol) was 
dissolved in DMF (10 mL), to which sodium hydride (0.034 g, 1.44 mmol) was added at 0 
°C. 1-Iodopropane (0.134 g, 0.789 mmol) was added next and after following the work up 
procedure mentioned above afforded 163 as a semi-solid. HCl salt was prepared by 
bubbling HCl gas through the solution of compound in ether to afford 163.HCl as light 
pink colored solid (0.078 g, 30%). TLC Rf = 0.95 (CH3OH: CHCl3; 1:10); mp, 165.7-167.8 
°C; 1H NMR, DMSO-d6 (400 MHz): 0.84-0.88 (t, 3 H, CH2CH2CH3), 1.50-1.59 (m, 2 H, 
CH2CH2CH3), 2.56 (s, 3 H, 2-CH3), 3.44-3.47 (m, 5 H, NCH3, CH2CH2CH3), 3.75 (s, 3 H, 
OCH3), 6.91-6.93 (d, 2 H, J = 8.97, Ar), 7.13-7.16 (d, 2 H, J = 8.90, Ar), 8.02 (br, s, 1 H, 
exch., NH). Anal. Calcd. for C16H21ClN4O. 0.96 HCl. 0.51H2O: C, 52.65; H, 6.35; N, 
15.35; Cl, 19.02. Found C, 52.68; H, 6.03; N, 15.7; Cl, 18.99. 
 
5-Chloro-N4-isopropyl-N6-(4-methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-diamine 
(164) 
Using the general procedure described above, compound 154 (0.150 g, 0.538 mmol) was 
dissolved in DMF (10 mL), to which sodium hydride (0.026 g, 1.08 mmol) was added at 0 
°C. Isopropyl iodide (0.1 g, 0.592 mmol) was added next and after following the work up 
procedure mentioned above afforded 164 as white colored crystalline solid (0.079 g, 46%). 
TLC Rf = 0.77 (Hex:EtOAc; 1:1); mp, 94-95.6 °C; 
1H NMR, DMSO-d6 (400 MHz): 0.13-
1.15 (d, 6 H, 2 CH3), 2.33 (s, 3 H, 2-CH3), 3.27 (s, 3 H, NCH3), 3.73 (s, 3 H, OCH3), 4.28-
4.29 (m, 1 H, CH(CH3)2), 6.21-6.23 (d, 1 H, exch., NH), 6.85-6.87 (d, 2 H, J = 9.0, Ar), 
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6.95-6.98 (d, 2 H, J =9.04, Ar). Anal. Calcd. for C16H21ClN4O: C, 59.90; H, 6.60; N, 17.46; 
Cl, 11.05. Found C, 60.17; H, 6.72; N, 17.51; Cl, 10.80. 
 
N4-Butyl-5-chloro-N6-(4-methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-diamine 
(165) 
Using the general procedure described above, compound 154 (0.150 g, 0.538 mmol) was 
dissolved in DMF (10 mL), to which sodium hydride (0.026 g, 1.08 mmol) was added at 0 
°C. 1-Iodobutane (0.109 g, 0.592 mmol) was added next and after following the work up 
procedure mentioned above afforded 165 as a semisolid. HCl salt was prepared by bubbling 
HCl gas through the solution of compound in ether to afford 165.HCl as light pink colored 
crystalline solid (0.042 g, 21%). TLC Rf = 0.97 (CH3OH: CHCl3; 1:10); mp, 144.8-147.1 
°C; 1H NMR, DMSO-d6 (400 MHz): 0.87-0.91 (t, 3 H, (CH2)3CH3), 1.25-1.34 (m, 2 H, 
CH2CH2CH2CH3), 1.48-1.55 (m, 2 H, CH2CH2CH2CH3), 2.53 (s, 3 H, 2-CH3), 3.43 (s, 3 
H, NCH3), 3.46-3.48 (m, 2 H, NH-CH2), 3.75 (s, 3 H, OCH3), 6.91-6.93 (d, 2 H, J = 8.98, 
Ar), 7.12-7.14 (d, 2 H, J = 8.91, Ar), 7.91 (s, 1 H, exch., NH). Anal. Calcd. for 
C17H23ClN4O. 0.97 HCl: C, 55.16; H, 6.52; N, 15.13; Cl, 18.86. Found C, 55.27; H, 6.66; 
N, 14.97; Cl, 18.91. 
 
5-Chloro-N4-isobutyl-N6-(4-methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-diamine 
(166) 
Using the general procedure described above, compound 154 (0.150 g, 0.538 mmol) was 
dissolved in DMF (10 mL), to which sodium hydride (0.026 g, 1.08 mmol) was added at 0 
°C. Isobutanol (0.109 g, 0.592 mmol) was added next and after following the work up 
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procedure mentioned above afforded 166 as a semisolid. HCl salt was prepared by bubbling 
HCl gas through the solution of compound in ether to afford 166.HCl as yellow colored 
crystalline solid (0.026 g, 13%). TLC Rf = 0.95 (CH3OH: CHCl3; 1:10); mp, 143.1-145.9 
°C; 1H NMR, DMSO-d6 (400 MHz): 0.85-0.87 (d, 6 H, CH(CH3)2), 1.85-1.95 (m, 1 H, 
CH(CH3)2, 2.52 (s, 3 H, 2-CH3), 3.29-3.33 (t, 2 H, NH-CH2), 3.43 (s, 3 H, NCH3), 3.76 (s, 
3 H, OCH3),  6.91-6.94 (d, 2 H, J = 8.90, Ar), 7.13-7.15 (d, 2 H, J = 8.77, Ar), 7.84 (s, 1 H, 
exch., NH). Anal. Calcd. for C17H23ClN4O. 0.96HCl. 0.40H2O: C, 54.13; H, 6.62; N, 14.85; 
Cl, 18.46. Found C, 54.14; H, 6.31; N, 14.77; Cl, 18.44. 
 
N4-Benzyl-5-chloro-N6-(4-methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-diamine 
(167) 
Using the general procedure described above, compound 154 (0.300 g, 1.08 mmol) was 
dissolved in DMF (20 mL), to which sodium hydride (0.052 g, 2.15 mmol) was added at 0 
°C. Benzyl bromide (0.203 g, 1.18 mmol) was added next and after following the work up 
procedure mentioned above afforded 167 as off-white colored crystalline solid  (0.115 g, 
29%). TLC Rf = 0.95 (CH3OH: CHCl3; 1:10); mp, 95.3-96.1 °C; 
1H NMR, DMSO-d6 (400 
MHz): 2.31 (s, 3 H, 2-CH3), 3.29 (s, 3 H, NCH3), 3.74 (s, 3 H, OCH3), 4.57-4.58 (d, 2 H, 
CH2C6H5), 6.86-6.88 (d, 2 H, J = 9.00, Ar), 6.98-7.00 (d, 2 H, J = 8.97, Ar), 7.20-7.23 (m, 
1 H, exch., NH), 7.28-7.33 (m, 5 H, Ar). Anal. Calcd. for C20H21ClN4O: C, 65.12; H, 5.74; 
N, 15.19; Cl, 9.61. Found C, 65.12; H, 5.68; N, 15.13; Cl, 9.47. 
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N4,N4-Dibenzyl-5-chloro-N6-(4-methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-
diamine (167a) 
Compound 167a was isolated as a white semisolid. TLC Rf = 0.97 (CH3OH: CHCl3; 1:10); 
1H NMR, DMSO-d6 (400 MHz): 2.35 (s, 3 H, 2-CH3), 3.32 (s, 3 H, NCH3), 3.71 (s, 3 H, 
OCH3), 4.65 (s, 4 H, CH2C6H5), 6.75-6.77 (dd, 2 H, J = 8.95, J = 1.66, Ar), 6.80-6.83 (dd, 
2 H, J = 8.71, J = 1.62, Ar), 7.20-7.22 (d, 4 H, Ar), 7.25-7.27 (d, 2 H, Ar), 7.30-7.34 (m, 4 
H, Ar). The compound was carried on directly without further characterization. 
 
5-Chloro-N4-ethyl-N6-(5-methoxynaphthalen-2-yl)-N6,2-dimethylpyrimidine-4,6-
diamine (168) 
Using the general procedure described above, compound 160 (0.130 g, 0.395 mmol) was 
dissolved in DMF (10 mL), to which sodium hydride (0.014 g, 0.593 mmol) was added at 
0 °C. Iodoethane (0.068 g, 0.435 mmol) was added next and after following the work up 
procedure mentioned above afforded 168 as pale yellow colored solid (0.040 g, 28%). TLC 
Rf = 0.92 (CH3OH: CHCl3; 1:10); 
1H NMR, DMSO-d6 (400 MHz): 1.10-1.14 (t, 3 H, 
CH2CH3), 2.37 (s, 3 H, 2-CH3), 3.39-3.43 (m, 5 H, CH2CH3, NCH3), 3.95 (s, 3 H, OCH3), 
6.84-6.85 (m, 1 H, Ar), 6.98-7.00 (t, 1 H, exch., NH), 7.12-7.15 (d, 1 H, Ar), 7.34-7.36 (m, 
3 H, Ar), 8.00-8.02 (d, 1 H, Ar). Anal. Calcd. for C19H21ClN4O: C, 63.85; H, 6.04; N, 
15.39; Cl, 9.67. Found C, 63.85; H, 6.04; N, 15.39; Cl, 9.67. 
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5-Chloro-N4-(5-methoxynaphthalen-2-yl)-N4,2-dimethyl-N6-propylpyrimidine-4,6-
diamine (169) 
Using the general procedure described above, compound 160 (0.130 g, 0.395 mmol) was 
dissolved in DMF (10 mL), to which sodium hydride (0.019 g, 0.791 mmol) was added at 
0 °C. 1-Iodopropane (0.074 g, 0.435 mmol) was added next and after following the work 
up procedure mentioned above afforded 169 as a semisolid. HCl salt was prepared by 
bubbling HCl gas through the solution of compound in ether to afford 169.HCl as light 
pink colored solid (0.083 g, 51%). TLC Rf = 0.95 (CH3OH: CHCl3; 1:10); mp, 180.6-182.8 
°C; 1H NMR, DMSO-d6 (400 MHz): 0.86-0.90 (t, 3 H, CH2CH2CH3), 1.53-1.62 (m, 2 H, 
CH2CH2CH3), 2.48 (s, 3 H, 2-CH3), 3.40-3.44 (q, 2 H, CH2CH2CH3), 3.50 (s, 3 H, NCH3), 
3.96 (s, 3 H, OCH3), 6.87-6.89 (dd, 1 H, Ar), 7.22-7.25 (dd, 1 H, Ar), 7.36-7.40 (m, 2 H, 
Ar), 7.47-7.48 (d, 1 H, Ar), 7.83 (s, br, 1 H, exch., NH), 8.04-8.06 (d, 1 H, Ar).  Anal. 
Calcd. for C20H23ClN4O . 0.97HCl . 0.97H2O: C, 56.66; H, 6.16; N, 13.22; Cl, 16.51. Found 
C, 56.71; H, 6.08; N, 12.99; Cl, 16.50. 
 
N-(5-Chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-4-
yl)acetamide (170) 
Compound 154 (0.120 g, 0.430 mmol) was dissolved in acetic acid (5 mL) and acetic 
anhydride (2 mL) was added to the above mixture and heated to 90 °C for 12 h. After the 
completion of reaction (monitored by TLC), the mixture was cooled to room temperature 
and water (5 mL) was added over 10 min. The mixture was then filtered, and the filter cake 
was washed with water, dried over P2O5 to yield 170 as white colored solid (0.040 g, 30%). 
TLC Rf = 0.55 (MeOH:CHCl3; 1:10); mp, 143.0-144.2 °C; 
1H NMR, DMSO-d6 (400 
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MHz): 2.04 (s, 3 H, COCH3), 2.45 (s, 3 H, 2-CH3), 3.38 (s, 3 H, NCH3), 3.76 (s, 3 H, 
OCH3), 6.89-6.92 (d, 2 H, J = 8.75, Ar), 7.05-7.07 (d, 2 H, J = 8.73, Ar), 9.98 (s, 1 H, exch., 
NH). Anal. Calcd. for C15H17ClN4O2: C, 56.16; H, 5.34; N, 17.47; Cl, 11.05. Found C, 
56.19; H, 5.42; N, 17.20; Cl, 11.21. 
 
4-Methoxyquinazoline (276) 
Quinazolin-4(3H)-one 274b (1.0 g, 6.84 mmol) was dissolved in phosphorus oxychloride 
(15 mL) and set for reflux for 4 h. The solvent was evaporated in vacuo, and the residue 
was adjusted to pH 8 with 7N ammonia solution in MeOH. The reaction mixture was 
extracted with ethyl acetate (20 mL × 3), the fractions were pooled, dried over Na2SO4 and 
the solvent was evaporated in vacuo to afford 276 as yellow colored liquid.267 TLC Rf = 
0.57 (MeOH:CHCl3; 1:5); 
1H NMR, DMSO-d6 (400 MHz): 4.24 (s, 3 H, OCH3), 7.80-7.84 
(m, 1 H, Ar), 8.06-8.10 (m, 2 H, Ar), 8.24-8.26 (m, 1 H, Ar), 9.12 (s, 1 H, Ar). The 
compound was not characterized further. 
 
4H-[3,4'-Biquinazolin]-4-one (277) 
Quinazolin-4(3H)-one 274b (1.0 g, 6.84 mmol) was dissolved in toluene (25 mL) to which 
phosphorus oxychloride (1 mL) and pyridine (0.8 mL) were added and the reaction mixture 
was refluxed for 1 h. After cooling, the reaction mixture to room temperature and 20 mL 
of cold water was added. The reaction mixture was extracted with ethyl acetate (20 mL × 
3), the fractions were pooled, dried over Na2SO4 and the solvent was evaporated in vacuo 
to afford 277 as off-white colored solid (0.200 g, 11%). TLC Rf = 0.77 (MeOH:CHCl3; 
1:5); mp, 210.7-212.0 °C (lit.268 229-230 °C);  1H NMR, DMSO-d6 (400 MHz): 7.68-7.82 
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(m, 2 H, Ar), 7.85-7.87 (d, 1 H, Ar), 7.98-8.05 (m, 2 H, Ar), 8.14-8.26 (m, 3 H, Ar), 8.63 
(s, 1 H, Ar), 9.46 (s, 1 H, Ar). The compound was not characterized further. 
 
4-Chloroquinazoline (273b) 
To a 250 mL round-bottomed flask were added quinazolin-4(3H)-one 274b (2.0 g, 13.68 
mmol), trimethylamine (3 mL), and toluene (30 mL). The mixture was cooled to 0 °C to 
which phosphorus oxychloride (2 mL) was added and stirred at room temperature for 1 h. 
The reaction was heated to 95 °C for 3 h. After monitoring the reaction on TLC, the reaction 
was cooled to room temperature and diluted with 30 mL of ethyl acetate. The solution was 
then washed with 10 mL of ice cold water, 10 mL of saturated NaHCO3, 10 mL of water, 
1N HCl (5 mL), 10 mL of water, 10 mL of saturated NaHCO3 and 10 mL of saturated 
NaCl. The organic layer was dried over Na2SO4, filtered and concentrated to obtain 273b 
as yellow colored solid (1.79 g, 80%). TLC Rf = 0.85 (MeOH:CHCl3; 1:5); mp, 144.2-
146.1 °C (lit.239 145-147.5 °C); 1H NMR, DMSO-d6 (400 MHz): 7.59-7.63 (dt, 1 H, J1 = 
1.09, J2 = 7.23, J3 = 8.01, Ar), 7.76-7.78 (d, 1 H, J = 8.24, Ar), 7.89-7.92 (dt, 1 H, J1 = 1.47, 
J2 = 7.24, J3 = 8.29, Ar), 8.15-8.17 (d, 1 H, J = 7.03, Ar), 8.58 (s, 1 H, Ar). 
 
4-Chloro-2-methylquinazoline (273a) 
Similar to the method described for compound 273b, 273a was synthesized from 2-
methylquinazolin-4(3H)-one 274a (1.0 g, 6.24 mmol) as yellow colored solid (0.600 g, 
54%). TLC Rf = 0.8 (MeOH:CHCl3; 1:5); mp, 83.9-85.3 °C (lit.
269 85-86 °C); 1H NMR, 
DMSO-d6 (400 MHz): 2.58 (s, 3 H, CH3), 7.59-7.63 (t, 1 H, J1 = 7.58, J2 = 7.58, Ar), 7.78-
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7.80 (d, 1 H, J = 7.98, Ar), 7.90-7.95 (t, 1 H, J1 = 7.67, J2 = 7.67, Ar), 8.13-8.15 (d, 1 H, J 
= 7.65, Ar). 
 
General method for the synthesis of compounds 172-180 and 182 
To a 100 mL round-bottomed flask substituted-4-chloroquinazolines (1 equivalent), 
appropriate anilines (1.2 equivalents) and iso-propanol (10 mL) were added and stirred at 
room temperature in isopropanol for 12 h. The compounds precipitated as HCl salts, which 
were filtered and dried in vacuo over P2O5 to afford the desired compounds. 
 
N-(4-Methoxyphenyl)-N,2-dimethylquinazolin-4-amine (172) 
Using the general method described above, 273a (0.150 g, 0.840 mmol) and 4-methoxy-
N-methylaniline 259 (0.138 g, 1.01 mmol) were reacted for 12 h. At the end of the reaction, 
solvent was evaporated, silica gel and methanol were added and evaporated in vacuo to 
give a dried plug. The reaction mixture was purified using flash chromatography using 
chloroform/methanol to the afford 172 as brown colored solid (0.136 g, 58%). TLC Rf = 
0.8 (MeOH:CHCl3; 1:5); mp, 99.1-101.2 °C; 
1H NMR, DMSO-d6 (400 MHz): 2.66 (s, 3 
H, 2-CH3), 3.60 (s, 3 H, NCH3), 3.81 (s, 3 H, OCH3), 6.88-6.90 (d,1 H, J = 8.35, Ar), 7.04-
7.06 (d, 2 H, J = 8.89, Ar), 7.14-7.18 (t, 1 H, J1 = 7.49, J2 = 7.49, Ar), 7.30-7.32 (d, 2 H, J 
= 8.78, Ar), 7.68-7.75 (m, 2 H, Ar). Anal. Calcd. for C17H17N3O .0.52 HCl: C, 68.46; H, 
5.92; N, 14.08. Found C, 68.50; H, 6.24; N, 13.80; Cl, 4.54. 
 
4-(6-Methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylquinazoline (173) 
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Using the general method described above, 273a (0.150 g, 0.840 mmol) and 6-methoxy-
1,2,3,4-tetrahydroquinoline 271 (0.164 g, 1.01 mmol) were reacted to afford 173 as a 
yellow colored precipitate (0.188 g, 65%). TLC Rf = 0.85 (MeOH:CHCl3; 1:5); mp, 255.8-
257.9 °C; 1H NMR, DMSO-d6 (400 MHz): 2.1 (quin, 2 H, CH2), 2.75 (s, 3 H, 2-CH3), 2.87-
2.90 (t, 2 H, CH2), 3.79 (s, 3 H, OCH3), 4.20 (t, 2 H, NCH2), 6.68-6.71 (dd, 1 H, J1 = 2.88, 
J2 = 8.85, Ar), 7.02-7.03 (d, 1 H, J = 2.81, Ar), 7.05-7.08 (d, 1 H, J = 8.87, Ar), 7.26-7.28 
(d, 1 H, J = 8.53, Ar), 7.36-7.40 (dt, J1 = 1.38 , J2 = 6.83, J3 = 8.28, Ar), 7.88-7.96 (m, 2 H, 
Ar), 15.28 (s, 1 H, exch., NH). Anal. Calcd. for C19H19N3O. 1.07HCl: C, 66.26; H, 5.87; 
N, 12.20. Found C, 66.28; H, 5.75; N, 12.11; Cl, 10.49. 
 
N,2-Dimethyl-N-(4-(methylthio)phenyl)quinazolin-4-amine (174) 
Using the general method described above, 273a (0.135 g, 0.756 mmol) and N-methyl-4-
(methylthio)aniline 263 (0.135 g, 0.907 mmol) were reacted to afford 174 as white colored 
precipitate (0.175 g, 70%). TLC Rf = 0.9 (MeOH:CHCl3; 1:5); mp, 235.2-236.4 °C; 
1H 
NMR, DMSO-d6 (400 MHz): 2.55 (s, 3 H, 2-CH3), 2.77 (s, 3 H, SCH3), 3.74 (s, 3 H, 
NCH3), 6.87-6.89 (d, 1 H, J = 8.39, Ar), 7.30-7.34 (dt, 1 H, J1 = 1.33, J2 = 7.0, J3 = 8.48, 
Ar), 7.43-7.50 (m, 4 H, Ar), 7.85-7.89 (dt, 1 H, J1 = 1.14, J2 = 7.05, J3 = 8.34, Ar), 7.93-
7.95 (d, 1 H, J = 8.32, Ar), 15.22 (s, 1 H, exch., NH). Anal. Calcd. for C17H17N3S. 1.34 
HCl: C, 59.28; H, 5.37; N, 12.20; S, 9.31. Found C, 59.37; H, 5.62; N, 11.93; S, 9.03; Cl, 
10.55. 
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N-(5-Methoxynaphthalen-2-yl)-N,2-dimethylquinazolin-4-amine (175) 
Using the general method described above, 273a (0.135 g, 0.840 mmol) and 5-methoxy-
N-methylnaphthalen-2-amine 269 (0.156 g, 0.831 mmol) were reacted for 12 h. At the end 
of reaction, solvent was evaporated, silica gel and methanol were added and evaporated in 
vacuo to give a dried plug. The reaction mixture was purified using flash chromatography 
using chloroform/methanol to the afford 175 as a yellow colored solid (0.170 g, 68%). TLC 
Rf = 0.9 (MeOH:CHCl3; 1:10); mp, 203.0-204.4 °C; 
1H NMR, DMSO-d6 (400 MHz): 2.70 
(s, 3 H, 2-CH3), 3.72 (s, 3 H, NCH3), 3.99 (s, 3 H, OCH3), 6.91-6.93 (d, 1 H, J = 8.26, Ar), 
7.00-7.02 (d, 1 H, J = 7.46, Ar), 7.05-7.09 (t, 1 H, J1 = 7.70, J2 = 7.70, Ar), 7.40-7.49 (m, 
3 H, Ar), 7.66-7.69 (t, 1 H, J1 = 7.59, J2 = 7.59, Ar), 7.74-7.76 (d, 1 H, J = 8.33, Ar), 7.84 
(s, 1 H, Ar), 8.21-8.23 (d, 1 H, J = 8.99, Ar). Anal. Calcd. for C21H19N3O. 0.41 HCl: C, 
73.22; H, 5.68; N, 12.20. Found C, 73.19; H, 5.82; N, 12.35; Cl, 2.22. 
 
N-(4-Methoxyphenyl)-N-methylquinazolin-4-amine (176) 
Using the general method described above, 273b (0.150 g, 0.911 mmol) and N-methyl-4-
methoxyaniline 259 (0.150 g, 1.09 mmol) were reacted to afford 176 as a pale yellow 
colored precipitate (0.210 g, 76%). TLC Rf = 0.8 (MeOH:CHCl3; 1:5); mp, 244.3-245.3 
°C; 1H NMR, DMSO-d6 (400 MHz): 3.75 (s, 3 H, NCH3), 3.84 (s, 3 H, OCH3), 6.84-6.86 
(d, 1 H, J = 8.43, Ar), 7.12-7.16 (d, 2 H, J = 8.97, Ar), 7.32-7.36 (dt, 1 H, J1 = 1.12, J2 = 
6.93, J3 = 8.45, Ar), 7.46-7.50 (d, 2 H, J = 8.96, Ar), 7.87-7.91 (dt, 1 H, J1 = 1.05, J2 = 6.94, 
J3 = 8.25, Ar), 7.95-7.97 (d, 1 H, J = 8.15, Ar), 9.06 (s, 1 H, Ar). Anal. Calcd. for 
C16H15N3O. 1.10HCl: C, 62.89; H, 5.31; N, 13.75. Found C, 62.89; H, 5.33; N, 13.75; Cl, 
11.43. 
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4-(6-Methoxy-3,4-dihydroquinolin-1(2H)-yl)quinazoline (177) 
Using the general method described above, 273b (0.150 g, 0.911 mmol) and 6-methoxy-
1,2,3,4-tetrahydroquinoline 271 (0.179 g, 1.09 mmol) were reacted to afford 177 as a 
yellow colored precipitate (0.211 g, 70%). TLC Rf = 0.8 (MeOH:CHCl3; 1:5); mp, 234.2-
235.3 °C; 1H NMR, DMSO-d6 (400 MHz): 2.05-2.13 (quint, 2 H, CH2), 2.87-2.91 (t, 2 H, 
CH2), 3.79 (s, 3 H, OCH3), 4.20-4.21 (t, 2 H, NCH2), 6.67-6.70 (dd, 1 H, J1 = 2.91, J2 = 
8.85, Ar), 7.02-7.03 (d, 1 H, J = 2.82, Ar), 7.08-7.10 (d, 1 H J = 8.85, Ar), 7.33-7.35 (d, 1 
H, J = 8.50, Ar), 7.42-7.46 (dt, 1 H, J1 = 1.55, J2 = 6.67, J3 = 8.32, Ar), 7.91-7.98 (m, 2 H, 
Ar), 9.04 (s, 1 H, Ar). Anal. Calcd. for C18H17N3O. 1.22HCl: C, 64.38; H, 5.47; N, 12.51. 
Found C, 64.39; H, 5.47; N, 12.45; Cl, 10.41. 
 
N-Methyl-N-(4-(methylthio)phenyl)quinazolin-4-amine (178) 
Using the general method described above, 273b (0.150 g, 0.911 mmol) and N-methyl-4-
(methylthio)aniline 263 (0.168 g, 1.09 mmol) were reacted to afford 178 as a pale yellow 
colored precipitate (0.209 g, 72%). TLC Rf = 0.8 (MeOH:CHCl3; 1:5); mp, 233.4-235.9 
°C; 1H NMR, DMSO-d6 (400 MHz): 2.54 (s, 3 H, SCH3), 3.75 (s, 3 H, NCH3), 6.94-6.96 
(d, 1 H, J = 8.74, Ar), 7.35-7.39 (t, 1 H, J1 = 7.69, J2 = 7.69, Ar), 7.43-7.45 (d, 2 H, J = 
8.70, Ar), 7.48-7.50 (d, 2 H, J = 8.68, Ar), 7.88-7.92 (t, 1 H, J1 = 7.55, J2 = 7.55, Ar), 7.95-
7.97 (d, 1 H, J = 7.68, Ar), 9.08 (s, 1 H, Ar).  Anal. Calcd. for C16H15N3S. 1.13HCl: C, 
59.59; H, 5.04; N, 13.03; S, 9.94. Found C, 59.56; H, 5.13; N, 12.97; S, 10.22; Cl, 10.22. 
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2-Chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (179) 
Using the general method described above, 273c (0.500 g, 2.51 mmol) and 4-methoxy-N-
methylaniline 259 (0.413 g, 3.01 mmol) were reacted for 12 h. At the end of reaction, 
solvent was evaporated, silica gel and methanol were added and evaporated in vacuo to 
give a dried plug. The reaction mixture was purified using flash chromatography using 
chloroform/methanol to the afford 179 as buff colored solid (0.070 g, 9%). TLC Rf = 0.95 
(MeOH:CHCl3; 1:5); mp, 146.3-148.7 °C; 
1H NMR, DMSO-d6 (400 MHz): 3.52 (s, 3 H, 
NCH3), 3.81 (s, 3 H, OCH3), 6.86-6.88 (d, 1 H, Ar), 7.03-7.06 (d, 2 H, J = 8.96, Ar), 7.11-
7.16 (m, 1 H, Ar), 7.32-7.35 (d, 2 H, J = 8.95, Ar), 7.66-7.67 (m, 2 H, Ar). Anal. Calcd. for 
C16H14ClN3O: C, 64.11; H, 4.71; N, 14.02; Cl, 11.83. Found C, 64.08; H, 4.77; N, 13.93; 
Cl, 11.97. 
 
2-Chloro-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)quinazoline (180) 
Using the general method described above, 273c (0.300 g, 1.51 mmol) and 6-methoxy-
1,2,3,4-tetrahydroquinoline 271 (0.295 g, 1.81 mmol) were reacted for 12 h. At the end of 
reaction, solvent was evaporated, silica gel and methanol were added and evaporated in 
vacuo to give a dried plug. The reaction mixture was purified using flash chromatography 
using chloroform/methanol to the afford 180 as yellow colored solid (0.121 g, 25%). TLC 
Rf = 0.97 (MeOH:CHCl3; 1:5); mp, 135.9-137.0 °C (lit.
241 136-138 °C); 1H NMR, DMSO-
d6 (400 MHz): 2.13-2.18 (m, 2 H, CH2), 2.88-2.91 (t, 2 H, CH2), 3.85 (s, 3 H, OCH3), 4.11-
4.16 (m, 2 H, CH2),  6.59-6.62 (dd, 1 H, J1 = 2.89, J2 = 8.81, 7´-Ar), 6.75-6.77 (d, 1 H, J = 
8.85, 8´-Ar), 6.857-6.863 (d, 1 H, J = 2.86, 5´-Ar), 7.16-7.19 (m, 1 H, J1 = 1.26, J2 = 6.96, 
J3 = 8.43,  Ar), 7.31-7.33 (dd, 1 H, J1 = 0.90, J2 = 8.53, Ar), 7.68-7.71 (m, 1 H, J1 = 1.36, 
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J2 = 6.97, J3 = 8.39,  Ar), 8.05-8.07 (d, 1 H, Ar). Anal. Calcd. for C18H16ClN3O . 
0.24(CH3)2CHOH: C, 66.08; H, 5.31; N, 12.34; Cl, 10.41. Found C, 66.30; H, 5.19; N, 
12.35; Cl, 10.17. 
 
N2,N4-Dimethyl-N2,N4-bis(4-(methylthio)phenyl)quinazoline-2,4-diamine (279) 
Compound 273c (0.200 g, 1.00 mmol) and N-methyl-4-(methylthio)aniline 263 (0.185 g, 
1.21 mmol) were stirred at room temperature for 12 h. At the end of reaction, solvent was 
evaporated, silica gel and methanol were added and evaporated in vacuo to give a dried 
plug. The reaction mixture was purified using flash chromatography using 
chloroform/methanol which afforded dimer 279 as a yellow colored semisolid (0.195 g, 
45%). TLC Rf = 0.87 (Hex:EtOAc; 1:1); 
1H NMR, DMSO-d6 (400 MHz): 2.48 (s, 3 H, 
SCH3), 2.49 (s, 3 H, SCH3), 3.29 (s, 3 H, NCH3), 3.57 (s, 3 H, NCH3), 6.76-6.81 (m, 1 H, 
Ar), 6.88-6.90 (dd, 1 H, J = 0.89, J = 8.43, Ar), 7.14-7.16 (d, 2 H, J = 8.68, Ar) 7.25-7.29 
(m, 4 H, Ar), 7.37-7.45 (m, 4 H, Ar). The compound was carried on directly without further 
characterization. 
 
6-((2-Chloroquinazolin-4-yl)amino)naphthalen-1-ol (280) 
Using the general method described above, 273c (0.200 g, 1.00 mmol) and 6-
aminonaphthalen-1-ol 266 (0.144 g, 0.904 mmol) were reacted for 12 h. At the end of 
reaction, solvent was evaporated, silica gel and methanol were added and evaporated in 
vacuo to give a dried plug. The reaction mixture was purified using flash chromatography 
using chloroform/methanol to the afford 280 as white colored solid (0.070 g, 22%). TLC 
Rf = 0.67 (MeOH:CHCl3; 1:5); 
1H NMR, DMSO-d6 (400 MHz): 6.83-6.87 (t, 1 H, Ar), 
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7.32-7.33 (d, 2 H, J = 4.55, Ar), 7.67-7.71 (dt, 1 H, J1 = 1.13, J2 = 6.96, J3 = 8.09, Ar), 7.74-
7.76 (dd, 1 H, J1 = 0.79, J2 = 8.31, Ar), 7.81-7.84 (dd, 1 H, J1 = 2.11, J2 = 9.07, Ar), 7.90-
7.94 (dt, 1 H, J1 = 1.13, J2 = 7.08, J3 = 8.35, Ar), 8.16-8.18 (d, 1 H, J = 9.02, Ar), 8.24-8.25 
(d, 1 H, J = 2.03, Ar), 8.63-8.65 (dd, 1 H, J1 = 1.35, J2 = 8.66, Ar), 10.16 (s, 1 H, exch., 
NH), 10.40 (s, br, 1 H, exch., OH). The compound was used without further 
characterization. 
 
2-Chloro-N-(5-methoxynaphthalen-2-yl)-N-methylquinazolin-4-amine (182) 
Compound 280 (0.070 g, 0.218 mmol) was dissolved in anhydrous DMF (10 mL) in a three 
necked round-bottomed flask and was stirred at 0 °C under argon. Sodium hydride (0.016 
g, 0.653 mmol) was added the above mixture and stirred at 0 °C for additional 15 min 
followed by addition of methyl iodide (0.068 g, 0.479 mmol) while maintaining the 
reaction at room temperature for 4 h. Methanol was added at the end of the reaction, solvent 
was evaporated and the reaction mixture was then extracted with water and ethyl acetate 
(25 mL × 3) and dried over Na2SO4. Silica gel was added next to the combined fractions, 
the solvent was removed by evaporation to yield a dry plug and column was the run using 
hexanes/ethyl acetate. The fractions containing the desired product (TLC) were pooled and 
evaporated to obtain the desired compounds 182 as off-white colored solid (0.036 g, 47%). 
TLC Rf = 0.82 (MeOH:CHCl3; 1:5); mp, 171.9-173.8 °C; 
1H NMR, DMSO-d6 (400 MHz): 
3.64 (s, 3 H, NCH3), 3.99 (s, 3 H, OCH3), 6.86-6.88 (d, 1 H, J = 8.54, Ar), 7.00-7.06 (m, 2 
H, Ar), 7.40-7.49 (m, 3 H, Ar), 7.63-7.71 (m, 2 H, Ar), 7.88-7.89 (d, 1 H, J = 2.02, Ar), 
8.21-8.23 (d, 1 H, J = 8.92, Ar). Anal. Calcd. for C20H16ClN3O . 0.11CH3(CH2)4CH3: C, 
69.07; H, 4.93; N, 11.68; Cl, 9.86. Found C, 68.84; H, 5.06; N, 11.69; Cl, 9.64. 
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Pyrido[2,3-d]pyrimidin-4(3H)-one (274d) 
To a 10-20 mL Biotage microwave vial were added 2-aminopicolinic acid 275 (2 g, 14.5 
mmol) and formamide (3.26 g, 72.5 mmol) which were set up for microwave irradiation at 
170 °C for 90 min to yield 274d as buff colored solid (1.48 g, 70%). TLC Rf = 0.43 
(MeOH:CHCl3; 1:5); mp, >250 °C (lit.
270 255-257 °C); 1H NMR, DMSO-d6 (400 MHz): 
7.54-7.57 (dd, 1 H, J1 = 7.92, J2 = 4.57, 6-Ar), 8.32 (s, 1 H, 2-H), 8.50-8.53 (dd, 1 H, J1 = 
7.85, J2 = 2.02, 5-Ar), 8.95-8.97 (dd, 1 H, J1 = 1.98, J2 = 4.54, 7-Ar), 12.57 (s, br, exch., 
NH). 
 
4-Chloropyrido[2,3-d]pyrimidine (273d) 
To a 250 mL round-bottomed flask were added quinazolin-4(3H)-one 273d (2.5 g, 16.99 
mmol), trimethylamine (3.5 mL), and toluene (30 mL). The mixture was cooled to 0 °C to 
which phosphorus oxychloride (4.2 mL) was added and stirred at room temperature for 1 
h. The reaction was heated to 95 °C for 3 h. After monitoring the reaction on TLC, the 
reaction was cooled. The work up procedure was similar to that provided for compound 
273b above. Compound 273d was obtained as brown colored solid (0.455 g, 20%). TLC 
Rf = 0.48 (MeOH:CHCl3; 1:5); mp, 250.0-251.1 °C (lit.
239 240 °C). 1H NMR, DMSO-d6 
(400 MHz): 7.65-7.68 (q, 1 H, J1 = 7.90, J2 = 4.75, 6-Ar), 8.54 (s, 1 H, 2-H), 8.62-8.64 (dd, 
1 H, J1 = 7.90, J2 = 1.90, 5-Ar), 9.00-9.01 (dd, 1 H, J1 = 1.90, J2 = 4.73, 7-Ar). 
 
N-(4-methoxyphenyl)-N-methylpyrido[2,3-d]pyrimidin-4-amine (183) 
Compound 273d (0.100 g, 0.604 mmol) and 4-methoxy-N-methylaniline 259 (0.099 g, 
0.725 mmol) were stirred at room temperature for 12 h. At the end of reaction, solvent was 
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evaporated, silica gel and methanol were added and evaporated in vacuo to give a dried 
plug. The reaction mixture was purified using flash chromatography using 
chloroform/methanol which afforded 183 as yellow colored solid (0.047 g, 29%). TLC Rf 
= 0.67 (MeOH:CHCl3; 1:5); mp, 105.4-106.4 °C; 
1H NMR, DMSO-d6 (400 MHz): 3.55 
(s, 3 H, NCH3), 3.80 (s, 3 H, OCH3), 7.02-7.05 (d, 2 H, J = 8.88, Ar), 7.16-7.19 (q, 1 H, J1 
= 4.25, J2 = 8.51, 6-Ar), 7.27-7.30 (m, 1 H, 5-Ar), 7.29-7.31 (d, 2 H, J = 8.85, Ar), 8.82 (s, 
1 H, Ar), 8.86-8.88 (dd, 1 H, J1 = 1.91, J2 = 4.23, 7-Ar). Anal. Calcd. for C15H14N4O. 0.57 
H2O: C, 65.16; H, 5.52; N, 20.26. Found C, 65.17; H, 5.58; N, 20.24. 
 
2-Amino-6-chlorobenzaldehyde (282a) 
To a solution of (2-amino-6-chlorophenyl)methanol 283 (0.4 g, 2.54 mmol) in CH2Cl2 (10 
mL) was added MnO2 (0.883 g, 10.15 mmol) and stirred at room temperature for 24 h. 
After the completion of reaction silica gel was added and the solvent was dried in vacuo to 
give a dry plug. The reaction mixture was purified using flash chromatography with 
chloroform/methanol to yield pure 282a as yellow needles (0.326 g, 83%). TLC Rf = 0.78 
(Hex:EtOAc; 1:1); mp, 92.4-95.0 °C (lit.244 96-97 °C); 1H NMR, DMSO-d6 (400 MHz): 
6.62-6.64 (d, 1 H, J = 7.58, Ar), 6.75-6.77 (dd, 1 H, J1 = 0.51, J2 = 8.75, Ar), 7.24-7.28 (t, 
1 H, J = 8.33, Ar), 7.68 (s, br, 2 H, exch., NH2), 10.32 (s, 1 H, CHO). 
 
5-Chloro-3-pentylquinolin-2-amine (281a) 
To a solution of compound 282a (0.200 g, 1.29 mmol) in DMSO (5 mL) were added 
heptanenitrile (0.286 g, 2.57 mmol) and potassium tert-butoxide (0.289 g, 2.57 mmol). The 
reaction mixture was stirred at 60 °C for 3 h and was subsequently diluted with water and 
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extracted with ethyl acetate (50 × 3 mL) and dried over Na2SO4. The combined organic 
layer was pooled, silica gel was added and concentrated under reduced pressure to give a 
dry plug. The crude mixture was purified by flash chromatography (hexanes/ethyl acetate) 
to yield pure 281a as an off-white solid (0.152 g, 48%). TLC Rf = 0.45 (Hex:EtOAc; 1:1); 
mp, 104.2-106.0 °C; 1H NMR, DMSO-d6 (400 MHz): 0.87-0.90 (t, 3 H, CH3), 1.34-1.35 
(m, 4 H, CH2), 1.58-1.65 (quin, 2 H, CH2), 2.60-2.64 (t, 2 H, CH2), 6.58 (s, 2 H, exch., 
NH2), 7.25-7.27 (dd, 1 H, J1 = 6.89, J2 = 1.69, 7-Ar), 7.38-7.45 (m, 2 H, Ar), 7.88 (s, 1 H, 
4-Ar). The compound was used directly without further characterization. 
 
N-(5-Chloro-3-pentylquinolin-2-yl)pivalamide (284) 
Compound 281a (0.200 g, 0.804 mmol) was dissolved in ethyl acetate (10 mL) to which 
pivalic anhydride (3 mL) was added and heated at 60 °C for 12 h. After the reaction 
completion, silica gel was added and the solvent was evaporated in vacuo to afford a dry 
plug. Flash chromatography of the crude mixture in hexanes/ethyl acetate yielded pure 284 
as buff colored solid (0.150 g, 58%). TLC Rf = 0.74 (Hex:EtOAc; 1:1); mp, 105.4-106.4 
°C;  1H NMR, DMSO-d6 (400 MHz): 0.85-0.88 (t, 3 H, CH3), 1.28 (m, 13 H, 2 CH2, 
(CH3)3), 1.57-1.64 (quin, 2 H, CH2), 2.69-2.73 (t, 2 H, CH2), 7.68-7.72 (t, 1 H, 7-Ar), 7.74-
7.76 (dd, 1 H, J1 = 1.30, J2 = 7.55, Ar), 7.93-7.95 (dd, 1 H, J1 = 8.18, J2 = 0.71, Ar), 8.35 
(s, 1 H, 4-Ar), 9.96 (s, 1 H, exch., NH). Anal. Calcd. for C19H25ClN2O: C, 68.56; H, 7.57; 
N, 8.41; Cl, 10.65. Found C, 68.48; H, 7.47; N, 8.22; Cl, 10.36. 
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5-Bromo-3-pentylquinolin-2-amine (281b) 
To a solution of 2-amino-6-bromobenzaldehyde 282a (0.500 g, 2.5 mmol) in DMSO (10 
mL) were added heptanenitrile (0.556 g, 5 mmol) and potassium tert-butoxide (0.561 g, 5 
mmol). The reaction mixture was stirred at 60 °C for 3 h and was subsequently diluted with 
water and extracted with ethyl acetate (50 × 3 mL) and dried over Na2SO4. The combined 
organic layer was pooled, silica gel was added and concentrated under reduced pressure to 
give a dry plug. The crude mixture was purified by flash chromatography (hexanes/ethyl 
acetate) to yield pure 281b as light brown colored solid (0.217 g, 30%). TLC Rf = 0.45 
(Hex:EtOAc; 1:1); mp, 108.8-111.1 °C; 1H NMR, DMSO-d6 (400 MHz): 0.88-0.91 (t, 3 
H, CH3), 1.35-1.37 (m, 4 H, CH2), 1.59-1.66 (quin, 2 H, CH2), 2.60-2.64 (t, 2 H, CH2), 6.58 
(s, 2 H, exch., NH2), 7.32-7.36 (t, 1 H, Ar), 7.43-7.47 (m, 2 H, Ar), 7.83 (s, 1 H, 4-Ar). 
1H 
NMR agreed well with the literature76 reported values. 
 
N-(5-Bromo-3-pentylquinolin-2-yl)pivalamide (285) 
Compound 281b (0.200 g, 0.682 mmol) was dissolved in ethyl acetate (10 mL) to which 
pivalic anhydride (3 mL) was added and heated at 60 °C for 12 h. After the reaction 
completion, silica gel was added and the solvent was evaporated in vacuo to afford a dry 
plug. Flash chromatography of the crude mixture in hexanes/ethyl acetate yielded pure 285 
as buff colored solid (0.202 g, 68%). TLC Rf = 0.74 (Hex:EtOAc; 1:1); mp, 109.5-112.1 
°C; 1H NMR, DMSO-d6 (400 MHz): 0.85-0.88 (t, 3 H, CH3), 1.28-1.32 (m, 13 H, 2 CH2, 
(CH3)3), 1.57-1.64 (quin, 2 H, CH2), 2.69-2.73 (t, 2 H, CH2), 7.61-7.65 (t, 1 H, 7-Ar), 7.91-
7.93 (dd, 1 H, J1 = 7.51, J2 = 0.80, Ar), 7.96-7.98 (d, 1 H, J = 8.42, Ar), 8.29 (s, 1 H, 4-Ar), 
9.97 (s, 1 H, exch., NH). The compound was used directly without further characterization. 
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 General method for Pd-catalyzed cross coupling reactions 
To a 2-5 mL Biotage microwave vial were added 5-haloquinoline (1 equivalent), aniline 
(1.2-1.4 equivalents), Pd-catalyst (1-10 mol%), ligand (1-10 mol%) and the base (1.5-3.2 
equivalents) and the vial was sealed. Vacuum was applied to the vial and was back filled 
with argon. The procedure was repeated 2 more times. Suitable solvent (1-3 mL) was added 
and the reaction was set for microwave irradiation. At the end of the reaction, the solvent 
was evaporated and the reaction mixture was extracted with ethyl acetate (10 × 3 mL) and 
dried over Na2SO4. The fractions were combined to which silica gel was added and the 
solvent was evaporated to give a dry plug. Flash chromatography of the crude mixture in 
hexanes/ethyl acetate was carried out to afford pure compounds. 
 
N5-(5-Bromo-3-pentylquinolin-2-yl)-3-pentylquinoline-2,5-diamine (287) 
Using the general method specified above, 285 (0.020 g, 0.053 mmol), 4-methoxy-N-
methlaniline 259 (0.013 g, 0.074 mmol), Pd2(dba)3 (0.001 g, 2 mol%), SPhos (0.008 g, 8 
mol%) and sodium tert-butoxide (0.013 g, 0.132 mmol) were added to a microwave vial. 
2 mL of THF was added and the reaction was carried out at 85 °C for 4 h. TLC Rf = 0.40 
(Hex:EtOAc; 1:1); 1H NMR, DMSO-d6 (400 MHz): 0.87-0.90 (m, 6 H, CH3), 1.34-1.38 
(m, 8 H, CH2), 1.60-1.69 (m, 4 H, CH2), 2.57-2.64 (m, 4 H, CH2), 6.48 (s, 1 H, exch., NH), 
6.59 (s, 2 H, exch., NH2), 7.30-7.51 (m, 6 H, Ar), 7.83 (s, 1 H, Ar), 7.94 (s, 1 H, Ar). The 
compound was used directly without further characterization. 
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N-(5-((4-Methoxyphenyl)amino)-3-pentylquinolin-2-yl)pivalamide (288) 
Using the general method specified above, 285 (0.020 g, 0.053 mmol), p-anisidine 270 
(0.009 g, 0.074 mmol), XPhos Pd G3 (0.009 g, 2 mol%), XPhos (0.005 g, 2 mol%) and 
sodium tert-butoxide (0.013 g, 0.132 mmol) were added to a microwave vial. A 2 mL 
volume of 1,4-dioxane was added and the reaction was carried out at 110 °C for 24 h. New 
spot of 288 appeared when the reaction mixture was monitored on TLC. TLC Rf = 0.61 
(MeOH: CHCl3; 1:10); 
1H NMR, DMSO-d6 (400 MHz): 0.87-0.90 (t, 3 H, CH3), 1.12 (s, 
9 H, (CH3)3), 1.33-1.37 (m, 4 H, CH2), 1.58-1.66 (quin, 2 H, CH2), 2.54-2.57 (t, 2 H, CH2), 
3.72 (s, 3 H, OCH3), 6.20 (s, 1 H, exch., NH), 6.68-6.70 (d, 1 H, J = 7.68,  6-Ar), 6.87-6.89 
(d, 2 H, J = 8.89, Ar), 6.94-6.96 (d, 1 H, J =8.15, 8-Ar), 7.04-7.06 (d, 2 H, J = 8.89, Ar), 
7.18-7.22 (t, 1 H, J1 = J2 = 8.00, 7-Ar), 7.81 (s, 1 H, exch., NH), 8.01 (s, 1 H, 4-Ar). The 
compound was used directly without further characterization. 
 
N5-(4-Methoxyphenyl)-N5-methyl-3-pentylquinoline-2,5-diamine (190) 
Using the general method specified above, 285 (0.150 g, 0.397 mmol), 4-methoxy-N-
methylaniline 259 (0.076 g, 0.557 mmol), XPhos Pd G3 (0.034 g, 10 mol%), XPhos (0.019 
g, 10 mol%) and cesium carbonate (0.388 g, 1.19 mmol) were added to a microwave vial. 
2 mL of tert-butanol was added and the reaction was carried out at 100 °C for 24 h. 
Following the work up procedure mentioned above and purification afforded 286 as a 
yellow colored semisolid (0.095 g, 55%), TLC Rf = 0.61 (Hex:EtOAc; 1:1), which was 
used without further characterization. To a solution of 286 (0.062 g, 0.143 mmol) in 
methanol (10 mL), 1N NaOH was added (2 mL) and the reaction was stirred at reflux for 
8 h. At the end of the reaction the solvent was evaporated in vacuo, the reaction mixture 
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was extracted with ethyl acetate (10 × 3 mL), dried over Na2SO4 and the fractions were 
pooled. After evaporating the solvent, the compound was dried over P2O5 to yield 190 as a 
brown colored powder (0.063 g, 83%). TLC Rf = 0.24 (Hex:EtOAc; 1:1); mp, 132.6-133.9 
°C; 1H NMR, DMSO-d6 (400 MHz): 0.78-0.82 (t, 3 H, CH3), 1.13-1.26 (m, 4 H, CH2), 
1.39-1.46 (quin, 2 H, CH2), 2.42-2.46 (t, 2 H, CH2), 3.26 (s, 3 H, NCH3), 3.65 (s, 3 H, 
OCH3), 6.31 (s, 2 H, exch., NH2), 6.57-6.59 (d, 2 H, J = 9.0, Ar), 6.74-6.76 (d, 2 H, J = 
9.03, Ar), 6.93-6.95 (d, 1 H, J = 7.32, Ar), 7.31-7.33 (d, 1 H, J = 8.28, Ar), 7.41-7.45 (t, 1 
H, J1 = J2 = 7.89, Ar), 7.50 (s, 1 H, 4-Ar). Anal. Calcd. for C22H27N3O: C, 75.61; H, 7.79; 
N, 12.02. Found C, 75.40; H, 7.96; N, 11.77. 
 
N-(5-((4-Methoxyphenyl)(methyl)amino)-3-methylquinolin-2-yl)pivalamide (290a) 
To a solution of 2-amino-6-bromobenzaldehyde 282b (1.0 g, 5 mmol) in DMSO (20 mL) 
were added propionitrile 289a (0.551 g, 10 mmol) and potassium tert-butoxide (1.12 g, 10 
mmol). The reaction mixture was stirred at 60 °C for 3 h and was subsequently diluted with 
water and extracted with ethyl acetate (50 × 3 mL) and dried over Na2SO4. The combined 
organic layer was pooled, silica gel was added and concentrated under reduced pressure to 
give a dry plug. The crude mixture was purified by flash chromatography (hexanes/ethyl 
acetate) to yield semi-solid intermediate which was pivaloyl protected by dissolving the 
intermediate in ethyl acetate (20 mL) to which pivalic anhydride (4 mL) was added and 
heated at 60 °C for 12 h. After the reaction completion, silica gel was added and the solvent 
was evaporated in vacuo to afford a dry plug. Flash chromatography of the crude mixture 
in hexanes/ethyl acetate yielded pure 290a as buff colored solid (0.788 g, 49%). TLC Rf = 
0.80 (Hex:EtOAc; 1:1); mp, 103.7-105.5 °C; 1H NMR, DMSO-d6 (500 MHz): 1.29 (s, 9 H, 
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(CH3)3), 2.367-2.369 (d, 3 H, CH3), 7.62-7.65 (dd, 1 H, J1 = 7.58, J2 = 8.38, Ar), 7.90-7.92 
(dd, 1 H, J1 = 1.03, J2 = 7.53, Ar), 7.95-7.97 (m, 1 H, J1 = 0.93, J2 = 0.93, J3 = 8.43, Ar), 
8.32 (s, 1 H, Ar), 10.02 (s, 1 H, exch., NH). The compound was used directly without 
further characterization. 
 
N-(3-ethyl-5-((4-methoxyphenyl)(methyl)amino)quinolin-2-yl)pivalamide (290b) 
To a solution of 2-amino-6-bromobenzaldehyde 282b (0.500 g, 2.5 mmol) in DMSO (20 
mL) were added butyronitrile 289b (0.345 g, 5 mmol) and potassium tert-butoxide (0.561 
g, 5 mmol). The reaction mixture was stirred at 60 °C for 3 h and was subsequently diluted 
with water and extracted with ethyl acetate (25 × 3 mL) and dried over Na2SO4. The 
combined organic layer was pooled, silica gel was added and concentrated under reduced 
pressure to give a dry plug. The crude mixture was purified by flash chromatography 
(hexanes/ethyl acetate) to yield semi-solid intermediate which was pivaloyl protected by 
dissolving the intermediate in ethyl acetate (20 mL) to which pivalic anhydride (4 mL) was 
added and heated at 60 °C for 12 h. After the reaction completion, silica gel was added and 
the solvent was evaporated in vacuo to afford a dry plug. Flash chromatography of the 
crude mixture in hexanes/ethyl acetate yielded pure 290b as buff colored solid (0.288 g, 
36%). TLC Rf = 0.80 (Hex:EtOAc; 1:1); mp, 112.7-133.3 °C;
 1H NMR, DMSO-d6 (400 
MHz): 1.23-1.26 (t, 3 H, CH3), 1.29 (s, 9 H, (CH3)3), 2.72-2.78 (q, 2 H, CH2), 7.62-7.66 (t, 
1 H, Ar), 7.91-7.93 (d, 1 H, J = 7.48, Ar), 7.97-7.99 (d, 1 H, J = 8.41, Ar), 8.30 (s, 1 H, 
Ar), 9.97 (s, 1 H, exch., NH). The compound was used directly without further 
characterization. 
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N-(5-((4-Methoxyphenyl)(methyl)amino)-3-propylquinolin-2-yl)pivalamide (290c) 
To a solution of 2-amino-6-bromobenzaldehyde 282b (1.0 g, 5 mmol) in DMSO (20 mL) 
were added pentanenitrile 289c (0.831 g, 10 mmol) and potassium tert-butoxide (1.12 g, 
10 mmol). The reaction mixture was stirred at 60 °C for 3 h and was subsequently diluted 
with water and extracted with ethyl acetate (50 × 3 mL) and dried over Na2SO4. The 
combined organic layer was pooled, silica gel was added and concentrated under reduced 
pressure to give a dry plug. The crude mixture was purified by flash chromatography 
(hexanes/ethyl acetate) to yield an intermediate which was pivaloyl protected by dissolving 
the intermediate in ethyl acetate (20 mL) to which pivalic anhydride (4 mL) was added and 
heated at 60 °C for 12 h. After the reaction completion, silica gel was added and the solvent 
was evaporated in vacuo to afford a dry plug. Flash chromatography of the crude mixture 
in hexanes/ethyl acetate yielded pure 290c as a brown colored semisolid (0.788 g, 32%). 
TLC Rf = 0.80 (Hex:EtOAc; 1:1); 
1H NMR, DMSO-d6 (500 MHz): 0.91-0.94 (t, 3 H, CH3), 
1.29 (s, 9 H, (CH3)3), 1.59-1.67 (m, 2 H, CH2), 2.68-2.71 (t, 2 H, CH2), 7.62-7.66 (dd, 1 H, 
J1 = 7.56, J2 = 8.41, Ar), 7.92-7.94 (dd, 1 H, J1 = 1.02,  J2 = 7.54, Ar), 7.97-7.99 (m, 1 H, 
J1 = J2 = 0.91,  J3 = 8.43, Ar), 8.29 (s, 1 H, Ar), 9.96 (s, 1 H, exch., NH). The compound 
was used directly without further characterization. 
 
N-(3-Butyl-5-((4-methoxyphenyl)(methyl)amino)quinolin-2-yl)pivalamide (290d) 
To a solution of 2-amino-6-bromobenzaldehyde 282b (1.0 g, 5 mmol) in DMSO (20 mL) 
were added hexanenitrile 289d (0.971 g, 10 mmol) and potassium tert-butoxide (1.12 g, 10 
mmol). The reaction mixture was stirred at 60 °C for 3 h and was subsequently diluted with 
water and extracted with ethyl acetate (50 × 3 mL) and dried over Na2SO4. The combined 
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organic layer was pooled, silica gel was added and concentrated under reduced pressure to 
give a dry plug. The crude mixture was purified by flash chromatography (hexanes/ethyl 
acetate) to yield an intermediate which was pivaloyl protected by dissolving the 
intermediate in ethyl acetate (20 mL) to which pivalic anhydride (4 mL) was added and 
heated at 60 °C for 12 h. After the reaction completion, silica gel was added and the solvent 
was evaporated in vacuo to afford a dry plug. Flash chromatography of the crude mixture 
in hexanes/ethyl acetate yielded pure 290d as a brown colored semisolid (0.436 g, 24%). 
TLC Rf = 0.80 (Hex:EtOAc; 1:1); 
1H NMR, DMSO-d6 (500 MHz): 0.90-0.92 (t, 3 H, CH3), 
1.29 (s, 9 H, (CH3)3), 1.32-1.36 (m, 2 H, CH2), 1.56-1.62 (m, 2 H, CH2), 2.71-2.74 (t, 2 H, 
CH2), 7.62-7.65 (dd, 1 H, J1 = 7.72, J2 = 8.25, Ar), 7.92-7.93 (dd, 1 H, J1 = 0.86, J2 = 7.51,  
Ar), 7.96-7.98 (d, 1 H, J = 8.41, Ar), 8.29 (s, 1 H, Ar), 9.96 (s, 1H, exch., NH). The 
compound was used directly without further characterization. 
 
N5-(4-Methoxyphenyl)-N5,3-dimethylquinoline-2,5-diamine (186) 
Using the general method for Pd-catalyzed cross coupling reaction specified above, 290a 
(0.150 g, 0.467 mmol), 4-methoxy-N-methylaniline 259 (0.090 g, 0.654 mmol), XPhos Pd 
G3 (0.040 g, 10 mol%), XPhos (0.022 g, 10 mol%) and cesium carbonate (0.456 g, 1.4 
mmol) were added to a microwave vial. A 2 mL volume of tert-butanol was added and the 
reaction was carried out at 110 °C for 24 h. Following the work up procedure mentioned 
above subsequent separation and purification afforded 186 as a brown colored solid (0.027 
g, 20%). TLC Rf = 0.12 (Hex:EtOAc; 1:1); 
1H NMR, DMSO-d6 (400 MHz): 2.13 (s, 3 H, 
CH3), 3.24 (s, 3 H, NCH3), 3.66 (s, 3 H, OCH3), 6.40 (s, 2 H, exch., NH2), 6.53-6.56 (d, 2 
H, J = 9.07, Ar), 6.74-6.76 (d, 2 H, J = 9.04, Ar), 6.93-6.95 (d, 1 H, J = 7.31, Ar), 7.35-
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7.37 (d, 1 H, J = 7.88, Ar), 7.43-7.47 (t, 1 H, Ar), 7.61 (s, 1 H, Ar). Anal. Calcd. for 
C18H19N3O: C, 73.69; H, 6.53; N, 14.32. Found C, 76.39; H, 8.42; N, 6.36. Sample did not 
pass CHN analysis. MS (ESI): m/z calculated for  C18H19N3O + H
+ [M+H+]: 294.15. Found: 
294.2. The compound was not sent for biological evaluation and requires further 
characterization. 
 
3-Ethyl-N5-(4-methoxyphenyl)-N5-methylquinoline-2,5-diamine (187) 
Using the general method for Pd-catalyzed cross coupling reaction specified above, 290b 
(0.150 g, 0.447 mmol), 4-methoxy-N-methylaniline 259 (0.086 g, 0.626 mmol), XPhos Pd 
G3 (0.038 g, 10 mol%), XPhos (0.021 g, 10 mol%) and cesium carbonate (0.437 g, 1.34 
mmol) were added to a microwave vial. 2 mL of tert-butanol was added and the reaction 
was carried out at 110 °C for 24 h. Following the work up procedure mentioned above and 
purification afforded a yellow colored semisolid intermediate 291b (0.106 g, crude yield 
60%). To a solution of the intermediate in methanol (10 mL), 1N NaOH was added (2 mL) 
and the reaction was stirred at reflux for 8 h. At the end of the reaction the solvent was 
evaporated in vacuo, the reaction mixture was extracted with ethyl acetate (10 × 3 mL), 
dried over Na2SO4 and the fractions were pooled. After evaporating the solvent, the 
compound was dried over P2O5 to yield 187 as a brown colored powder (0.045 g, 54%). 
TLC Rf = 0.15 (Hex:EtOAc; 1:1); mp, 163.9-166.7 °C; 
1H NMR, DMSO-d6 (400 MHz): 
1.03-1.06 (t, 3 H, CH3), 2.44-2.48 (q, 2 H, CH2), 3.25 (s, 3 H, NCH3), 3.66 (s, 3 H, OCH3), 
6.32 (s, 2 H, exch., NH2), 6.58-6.60 (d, 2 H, J = 8.84, Ar), 6.75-6.77 (d, 2 H, J = 8.88, Ar), 
6.92-6.94 (d, 1 H, J = 7.24, Ar), 7.32-7.34 (d, 1 H, J = 8.14, Ar), 7.41-7.45 (t, 1 H, Ar), 
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7.55 (s, 1 H, Ar). Anal. Calcd. for C19H21N3O. 0.27CH3CO2C2H5: C, 72.83; H, 7.05; N, 
12.69. Found C, 73.10; H, 7.19; N, 12.30. 
 
N5-(4-Methoxyphenyl)-N5-methyl-3-propylquinoline-2,5-diamine (188) 
Using the general method for Pd-catalyzed cross coupling reaction specified above, 290c 
(0.150 g, 0.429 mmol), 4-methoxy-N-methylaniline (0.082 g, 0.601 mmol), XPhos Pd G3 
(0.036 g, 10 mol%), XPhos (0.020 g, 10 mol%) and cesium carbonate (0.420 g, 1.29 mmol) 
were added to a microwave vial. 2 mL of tert-butanol was added and the reaction was 
carried out at 110 °C for 24 h. Following the work up procedure mentioned above and 
purification afforded a yellow colored semisolid intermediate 291c (0.102 g, crude yield 
59%). To a solution of the intermediate in methanol (10 mL), 1N NaOH was added (2 mL) 
and the reaction was stirred at reflux for 8 h. At the end of the reaction the solvent was 
evaporated in vacuo, the reaction mixture was extracted with ethyl acetate (10 × 3 mL), 
dried over Na2SO4 and the fractions were pooled. After evaporating the solvent, the 
compound was dried over P2O5 to yield 188 as a brown colored powder (0.042 g, 52%). 
TLC Rf = 0.18 (Hex:EtOAc; 1:1); mp, 168.1-170 °C; 
1H NMR, DMSO-d6 (500 MHz): 
0.79-0.82 (t, 3 H, CH3), 1.43-1.51 (m, 2 H, CH2), 2.42-2.45 (t, 2 H, CH2), 3.25 (s, 3 H, 
NCH3), 3.65 (s, 3 H, OCH3), 6.34 (s, 2 H, exch., NH2), 6.57-6.59 (d, 2 H, J = 9.06, Ar), 
6.75-6.77 (d, 2 H, J = 9.09, Ar), 6.93-6.95 (dd, 1 H, J1 = 0.77, J2 = 7.39, Ar), 7.31-7.33 (d, 
1 H, J = 8.32, Ar), 7.42-7.46 (t, 1 H, Ar), 7.53 (s, 1 H, Ar). Anal. Calcd. for C20H23N3O. 
0.36CH3COCH3: C, 73.96; H, 7.41; N, 12.28. Found C, 74.33; H, 7.69; N, 11.97. 
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3-Butyl-N5-(4-methoxyphenyl)-N5-methylquinoline-2,5-diamine (189) 
Using the general method for Pd-catalyzed cross coupling reaction specified above, 290d 
(0.150 g, 0.429 mmol), 4-methoxy-N-methylaniline (0.079 g, 0.578 mmol), XPhos Pd G3 
(0.035 g, 10 mol%), XPhos (0.020 g, 10 mol%) and cesium carbonate (0.403 g, 1.24 mmol) 
were added to a microwave vial. 2 mL of tert-butanol was added and the reaction was 
carried out at 110 °C for 24 h. Following the work up procedure mentioned above and 
purification afforded a yellow colored semisolid intermediate 291b (0.070 g, crude yield 
40%). To a solution of the intermediate in methanol (10 mL), 1N NaOH was added (2 mL) 
and the reaction was stirred at reflux for 8 h. At the end of the reaction the solvent was 
evaporated in vacuo, the reaction mixture was extracted with ethyl acetate (10 × 3 mL), 
dried over Na2SO4 and the fractions were pooled. After evaporating the solvent, the 
compound was dried over P2O5 to yield 189 as a brown colored powder (0.038 g, 68%). 
TLC Rf = 0.18 (Hex:EtOAc; 1:1); mp, 97.7-100.1 °C; 
1H NMR, DMSO-d6 (500 MHz): 
0.79-0.82 (t, 3 H, CH3), 1.15-1.20 (m, 2H, CH2), 1.38-1.44 (m, 2 H, CH2), 2.43-2.46 (t, 2 
H, CH2), 3.26 (s, 3 H, NCH3), 3.65 (s, 3 H, OCH3), 6.29 (s, 2 H, exch., NH2), 6.58-6.60 (d, 
2 H, J = 8.93, Ar), 6.75-6.77 (d, 2 H, J = 9.01, Ar), 6.93-6.95 (dd, 1 H, J1 = 0.90, J2 = 7.41, 
Ar), 7.31-7.32 (d, 1 H, J = 7.78, Ar), 7.42-7.45 (t, 1 H, Ar), 7.51 (s, 1 H, Ar). Anal. Calcd. 
for C21H25N3O. 0.13CH3(CH2)4CH3: C, 75.41; H, 7.77; N, 12.18. Found C, 75.02; H, 7.63; 
N, 11.80. 
 
N5-(4-Methoxyphenyl)-3-methylquinoline-2,5-diamine (191) 
Using the general method for Pd-catalyzed cross coupling reaction specified above, 290a 
(0.125 g, 0.389 mmol), p-anisidine 270 (0.067 g, 0.545 mmol), XPhos Pd G3 (0.034 g, 10 
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mol%), XPhos (0.019 g, 10 mol%) and cesium carbonate (0.380 g, 1.17 mmol) were added 
to a microwave vial. 2 mL of tert-butanol was added and the reaction was carried out at 
110 °C for 12 h. Following the work up procedure mentioned above and purification 
afforded deprotected 191 as a brown colored solid (0.070 g, 64%). TLC Rf = 0.05 
(Hex:EtOAc; 1:1); mp, 189.1-190.9 °C; 1H NMR, DMSO-d6 (400 MHz): 2.22 (s, 3 H, 
CH3), 3.72 (s, 3 H, OCH3), 6.20 (s, 2 H, exch., NH2), 6.70-6.72 (d, 1 H, J = 9.06, Ar), 6.86-
6.88 (d, 2 H, J = 9.09, Ar), 6.95-6.97 (d, 1 H, J = 7.45, Ar), 7.04-7.06 (d, 1 H, J = 8.32, Ar), 
7.18-7.22 (t, 1 H, Ar), 7.79 (s, 1 H, exch., NH), 8.06 (s, 1 H, Ar). Anal. Calcd. for 
C17H17N3O. 0.13CH3CO2C2H5: C, 72.34; H, 6.26; N, 14.44. Found C, 72.33; H, 6.24; N, 
14.45. 
 
2-Amino-4-methylthiophene-3-carbonitrile (293)  
To a 250 ml round-bottomed flask were added acetone 292 (0.500 g, 8.61 mmol), sulfur 
(2.21 g, 8.61 mmol), malononitrile (0.567 g, 8.61 mmol) and 25 mL of DMF.  The reaction 
was put to stirring at 60 °C. L-lysine (0.189 g, 1.29 mmol) was added after 15 min. After 
5 h, the reaction was run at room temperature for approx. 12 h. At end of the reaction, 
solvent was evaporated in vacuo and ethyl acetate (30 mL) was added. The reaction mixture 
was filtered to remove excess sulfur and the filtrate was extracted with water. The 
combined fractions were pooled, silica gel was added and the solvent was evaporated to 
afford a dry plug. The crude mixture was purified using hexanes/ethyl acetate to yield pure 
293 as pale orange colored solid (0.600 g, 42%). TLC Rf = 0.70 (Hex:EtOAc; 1:1); mp, 
116.8-118.7 °C (lit.271 118-119 °C); 1H NMR, DMSO-d6 (400 MHz): 2.047-2.05 (d, 3 H, 
J = 1.22, 4-CH3), 6.035-6.038 (d, 1 H, J =1.22, 5-Ar), 7.07 (s, 2 H, exch., NH2). 
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5-Methylthieno[2,3-d]pyrimidine-2,4-diamine (295)  
To a 500 ml round-bottomed flask cyanamide 296 (2.5 g, 0.060 mol) and 60 mL of 
anhydrous ether were added and stirred under argon. 120 mL of 1N HCl in ether (0.120 
mol) was added to round-bottomed flask using dropping funnel at room temperature with 
continuous stirring. After 2 h, the compound was filtered, washed with ether and dried over 
P2O5 to yield 294 as a chalky white solid (6.746 g, 98%). To a 100 ml round-bottomed 
flask were added 293 (0.165 g, 1.20 mmol), 294 (0.275 g, 2.40 mmol) and DMSO2 (2 g) 
were added. The reaction was run at 120 °C for 1 h. The reaction mixture was cooled down 
to room temperature. 20 mL of methanol was added to the round-bottomed flask and the 
solution was brought to neutral pH using ammonium hydroxide solution. Silica gel was 
added to the above mixture, solvent was evaporated to afford a dry plug. Flash 
chromatography on the crude mixture was carried out using chloroform/methanol to yield 
pure 295 as a pale yellow colored solid (0.215 g, 73%). TLC Rf = 0.63 (MeOH:CHCl3; 
1:5); mp, 213.7-214.7 °C (lit.272 210-212 °C); 1H NMR, DMSO-d6 (400 MHz): 2.412-2.416 
(d, 3 H, J = 1.27, 5-CH3), 5.98 (s, 2 H, exch., NH2), 6.40 (s, 2 H, exch., NH2), 6.508-6.511 
(q, 1 H, J = 1.26, 6-Ar). 
 
General method for oxidative iodination to synthesize 192-210 
To a 100 mL round-bottomed flask were added 295 (1 equivalent), substituted benzenethiol 
(2 equivalents) in EtOH/H2O (2:1) and set for reflux. Iodine (2 equivalents) was added 
after 10 min and the reaction was refluxed for 12 h. At the end of reaction, solvent was 
evaporated in vacuo and the residue was treated with saturated solution of sodium 
thiosulfate followed by extraction with ethyl acetate. Combined ethyl acetate fractions 
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were pooled, dried over Na2SO4, a plug was made using silica gel and flash 
chromatography was run using chloroform/methanol to yield pure compounds. 
 
5-Methyl-6-(phenylthio)thieno[2,3-d]pyrimidine-2,4-diamine (192) 
Compound 295 (0.100 g, 0.555 mmol), benzenethiol (0.122 g, 1.11 mmol) and iodine 
(0.282 g, 1.11 mmol) were reacted as mentioned above using the general method to afford 
192 as off-white colored solid (0.051 g, 32%). TLC Rf = 0.7 (MeOH:CHCl3; 1:5); mp, 
243.9-244.8 °C (lit.259 238.6-239.1 °C); 1H NMR, DMSO-d6 (400 MHz): 2.50 (s, 3 H, 5-
CH3), 6.27 (s, 2 H, exch., NH2), 6.67 (s, 2 H, exch., NH2), 7.10-7.12 (d, 2 H, J = 7.44, Ar), 
7.19-7.20 (d, 1 H, J = 6.77, Ar), 7.30-7.34 (t, 2H, ArH, J1 = J2 = 6.89, Ar). Anal. Calcd. for 
C13H12N4S2. 0.1C2H5OH: C, 54.11; H, 4.33; N, 19.13; S, 21.90. Found C, 54.30; H, 4.13; 
N, 19.00; S, 21.91. 1H NMR agreed well with the literature259 reported values. 
 
6-((2-Methoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (193) 
Compound 295 (0.100 g, 0.555 mmol), 2-methoxybenzenethiol (0.156 g, 1.11 mmol) and 
iodine (0.282 g, 1.11 mmol) were reacted as mentioned above using the general method to 
afford 193 as off-white colored solid (0.073 g, 41%). TLC Rf = 0.7 (MeOH:CHCl3; 1:5); 
mp, 201.3-203.4 °C; 1H NMR, DMSO-d6 (400 MHz): 2.46 (s, 3 H, 5-CH3), 3.86 (s, 3 H, 
OCH3), 6.26 (s, 2 H, exch., NH2), 6.61-6.63 (dd, 1 H, J1 = 1.47, J2 = 7.78, Ar), 6.65 (s, 2 
H, exch., NH2), 6.85-6.89 (t, 1 H, J1 = J2 = 7.34, Ar), 7.01-7.03 (d, 1 H, J = 7.86, Ar), 7.14-
7.17 (t, 1 H, J1 = J2 = 7.75, Ar). Anal. Calcd. for C14H14N4OS2. 0.72CH3OH: C, 51.77; H, 
4.99; N, 16.40; S, 18.77. Found C, 51.99; H, 4.66; N, 16.23; S, 18.61. 
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6-((3-Methoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (194) 
Compound 295 (0.070 g, 0.389 mmol), 3-methoxybenzenethiol (0.109 g, 0.778 mmol) and 
iodine (0.198 g, 0.778 mmol) were reacted as mentioned above using the general method 
to afford 194 as white colored solid (0.020 g, 16%). TLC Rf = 0.7 (MeOH:CHCl3; 1:5); 
mp, 205.5-206.8 °C; 1H NMR, CDCl3 (400 MHz): 2.61 (s, 3 H, 5-CH3), 3.77 (s, 3 H, 
OCH3), 4.84 (s, 2 H, exch., NH2), 5.31 (s, 2 H, exch., NH2), 6.69-6.75 (m, 3 H, Ar), 7.17-
7.21 (t, 1 H, J1 = J2 = 7.88, Ar).  Anal. Calcd. for C14H14N4OS2: C, 52.81; H, 4.43; N, 17.59; 
S, 20.14. Found C, 52.79; H, 4.56; N, 17.35; S, 19.98. 
 
6-((4-Methoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (195) 
Compound 295 (0.060 g, 0.333 mmol), 4-methoxybenzenethiol (0.093 g, 0.666 mmol) and 
iodine (0.169 g, 0.666 mmol) were reacted as mentioned above using the general method 
to afford 195 as colored solid (0.018 g, 17%). TLC Rf = 0.7 (MeOH:CHCl3; 1:5); mp, 
218.1-219.0 °C (lit.259 208.2-208.5 °C); 1H NMR, DMSO-d6 (400 MHz): 2.53 (s, 3 H, 5-
CH3), 3.72 (s, 3 H, OCH3), 6.22 (s, 2 H, exch., NH2), 6.62 (s, 2 H, exch., NH2), 6.90-6.92 
(d, 2 H, J = 8.84, Ar), 7.14-7.16 (d, 2H, J = 8.84, Ar).   Anal. Calcd. for C14H14N4OS2. 
1.0CH3OH: C, 51.25; H, 5.26; N, 15.81; S, 18.10. Found C, 51.54; H, 4.88; N, 15.53; S, 
17.96. 1H NMR agreed well with the literature259 reported values. 
 
6-((2,5-Dimethoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (196) 
Compound 295 (0.044 g, 0.244 mmol), 2,5-dimethoxybenzenethiol (0.083 g, 0.488 mmol) 
and iodine (0.124 g, 0.488 mmol) were reacted as mentioned above using the general 
method to afford 196 as buff colored solid (0.014 g, 17%). TLC Rf = 0.7 (MeOH:CHCl3; 
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1:5); mp, 216.7-219.3 °C (lit.259 213.8-214.0 °C); 1H NMR, DMSO-d6 (400 MHz): 2.45 (s, 
3 H, 5-CH3), 3.57 (s, 3 H, OCH3), 3.80 (s, 3 H, OCH3), 6.10-6.11 (d, 1 H, J = 2.95, 6´-Ar), 
6.26 (s, 2 H, exch., NH2), 6.66 (s, 2 H, exch., NH2), 6.70-6.73 (dd, 1 H, , J1 = 2.95, J2 = 
8.79, 4´-Ar), 6.94-6.96 (d, 1 H, J = 8.81, 3´-Ar). Anal. Calcd. for C15H16N4O2S2: C, 51.71; 
H, 4.63; N, 16.08; S, 18.40. Found C, 51.51; H, 4.77; N, 15.15; S, 18.20. 1H NMR agreed 
well with the literature259 reported values. 
 
6-((2,4-Dimethoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (197) 
Compound 295 (0.080 g, 0.444 mmol), 2,4-dimethoxybenzenethiol (0.151 g, 0.888 mmol) 
and iodine (0.225 g, 0.888 mmol) were reacted as mentioned above using the general 
method to afford 197 as buff colored solid (0.046 g, 30%). TLC Rf = 0.7 (MeOH:CHCl3; 
1:5); mp, 174.1-177.8 °C; 1H NMR, DMSO-d6 (400 MHz): 2.49 (s, 3 H, 5-CH3), 3.73 (s, 
3 H, OCH3), 3.84 (s, 3 H, OCH3), 6.20 (s, 2 H, exch., NH2), 6.48-6.50 (dd, 1 H, J1 = 2.44, 
J2 = 8.59, 5´Ar), 6.60-6.11 (d, 3 H, J = 2.38, 5´Ar, NH2, exch. ), 6.74-6.77 (d, 1 H, J = 8.60, 
6´Ar). Anal. Calcd. for C15H16N4O2S2. 0.44CH3OH: C, 51.15; H, 4.94; N, 15.46; S, 17.69. 
Found C, 51.06; H, 4.71; N, 15.26; S, 17.83. 
 
6-((2,6-Dimethoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (198) 
Compound 295 (0.125 g, 0.694 mmol), 2,6-dimethoxybenzenethiol (0.236 g, 1.388 mmol) 
and iodine (0.352 g, 1.388 mmol) were reacted as mentioned above using the general 
method to afford 198 as off-white colored solid (0.050 g, 21%). TLC Rf = 0.7 
(MeOH:CHCl3; 1:5); mp, 214.2-215.9 °C; 
1H NMR, DMSO-d6 (400 MHz): 2.59 (s, 3 H, 
5-CH3), 3.73 (s, 3 H, OCH3), 3.81 (s, 6 H, OCH3), 6.04 (s, 2 H, exch., NH2), 6.45 (s, 2 H, 
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exch., NH2), 6.67-6.69 (d, 2 H, J = 8.40, Ar), 7.29-7.33 (t, 1 H, J = 8.35, Ar). Anal. Calcd. 
for C15H16N4O2S2. 0.45H2O: C, 50.54; H, 4.77; N, 15.72; S, 17.99. Found C, 50.56; H, 
4.83; N, 15.56; S, 18.08. 
 
6-((3,4-Dimethoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (199) 
Compound 295 (0.420 g, 2.33 mmol), 3,4-dimethoxybenzenethiol (0.793 g, 4.66 mmol) 
and iodine (1.18 g, 4.66 mmol) were reacted as mentioned above using the general method 
to afford 199 as light brown colored solid (0.290 g, 36%). TLC Rf = 0.7 (MeOH:CHCl3; 
1:5); mp, 169.5-170.0 °C (lit.259 182.8-183.6 °C); 1H NMR, DMSO-d6 (400 MHz): 2.54 (s, 
3 H, 5-CH3), 3.71 (s, 6 H, OCH3), 6.22 (s, 2 H, exch., NH2), 6.62 (s, 2 H, exch., NH2), 6.65-
6.68 (dd, 1 H, J1 = 2.18, J2 = 8.37, 6´Ar), 6.84-6.85 (d, 1 H, J = 2.17, 2´Ar), 6.91-6.93 (d, 
1 H, J = 8.49, 5´Ar). Anal. Calcd. for C15H16N4O2S2 .04CHCl3: C, 47.09; H, 4.21; N, 14.30; 
S, 16.37. Found C, 47.05; H, 4.40; N, 14.49; S, 16.38; Cl, 9.44. 1H NMR agreed well with 
the literature259 reported values. 
 
5-Methyl-6-((4-(trifluoromethyl)phenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine 
(200) 
Compound 295 (0.250 g, 1.39 mmol), 4-(trifluoromethyl)benzenethiol (0.494 g, 2.77 
mmol) and iodine (0.704 g, 2.77 mmol) were reacted as mentioned above using the general 
method to afford 200 as off-white colored solid (0.125 g, 26%). TLC Rf = 0.7 
(MeOH:CHCl3; 1:5); mp, 208.0-209.1 °C; 
1H NMR, DMSO-d6 (400 MHz): 2.50 (s, 3 H, 
5-CH3), 6.01 (s, 2 H, CH2), 6.32 (s, 2 H, exch., NH2), 6.72 (s, 2 H, exch., NH2), 7.26-7.28 
(d, 2 H, J = 8.48, Ar), 7.65-7.67 (d, 2 H, J = 8.59, Ar). Anal. Calcd. for C14H11F3N4S2: C, 
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47.18; H, 3.11; N, 15.72; S, 17.99; F, 15.99. Found C, 47.28; H, 3.26; N, 15.65; S, 18.23; 
F, 15.71. 
 
5-Methyl-6-((3-(trifluoromethoxy)phenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine 
(201) 
Compound 295 (0.200 g, 1.11 mmol), 3-(trifluoromethoxy)benzenethiol (0.431 g, 2.22 
mmol) and iodine (0.563 g, 2.22 mmol) were reacted as mentioned above using the general 
method to afford 201 as off-white colored solid (0.055 g, 13%). TLC Rf = 0.7 
(MeOH:CHCl3; 1:5); mp, 195.3-197.4 °C; 
1H NMR, DMSO-d6 (400 MHz): 2.49 (s, 3 H, 
5-CH3), 6.33 (s, 2 H, exch., NH2), 6.72 (s, 2 H, exch., NH2), 7.03 (s, 1 H,2´Ar), 7.09-7.11 
(d, 1 H, J = 7.96, 6´Ar), 7.17-7.20 (d, 1 H, J = 8.27, 4´Ar), 7.43-7.47 (t, 1 H, J = 8.08, 5´Ar). 
Anal. Calcd. for C14H11F3N4OS2. 0.2CH3COCH3: C, 45.29; H, 3.17; N, 14.76; S, 16.89; F, 
15.01. Found C, 45.56; H, 3.10; N, 14.73; S, 16.98; F, 15.02. 
 
5-Methyl-6-((4-(trifluoromethoxy)phenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine 
(202) 
Compound 295 (0.200 g, 1.11 mmol), 4-(trifluoromethoxy)benzenethiol (0.431 g, 2.22 
mmol) and iodine (0.563 g, 2.22 mmol) were reacted as mentioned above using the general 
method to afford 202 as a off-white colored solid (0.100 g, 24%). TLC Rf = 0.7 
(MeOH:CHCl3; 1:5); mp, 197.6-198.7 °C; 
1H NMR, DMSO-d6 (400 MHz): 2.50 (s, 3 H, 
5-CH3), 6.30 (s, 2 H, exch., NH2), 6.69 (s, 2 H, exch., NH2), 7.19-7.22 (dd, 2 H, J1 = 2.10, 
J2 = 8.85, Ar), 7.32-7.34 (d, 2 H, J = 7.37, Ar). Anal. Calcd. for C14H11F3N4OS2: C, 45.15; 
H, 2.98; N, 14.05; S, 17.22; F, 15.31. Found C, 45.28; H, 3.05; N, 14.82; S, 17.37; F, 15.16. 
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6-((3,4-Dichlorophenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (203) 
Compound 295 (0.150 g, 0.832 mmol), 3,4-dichlorobenzenethiol (0.298 g, 1.664 mmol) 
and iodine (0.422 g, 1.664 mmol) were reacted as mentioned above using the general 
method to afford 203 as white colored solid (0.087 g, 29%). TLC Rf = 0.7 (MeOH:CHCl3; 
1:5); mp, 245.1-246.0 °C (lit.259 238.6-238.9 °C); 1H NMR, DMSO-d6 (400 MHz): 2.50 (s, 
3 H, 5-CH3), 6.33 (s, 2 H, exch., NH2), 6.72 (s, 2 H, exch., NH2), 7.02-7.05 (dd, 1 H, J1 = 
2.26, J2 = 8.52, 6´Ar), 7.34-7.35 (d, 1 H, J = 2.20, 2´Ar), 7.56-7.58 (d, 1 H, J = 8.53, 5´Ar).  
Anal. Calcd. for C13H10Cl2N4S2 . 0.32C2H5OH: C, 44.03; H, 3.22; N, 15.06; S, 17.24; Cl, 
19.06. Found C, 44.12; H, 2.84; N, 15.22; S, 17.22; Cl, 18.79. 1H NMR agreed well with 
the literature259 reported values. 
 
6-((3,4-Difluorophenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (204) 
Compound 295 (0.250 g, 1.39 mmol), 3,4-difluorobenzenethiol (0.405 g, 2.77 mmol) and 
iodine (0.704 g, 2.77 mmol) were reacted as mentioned above using the general method to 
afford 204 as off-white colored solid (0.255 g, 57%). TLC Rf = 0.7 (MeOH:CHCl3; 1:5); 
mp, 245.0-245.9 °C; 1H NMR, DMSO-d6 (400 MHz): 2.50 (s, 3 H, 5-CH3), 6.31 (s, 2 H, 
exch., NH2), 6.70 (s, 2 H, exch., NH2), 6.93-6.94 (m, 1 H, Ar), 7.18-7.22 (m, 1 H, Ar), 
7.37-7.44 (d, 1 H, Ar).  Anal. Calcd. for C13H10F2N4S2. 0.05CH3OH: C, 48.14; H, 3.11; N, 
17.27; S, 19.77; F, 11.71. Found C, 48.43; H, 3.24; N, 16.81; S, 20.02; F, 11.32. 
 
5-Methyl-6-((3,4,5-trifluorophenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine (205) 
Compound 295 (0.200 g, 1.11 mmol), 3,4,5-trifluorobenzenethiol (0.364 g, 2.22 mmol) 
and iodine (0.563 g, 2.22 mmol) were reacted as mentioned above using the general method 
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to afford 205 as pale yellow colored solid (0.140 g, 37%). TLC Rf = 0.7 (MeOH:CHCl3; 
1:5); mp, 230.2-230.8 °C; 1H NMR, DMSO-d6 (400 MHz): 2.50 (s, 3 H, 5-CH3), 6.32 (s, 
2 H, exch., NH2), 6.70 (s, 2 H, exch., NH2), 7.01-7.05 (dd, 2 H, J1 = 6.45, J2 = 8.17, Ar).  
Anal. Calcd. for C13H9F3N4S2: C, 45.61; H, 2.65; N, 16.36; S, 18.73; F, 16.65. Found C, 
45.78; H, 2.61; N, 16.28; S, 18.89; F, 16.39. 
 
5-Methyl-6-((2,3,4-trifluorophenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine (206) 
Compound 295 (0.200 g, 1.11 mmol), 2,3,4-trifluorobenzenethiol (0.364 g, 2.22 mmol) 
and iodine (0.563 g, 2.22 mmol) were reacted as mentioned above using the general method 
to afford 206 as off-white colored solid (0.230 g, 61%). TLC Rf = 0.7 (MeOH:CHCl3; 1:5); 
mp, 240.7-242.0 °C; 1H NMR, DMSO-d6 (400 MHz): 2.53 (s, 3 H, 5-CH3), 6.32 (s, 2 H, 
exch., NH2), 6.71 (s, 2 H, exch., NH2), 6.82-6.88 (m, 1 H, Ar), 7.28-7.33 (m, 1 H, Ar).  
Anal. Calcd. for C13H9F3N4S2: C, 45.61; H, 2.65; N, 16.36; S, 18.73; F, 16.36. Found C, 
45.93; H, 2.66; N, 16.23; S, 18.59; F, 16.27. 
 
5-Methyl-6-((perfluorophenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine (207) 
Compound 295 (0.200 g, 1.11 mmol), 2,3,4,5,6-pentafluorobenzenethiol (0.444 g, 2.22 
mmol) and iodine (0.563 g, 2.22 mmol) were reacted as mentioned above using the general 
method to afford 207 as light pink colored solid (0.152 g, 36%). TLC Rf = 0.7 
(MeOH:CHCl3; 1:5); mp, 258.3-260.5 °C; 
1H NMR, DMSO-d6 (400 MHz): 2.62 (s, 3 H, 
5-CH3), 6.30 (s, 2 H, exch., NH2), 6.68 (s, 2 H, exch., NH2). Anal. Calcd. for C13H7F5N4S2: 
C, 41.27; H, 1.86; N, 14.80; S, 16.95; F, 25.11. Found C, 41.44; H, 1.95; N, 14.62; S, 16.80; 
F, 25.14. 
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5-Methyl-6-(naphthalen-1-ylthio)thieno[2,3-d]pyrimidine-2,4-diamine (208) 
Compound 295 (0.200 g, 1.11 mmol), naphthalene-1-thiol (0.354 g, 2.22 mmol) and iodine 
(0.563 g, 2.22 mmol) were reacted as mentioned above using the general method to afford 
208 as light brown colored solid (0.037 g, 10%). TLC Rf = 0.7 (MeOH:CHCl3; 1:5); mp, 
236-238.7 °C (lit.259 233.8-234.4 °C); 1H NMR, DMSO-d6 (400 MHz): 2.55 (s, 3 H, 5-
CH3), 6.29 (s, 2 H, exch., NH2), 6.70 (s, 2 H, exch., NH2), 7.05-7.07 (d, 1 H, J= 6.71, Ar), 
7.41-7.45 (t, 1 H, J = 7.31, Ar), 7.61-7.66 (m, 2 H, Ar), 7.79-7.81 (d, 1 H, J =7.80, Ar), 
7.98-8.00 (d, 1 H, J =8.07, Ar), 8.24-8.26 (d, 1 H, J =8.15, Ar). Anal. Calcd. for 
C17H14N4S2. 0.43CH3OH: C, 59.43; H, 4.50; N, 15.9; S, 18.20. Found C, 59.59; H, 4.29; 
N, 15.76; S, 18.04. 1H NMR agreed well with the literature259 reported values. 
 
5-Methyl-6-(naphthalen-2-ylthio)thieno[2,3-d]pyrimidine-2,4-diamine (209) 
Compound 295 (0.300 g, 1.67 mmol), naphthalene-2-thiol (0.534 g, 3.33 mmol) and iodine 
(0.845 g, 3.33 mmol) were reacted as mentioned above using the general method to afford 
209 as light brown colored solid (0.0.29 g, 7%). TLC Rf = 0.7 (MeOH:CHCl3; 1:5); mp, 
254.4-256.0 °C; 1H NMR, DMSO-d6 (400 MHz): 2.56 (s, 3 H, 5-CH3), 6.29 (s, 2 H, exch., 
NH2), 6.70 (s, 2 H, exch., NH2), 7.26-7.29 (dd, 1 H, J1 = 1.90, J2 = 8.68, 8´Ar), 7.46-7.50 
(m, 2 H, 6´Ar, 7´Ar), 7.62 (s, 1 H, 1´Ar), 7.81-7.83 (d, 1 H, J = 8.70, 3´Ar), 7.86-7.89 (d, 
2 H, J = 8.34, 4´Ar, 5´Ar). Anal. Calcd. for C17H14N4S2 . 0.15CH3OH: C, 60.00; H, 4.29; 
N, 16.31; S, 18.67. Found C, 60.31; H, 4.12; N, 15.93; S, 18.54. 
 
  
 190 
6-([1,1'-Biphenyl]-4-ylthio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (210) 
Compound 295 (0.200 g, 1.11 mmol), naphthalene-2-thiol (0.413 g, 2.22 mmol) and iodine 
(0.563 g, 2.22 mmol) were reacted as mentioned above using the general method to afford 
210 as buff colored solid (0.019 g, 5%). TLC Rf = 0.7 (MeOH:CHCl3; 1:5); mp, 261.3-
264.3 °C; 1H NMR, DMSO-d6 (400 MHz): 2.54 (s, 3 H, 5-CH3), 6.32 (s, 2 H, exch., NH2), 
6.72 (s, 2 H, exch., NH2), 7.18-7.20 (d, 2 H, J = 8.52, Ar), 7.34-7.38 (t, 1 H, J = 7.31, Ar), 
7.43-7.47 (t, 2 H, J = 7.91, Ar), 7.61-7.63 (d, 4 H, J = 8.49, Ar). Anal. Calcd. for 
C19H16N4S2. 0.34CH3OH: C, 61.88; H, 4.66; N, 14.93; S, 17.09. Found C, 62.08; H, 4.33; 
N, 14.77; Cl, 16.78. 
 
General procedure for the synthesis of benzenethiols 299a-c from anilines 297a-c 
Aniline (1 equivalent), MeOH and 10% HCl were added to a round-bottomed flask at 0 °C. 
A solution of sodium nitrite (1.3 equivalent) in water was added dropwise to the aniline 
solution over a period of 15 min at 0 °C to generate diazonium salt. The above mixture was 
added to another 100 mL round-bottomed flask containing a solution of potassium ethyl 
acetate (2 equivalents) in water at 65 °C. The reaction was stirred at 65 °C for 15 min after 
which the reaction was cooled down to room temperature. Solvent was evaporated in vacuo 
and the compound was extracted with ethyl acetate (3 times), washed with brine and dried 
over Na2SO4. The combined fractions were pooled, silica gel was added solvent was 
removed to afford a dry plug. Crude compound was purified using flash chromatography 
in hexanes/ ethyl acetate to afford S-(substitutedphenyl) O-ethyl carbonothioate 298a-c. 
Hydrolysis of compounds 298a-c in KOH/NaOH was carried out at 65 °C for 2 h. The 
crude mixture was extracted with ethyl acetate, washed with brine, dried over Na2SO4 and 
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the solvent was evaporated in vacuo to yield 299a-c which were used further without 
purification. 
 
2,4-Dimethoxybenzenethiol (299a) 
2,4-dimethoxyaniline 297a (0.500 g, 3.264 mmol) was dissolved in MeOH (10 mL) to 
which 10% HCl (5 mL) was added and stirred at 0 °C as specified in the general procedure 
above. Sodium nitrite (0.293 g, 4.243 mmol) was dissolved in water (10 mL) and added to 
the aniline solution dropwise. Potassium ethyl xanthate (1.046 g, 6.528 mmol) was used to 
give the 298a (0.224 g, 26%) as pale white colored semisolid. TLC Rf = 0.7 (Hex:EtOAc; 
1:1); 1H NMR, DMSO-d6 (400 MHz): 1.21-1.24 (t, 3 H, CH3), 3.80 (s, 3 H, OCH3), 3.83 
(s, 3 H, OCH3), 4.52-4.58 (q, 2 H, CH2), 6.60-6.62 (dd, 1 H, J1 = 2.51, J2 = 8.53, 5-Ar), 
6.68-6.69 (d, 1 H, J = 2.48, 3-Ar), 7.34-7.36 (d, 1 H, J = 8.50, 6-Ar). Compound 298a 
(0.220 g, 0.908 mmol) was dissolved in EtOH (10 mL) to which 1N NaOH (3 mL) was 
added and heated at 65 °C for 2 h. Following the general procedure mentioned above, 299a 
(0.145 g, 94%) was obtained as a pale yellow liquid which was used further without 
purification. TLC Rf = 0.87 (Hex:EtOAc; 1:1); 
1H NMR, DMSO-d6 (400 MHz): 3.73 (s, 3 
H, OCH3), 3.80 (s, 3 H, OCH3), 4.51 (s, 1 H, exch., SH), 6.46-6.49 (dd, 1 H, J1 = 2.54, J2 
= 8.48, 5-Ar), 6.57-6.58 (d, 1 H, J = 2.52, 3-Ar), 7.19-7.21 (d, 1 H, J = 8.46, 6-Ar). The 
compound was carried without additional characterization. 
 
2,6-Dimethoxybenzenethiol (299b) 
2,6-dimethoxyaniline 297b (2.0 g, 13.056 mmol) was dissolved in MeOH (30 mL) to which 
10% HCl (5 mL) was added and stirred at 0 °C as specified in the general procedure above. 
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Sodium nitrite (1.15 g, 16.972 mmol) was dissolved in water (15 mL) and added to the 
aniline solution dropwise. Potassium ethyl xanthate (4.186 g, 26.112 mmols) was used to 
give the 298b (2.068 g, 47%) as pale yellow colored semisolid. TLC Rf = 0.77 
(Hex:EtOAc; 1:1);  1H NMR, DMSO-d6 (400 MHz): 1.18-1.21 (t, 3 H, CH3), 3.80 (s, 6 H, 
OCH3), 4.50-4.56 (q, 2 H, CH2), 6.76-6.78 (d, 2 H, J = 8.38, Ar), 7.46-7.50 (t, 1 H, J = 
8.41, Ar). Compound 298b (0.500 g, 2.06 mmol) was dissolved in EtOH (10 mL) to which 
1N NaOH (3 mL) was added and heated at 65 °C for 2 h. Following the general procedure 
mentioned above, 299b (0.339 g, 96%) was obtained as a pale yellow colored solid which 
was used further without purification. TLC Rf = 0.85 (Hex:EtOAc; 1:1); 
1H NMR, DMSO-
d6 (400 MHz): 3.83 (s, 6 H, OCH3), 4.28 (s, 1 H, exch., SH), 6.68-6.70 (d, 2 H, J = 8.33, 
Ar), 7.08-7.12 (t, 1 H, J1 = J2 = 8.32, Ar). The compound was carried without additional 
characterization. 
 
[1,1'-Biphenyl]-4-thiol (299c) 
[1,1'-biphenyl]-4-amine 297c (1.0 g, 5.91 mmol) was dissolved in MeOH (35 mL) to which 
10% HCl (10 mL) was added and stirred at 0 °C as specified in the general procedure 
above. Sodium nitrite (0.530 g, 7.68 mmol) was dissolved in water (20 mL) and added to 
the aniline solution dropwise. Potassium ethyl xanthate (1.89 g, 11.82 mmols) was used to 
give the 298c which was dissolved in EtOH (20 mL) and hydrolyzed using 1N NaOH (5 
mL) at 65 °C for 2 h. Following the general procedure mentioned above, 299c (0.707 g, 
64% over 2 steps) was obtained as a pale yellow liquid. TLC Rf = 0.9 (Hex:EtOAc; 1:1); 
1H NMR, DMSO-d6 (400 MHz): 5.35 (s, 1 H, exch., SH), 7.36-7.41 (m, 1 H, Ar), 7.45-
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7.50 (m, 2 H, Ar), 7.64-7.69 (m, 4 H, Ar), 7.71-7.74 (m, 2 H, Ar). The compound was 
carried directly without additional characterization. 
 
3-Amino-4-ethylthiophene-2-carbonitrile 301 and 3-amino-4,5-dimethylthiophene-2-
carbonitrile 301a 
To a 100 ml round-bottomed flask were added 2-butanone 300 (0.100 g, 1.39 mmol), sulfur 
(0.067 g, 2.085 mmol), malononitrile (0.101 g, 1.53 mmol) and 15 mL of DMF.  The 
reaction was put to stirring at 60 °C. L-proline (0.016 g, 0.139 mmol) was added after 15 
min. After 5 h, the reaction was run at room temperature for approx. 12 h. At end of the 
reaction, solvent was evaporated in vacuo and ethyl acetate (30 mL) was added. The 
reaction mixture was filtered to remove excess sulfur and the filtrate was extracted with 
water. The combined fractions were pooled, silica gel was added and the solvent was 
evaporated to afford a dry plug. The crude mixture was purified using hexanes/ethyl 
acetate. The purified fraction (TLC Rf = 0.77 (Hex:EtOAc; 1:1)) showed presence of two 
compounds 301 and 301a in 1:5.6 ratio.  1H NMR of 301, DMSO-d6 (400 MHz): 1.12-1.16 
(t, 3 H, CH3), 2.38-2.44 (q, 2 H, CH2), 6.02 (s, 1 H, Ar), 7.06 (s, 2 H, exch., NH2). 
1H NMR 
of 301a, DMSO-d6 (400 MHz): 1.94 (s, 3 H, CH3). 2.10 (s, 3 H, CH3), 6.89 (s, 2 H, exch., 
NH2). The compound was carried without additional characterization. 
 
2-Amino-4-isopropylthiophene-3-carbonitrile (303) 
To a 500 ml round-bottomed flask were added 3-methylbutan-2-one 302 (5.0 g, 58.05 
mmol), sulfur (1.86 g, 58.05 mmol), malononitrile (3.83 g, 58.05 mmol) and 50 mL of 
DMF. The reaction was put to stirring at 60 °C. L-lysine (0.848 g, 5.80 mmol) was added 
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after 15 min. After 5 h, the reaction was run at room temperature for approx. 12 h. At end 
of the reaction, solvent was evaporated in vacuo and ethyl acetate (30 mL) was added. The 
reaction mixture was filtered to remove excess sulfur and the filtrate was extracted with 
water. The combined fractions were pooled, silica gel was added and the solvent was 
evaporated to afford a dry plug. The crude mixture was purified using hexanes/ethyl acetate 
to yield pure 303 as brown solid (5.04 g, 52%). TLC Rf = 0.78 (Hex:EtOAc; 1:1); mp, 
67.1-68.7 °C;  1H NMR, DMSO-d6 (400 MHz): 1.16-1.18 (d, 6 H, (CH3)2), 2.68-2.78 (m, 
1 H, CH), 6.00 (s, 1 H, Ar), 7.05 (s, 2 H, exch, NH2). The compound was carried directly 
without additional characterization. 
 
5-Isopropylthieno[2,3-d]pyrimidine-2,4-diamine (304) 
To a 100 ml round-bottomed flask were added 303 (1.12 g, 6.74 mmol), 294 (1.55 g, 13.47 
mmol) and DMSO2 (4 g) were added. The reaction was run at 120 °C for 1 h. The reaction 
mixture was cooled down to room temperature. 20 mL of methanol was added to the round-
bottomed flask and the solution was brought to neutral pH using ammonium hydroxide 
solution. Silica gel was added to the above mixture, solvent was evaporated to afford a dry 
plug. Flash chromatography on the crude mixture was carried out using 
chloroform/methanol to yield pure 304 as buff colored solid (1.20 g, 85%). TLC Rf = 0.6 
(MeOH:CHCl3; 1:5); mp, 221.8-224.6 °C; 
1H NMR, DMSO-d6 (400 MHz): 1.20-1.22 (d, 
6 H, (CH3)2), 3.27-3.31 (m, 1 H, CH), 6.06 (s, 2 H, exch., NH2), 6.50 (s, 2 H, exch., NH2)  
6.59 (s, 1 H, Ar). Anal. Calcd. for C9H12N4S: C, 51.90; H, 5.81; N, 26.90; S, 15.39. Found 
C, 51.93; H, 5.66; N, 27.05; S, 15.18. 
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6-Iodo-5-isopropylthieno[2,3-d]pyrimidine-2,4-diamine (305) 
To a 100 mL round-bottomed flask were added 304 (0.500 g, 2.40 mmol), N-
iodosuccinimide (0.594 g, 2.64 mmol) and acetic acid (10 mL). The reaction mixture was 
heated at 50 °C for 2 h and then cooled to room temperature. Water (20 mL) was added 
and the mixture was stirred at room temperature for 15 min after which the compound was 
filtered, washed with water and dried over P2O5 to yield 305 (0.600 g, 75%) as pale yellow 
colored solid. TLC Rf = 0.62 (MeOH:CHCl3; 1:5); 
1H NMR, DMSO-d6 (500 MHz): 1.36-
1.37 (d, 6 H, (CH3)2), 3.47-3.53 (m, 1 H, CH), 6.13 (s, 2 H, exch., NH2), 6.41 (s, 2 H, exch., 
NH2). The compound was used directly without further characterization. 
 
5-Isopropyl-6-(naphthalen-2-ylthio)thieno[2,3-d]pyrimidine-2,4-diamine (212) 
To a 2-5 mL Biotage vial were added 305 (0.300 g, 0.898 mmol), Cs2CO3 (0.877 g, 2.69 
mmol), naphthalene-2-thiol 306 (0.575 g, 3.59 mmol), CuI (2.22 g, 1.17 mmol) and DMF 
(3 mL). The vial was sealed, the mixture was evacuated and back filled with argon (three 
cycles). The reaction mixture was irradiated in microwave at 150 °C for 90 min. After the 
reaction was cooled to room temperature, the solvent was evaporated and extracted with 
ethyl acetate. The fractions were pooled, dried over Na2SO4 and silica gel was added to 
afford a dry plug. Crude compound was purified using flash chromatography in 
chloroform/methanol to afford 212 (0.082 g, 25%) as pale brown colored solid. TLC Rf = 
0.67 (MeOH:CHCl3; 1:5); mp, 211.8-214.5 °C; 
1H NMR, DMSO-d6 (400 MHz): 1.36-1.38 
(d, 6 H, (CH3)2), 3.67-3.76 (m, 1 H, CH), 6.27 (s, 2 H, exch., NH2), 6.60 (s, 2 H, exch., 
NH2), 7.29-7.32 (dd, 1 H, J1 = 1.92, J2 = 8.68, Ar), 7.44-7.51 (m, 2 H, Ar), 7.62-7.63 (d, 1 
H, J = 1.64, Ar), 7.81-7.83 (dd, 1 H, J1 = 2.21, J2 = 7.03, Ar), 7.86-7.90 (m, 2 H, Ar). Anal. 
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Calcd. for C19H18N4S2 . 0.35HCON(CH3)2: C, 61.42; H, 5.25; N, 15.53; S, 16.36. Found 
C, 61.19; H, 5.11; N, 15.33; S, 16.44. 
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VI. SUMMARY 
This dissertation describes the design and synthesis of heterocycles (pyrimidines, 
quinazolines, quinoline-2,5-diamines and thieno[2,3-d]pyrimidines) as agents with cancer 
chemotherapeutic and anti-infective potential. For these projects a total of 44 novel 
compounds were synthesized and characterized, of which 37 were submitted for evaluation 
in in vitro biological assays. In addition, 7 compounds were resynthesized in the 
quinazolines series for additional evaluation of these previously published compounds as 
RTK inhibitors. 6 compounds were resynthesized in the thieno[2,3-d]pyrimidine series for 
their evaluation as pjDHFR inhibitors. The novel target compounds synthesized as part of 
this dissertation are listed below: 
1. 5-Chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,6-diamine (154) 
2. N4-(4-Methoxyphenyl)-N4,2,5-trimethylpyrimidine-4,6-diamine (153) 
3. 5-Chloro-N4-(4-methoxyphenyl)-2-methylpyrimidine-4,6-diamine (155) 
4. 5-Chloro-N4,2-dimethyl-N4-(4-(methylthio)phenyl)pyrimidine-4,6-diamine (156) 
5. 5-Chloro-6-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-4-amine 
(158) 
6. N-(5-Chloro-6-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-4-
yl)pivalamide (171) 
7. 5-Chloro-N4-(2,3-dihydrobenzofuran-5-yl)-N4,2-dimethylpyrimidine-4,6-diamine 
(159) 
8. 5-Chloro-N4-(3-methoxyphenyl)-N4,2-dimethylpyrimidine-4,6-diamine (157) 
9. 5-Chloro-N4-(5-methoxynaphthalen-2-yl)-N4,2-dimethylpyrimidine-4,6-diamine (160) 
10. 5-Chloro-N4-(4-methoxyphenyl)-N4,N6,2-trimethylpyrimidine-4,6-diamine (161) 
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11. 5-Chloro-N4-ethyl-N6-(4-methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-diamine 
(162) 
12. 5-Chloro-N4-(4-methoxyphenyl)-N4,2-dimethyl-N6-propylpyrimidine-4,6-diamine 
(163) 
13. 5-Chloro-N4-isopropyl-N6-(4-methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-diamine 
(164) 
14. N4-Butyl-5-chloro-N6-(4-methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-diamine 
(165) 
15. 5-Chloro-N4-isobutyl-N6-(4-methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-diamine 
(166) 
16. N4-Benzyl-5-chloro-N6-(4-methoxyphenyl)-N6,2-dimethylpyrimidine-4,6-diamine 
(167) 
17. 5-Chloro-N4-ethyl-N6-(5-methoxynaphthalen-2-yl)-N6,2-dimethylpyrimidine-4,6-
diamine (168) 
18. 5-Chloro-N4-(5-methoxynaphthalen-2-yl)-N4,2-dimethyl-N6-propylpyrimidine-4,6-
diamine (169) 
19. N-(5-Chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-4-
yl)acetamide (170) 
20. N-(5-Methoxynaphthalen-2-yl)-N,2-dimethylquinazolin-4-amine (175) 
21. N-Methyl-N-(4-(methylthio)phenyl)quinazolin-4-amine (178) 
22. 2-Chloro-N-(5-methoxynaphthalen-2-yl)-N-methylquinazolin-4-amine (182) 
23. N-(4-methoxyphenyl)-N-methylpyrido[2,3-d]pyrimidin-4-amine (183) 
24. N-(5-Chloro-3-pentylquinolin-2-yl)pivalamide (284) 
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25. N5-(4-Methoxyphenyl)-N5-methyl-3-pentylquinoline-2,5-diamine (190) 
26. 3-Ethyl-N5-(4-methoxyphenyl)-N5-methylquinoline-2,5-diamine (187) 
27. N5-(4-Methoxyphenyl)-N5-methyl-3-propylquinoline-2,5-diamine (188) 
28. 3-Butyl-N5-(4-methoxyphenyl)-N5-methylquinoline-2,5-diamine (189) 
29. N5-(4-Methoxyphenyl)-3-methylquinoline-2,5-diamine (191) 
30. 6-((2-Methoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (193) 
31. 6-((3-Methoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (194) 
32. 6-((2,4-Dimethoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (197) 
33. 6-((2,6-Dimethoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (198) 
34. 5-Methyl-6-((4-(trifluoromethyl)phenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine 
(200) 
35. 5-Methyl-6-((3-(trifluoromethoxy)phenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine 
(201) 
36. 5-Methyl-6-((4-(trifluoromethoxy)phenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine 
(202) 
37. 6-((3,4-Difluorophenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (204) 
38. 5-Methyl-6-((3,4,5-trifluorophenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine (205) 
39. 5-Methyl-6-((2,3,4-trifluorophenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine (206) 
40. 5-Methyl-6-((perfluorophenyl)thio)thieno[2,3-d]pyrimidine-2,4-diamine (207) 
41. 5-Methyl-6-(naphthalen-2-ylthio)thieno[2,3-d]pyrimidine-2,4-diamine (209) 
42. 6-([1,1'-Biphenyl]-4-ylthio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (210) 
43. 5-Isopropylthieno[2,3-d]pyrimidine-2,4-diamine (304) 
44. 5-Isopropyl-6-(naphthalen-2-ylthio)thieno[2,3-d]pyrimidine-2,4-diamine (212) 
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Among these compounds 153-170 were evaluated as microtubule targeting agents 
binding at the colchicine site of tubulin. Compounds 175, 178, 182 and 183 were evaluated 
as single agents with combination chemotherapy potential and tested for antitubulin and 
RTK inhibitory assays in vitro. Compounds 193-210 and 212 were evaluated for selective 
inhibition of pjDHFR over hDHFR. During this study, palladium catalyzed cross coupling 
amination reactions on quinoline-2,5-diamines were also optimized and mechanistic details 
were explored. XPhos precatalyst (XPhos Pd G3) was effectively used for the synthesis of 
target compounds 186-191. 
In addition, molecular modeling studies were performed on analogs of pyrimido[4,5-
b]indoles, cyclopenta[d]pyrimidines, furo[2,3-d]pyrimidines and pyrrolo[3,2-
d]pyrimidines to rationalize the biological activities of these compounds. 
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VIII. APPENDIX 
Biological Evaluation 
 
The tumor inhibitory assays, microtubule depolymerization assays were performed 
by Dr. Susan L. Mooberry (Department of Pharmacology. University of Texas Health 
Science Center at San Antonio, San Antonio, TX 78229). The colchicine binding assays 
and bovine brain tubulin polymerization assays were performed by Dr. Ernest Hamel 
(Screening Technologies Branch, Developmental Therapeutics Program, Division of 
Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, 
National Cancer Institute, Frederick, MD 21702). RTK inhibitory assays, CAM assays 
were performed by Dr. Michael Ihnat (Department of Pharmaceutical Sciences, University 
of Oklahoma College of Pharmacy, Oklahoma City, OK 73117). DHFR inhibitory assays 
were performed by Dr. Vivian Cody (Hauptman-Woodward Medical Research Institute, 
Buffalo, NY 14203). 
 
1. Biological evaluation of pyrimidine analogs as microtubule targeting agents 
 
Compounds 153 and 154 were initially evaluated for their ability to depolymerize 
microtubules (Table 12). These compounds were also tested for their antiproliferative 
activity in MDA-MB-435 cells lines. Compound 154 with 5-Cl group was 3-fold more 
potent than the 5-Me analog 153, suggesting that the EWG at 5-position was conducive 
towards improving potency. Compounds 155 and 157 with p-anisidine and 3-methoxy-
N-methyl aniline substitutions at N4-position led to complete loss of depolymerizing 
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activity, suggesting that the confoamtional restriction afforded by the N4-Me group in 
154 and the position of HBA at 4´-position of the N4-phenyl group was essential for 
activity. 
 
Table 12. Biological data for monocyclic pyrimidine analogs 153-171 
Compd IC50 ± SD in MDA-
435 Cells 
EC50 for 
Microtubule 
Depolymerization 
Inhibition of colchicine 
binding % Inhibition ± SD 
5 µM inhibitor 
153 206.4 ± 8.9 nM > 8000 nM 45 ± 0.3 
154 71.3 ± 6.1 nM 1.5 µM 76 ± 2 
155 ND - - 
156 140 ± 12 nM 3.3 µM 71 ± 4 
157 ND - - 
158 220 ± 25 nM 1.4 µM 61 ± 5 
159 620 ± 89 nM 9.2 µM 60 ± 3 
160 56.1 ± 5.0 nM 831nM 74 ± 4 
161 103.3 ± 11.8 nM 2.1 µM 68 ± 4 
162 50.4 ± 8.0 nM 305 nM 74 ± 3 
163 24.4 ± 1.4 nM 123 nM 82 ± 0.1 
164 684.8 ± 53.7 nM 7.4 µM - 
165 84.4 ± 8.0 nM 432 nM 84 ± 2 
166 78.1 ± 2.8 nM 394 nM 57 ± 0.1 
167 ND > 10,000 nM 14 ± 0.02 
170 3,770 ± 350 nM >15 µM - 
171 2.08 ± 0.46 μM > 10 μM - 
CA4 4.4 ± 0.46 nM 9.8 nM 97 ± 0.8 
Paclitaxel 4.5 ± 0.52 nM - - 
ND-Not Determined 
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Compounds 156 and 158 with the N-methyl-4-(methylthio)aniline and 6-methoxy-
1,2,3,4-tetrahydroquinoline substitutions at 4-position were 2-fold and 3-fold less 
potent than 154 in the antiproliferative activity, respectively. The N6-alkylated analogs 
161-166 led to an improvement in both depolymerizing and antiproliferative activities 
(except 161 and 164), suggesting that these alkyl groups are able to occupy the binding 
site by undergoing hydrophobic interactions with residues in the binding pocket more 
completely than 154. Compounds 163 and 165 were able to displace [3H] colchicine 
similar to that seen for CA4. Benzyl substitution at N6-position in 167 was not tolerated 
and led to loss of activity. Compounds 170 and 171 with N6-acetyl and N6-pivaloyl 
substitutions also led to a loss in activity suggesting that EWG in these compounds is 
not tolerated. 
 
2. Biological evaluation of quinazolines (172-183) as MTAs and RTK inhibitors 
 
In the antiproliferative assays and the microtubule depolymerization assays compounds 
172-180 displayed potent inhibitory activities (Table 13). The 2-H substituted compounds 
(176-178) were 7- to 10-fold less potent than the 2-Me (172-175) and 2-Cl (179-180) 
substituted compounds, suggesting bulk is important for antitubulin activity at the 2-
position of the quinazoline scaffold. The pyrido[2,3-d]pyrimidine analog 183 lost activity 
in the antiproliferative assay suggesting that replacement of fused benzene ring with 
electron withdrawing pyridine ring is not conducive for activity. In the RTK inhibitory 
assays, the 2-Me and 2-Cl substituted compounds were more potent than 2-H substituted 
compounds. For 2-substituted quinazolines (172-175), varying the anilne substitution at 4-
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position was well tolerated. The 2-Cl substituted compound 179 was a potent inhibitor of 
EGFR but resulted in loss of 10-fold and 15-fold activity in VEGFR-2 and PDGFR-β, when 
compared to corresponding 2-Me compound 172. As seen with tubulin activity, compound 
183 was inactive in RTK inhibitory assays. 
 
Table 13. Biological activities of quinazolines 172-183  
Compd IC50 ± SD 
in MDA-
MB-435 
Cells (nM) 
EC50 
microtubule 
depolymerizati
-on (nM) 
EGFR 
kinase 
inhibition 
(nM) 
 VEGFR-2 
 kinase 
inhibition 
(nM) 
PDGFR 
kinase 
inhibition 
(nM) 
CAM 
inhibition 
(µM) 
172 1.7 ± 0.1  2.1 2.8 ± 1.1 8.4 ± 2.2 5.6 ± 0.4 2.8 ± 1.1 
173 1.1 ± 0.2  3 5.0 ± 0.4 9.3 ± 3.9 7.8 ± 0.5 3.1 ± 1.3 
174 1.2 ± 0.2  2 8.7 ± 1.6 14.7 ± 2.8 231.5± 29.9 9.8 ± 0.7 
175 2.0 ± 0.4 2.5 10.6 ± 1.8 16.8 ± 4.1 29.4 ± 5.1 ND 
176 7.1 ± 0.8  8.15 - - - - 
177 12.4 ± 1.7  23.9 48.9 ± 6.0 111.1 ± 19.2 54 ± 14.1 ND 
178 7.8 ± 0.8  12.3 - - - - 
179 0.6 ± 0.1  2 3.6 ± 0.6 97.5 ± 10.1 76.6 ± 16.2 130.0± 22.2 
180 0.7 ± 0.2 2 5.4 ± 0.3 55.2 ± 11.1 80.6 ± 12.1 41.4 ± 6.1 
183 324.0± 47.4  2.7 µM 1.8 ± 0.5 µM 3.3 ± 1.0 µM 6 ± 3 µM 1.1±0.3 µM 
CA4 4.4 ± 0.46 9.8 - - - - 
Sunitinib - - 172.1 ± 19.4 18.9 ± 2.7 83.1 ± 10.1 1.3 ± 0.07 
Erlotinib - - 1.2 ± 0.2 124.7 ± 18.2 12.2 ± 1.9 29.1 ± 1.9 
ND-Not Determined  
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3. Biological evaluation of thieno[2,3-d]pyrimidines as selective pjDHFR inhibitors 
 
Table 14. Biological activities of 192-209 
Compd pjDHFR IC50 
(µM) 
hDHFR IC50 
(µM) 
h/pj 
192 0.399 0.755 1.89 
193 0.7 1.5 2.14 
194 2.3 4.7 2.04 
195 0.069 1.035 15.00 
196 0.124 1.233 9.94 
197 2.95 2.1 0.71 
198 0.21 0.059 0.28 
199 0.133 0.982 7.38 
200 0.8 1.5 1.9 
201 0.528 5.05 9.6 
202 0.55 19.7 35.8 
203 0.148 1.054 7.12 
204 0.064 1.5 23.4 
205 0.32 0.52 1.6 
206 0.12 0.93 7.8 
207 1.199 28.95 24.1 
208 1.055 0.394 0.4 
209 0.599 32.9 54.9 
         
Thieno[2,3-d]pyrimidines 192-209 were evaluated for their inhibitory activities in 
pjDHFR and hDHFR. Compound 192 with phenyl and compounds 193 and 194 with 2´-
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OMe phenyl and 3´-OMe phenyl substitutions at 6-positionrespectively, had similar 
inhibitory activities in hDHFR and pjDHFR. The 4´-OMe substituted compound 195 was 
however, 15-fold selective for inhibition of pjDHFR with an IC50 value of 69 nM 
suggesting that bulk at 4´-position is not conducive for binding in hDHFR. The 
disubstituted compounds 196-199 and the 4´-CF3 substituted compound 200 inhibited 
pjDHFR with low potencies and displayed low selectivity for inhibition. Moving the 
trifluoromethoxy substitution from 3´-position in 201 to 4´-position in 202 led to 3 fold 
improvement in selectivity ratio. While the inhibition of pjDHFR was similar for 201 and 
202, the change led to 4-fold loss of activity in hDHFR. Similarly for compounds 204 
(3´,4´-diF) and 207 (2´,3´,4´,5´,6´-pentaF), substitution at 4´-position led to improvement 
in selectivity ratios, with improved binding of 204 at pjDHFR (64 nM). The 2-naphthyl 
substituted compound 209 was the most selective compound in the series (55-fold), 
suggesting bulk in the side chain of the thieno[2,3-d]pyrimidine scaffold is not conducive 
for binding in hDHFR. Compared to unsubstituted compound 192, the 2-naphthyl 
substitution in 209 causes a 1.5-fold loss in potency in pjDHFR but results in 44-fold loss 
in activity in hDHFR. 
 
Methods 
 
Effects of compounds on cellular microtubules: The effect of the compounds on 
interphase and mitotic microtubules were evaluated in A-10 cells using indirect 
immunofluorescence techniques, and the EC50 ((concentration required to cause 50% loss 
of cellular microtubules)) values were calculated from a minimum of three experiments. 
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Sulforhodamine B (SRB) assay: The cytotoxic and antiproliferative effects of the 
compounds against cancer cells was evaluated using SRB assay. MDA-MB-435 cells were 
used for determining IC50 values (concentration required to cause 50% inhibition of 
proliferation). 
 
 [3H] Colchicine displacement assay: The binding of [3H]colchicine to tubulin was 
performed by the DEAE-cellulose filter technique  with a stack of two filters, as described 
in detail previously. In brief, reaction mixtures contained, in a 0.10 mL volume, 1.0 µM 
purified tubulin, 5.0 µM [3H]colchicine, potential inhibitor at 5.0 µM, 5% (v/v) dimethyl 
sulfoxide (the compound solvent), and other components previously found to stabilize the 
colchicine binding activity of tubulin for prolonged periods at 37°C. Incubation was at 
37°C for 10 min, at which time samples were diluted with 2 mL of ice-cold water and 
poured over the DEAE-filters under mild suction, with several rinses of the reaction vessel 
and of the filtration chamber. The amount of radiolabel bound to the filters was determined 
by liquid scintillation counting, and samples containing test compounds were compared to 
reaction mixtures without compound. The percent inhibition relative to the control was 
determined for each compound in 2-4 independent experiments. 
 
Phosphotyrosine ELISA: Cells used were tumor cell lines naturally expressing high 
levels of VEGFR-2 (U251). Expression levels at the RNA level were derived from the NCI 
Developmental Therapeutics Program (NCI-DTP) web site public molecular target 
information. Briefly, cells at 60–75% confluence are placed in serum-free medium for 18 h 
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to reduce the background phosphorylation. Cells were always >98% viable by trypan blue 
exclusion. Cells were then pretreated for 60 min with a dose-response relation of 100-1.4 
µM compound followed in ⅓ Log increments by 100 ng/mL VEGF for 10 min. The 
reaction was stopped and cells permeabilized by quickly removing the media from the cells 
and adding ice-cold Tris-buffered saline (TBS) containing 0.05% Triton X-100, protease 
inhibitor cocktail and tyrosine phosphatase inhibitor cocktail. tion was then removed and 
cells fixed to the plate for 30 min at 60 C with a further incubation in 70% ethanol for 30 
min. Cells were exposed to a blocking solution (TBS with 1% BSA) for 1 h, washed, and 
then a horseradish peroxidase (HRP)-conjugated phosphotyrosine (PY) antibody was 
added overnight. The antibody was removed, and the cells were washed again in TBS, 
exposed to an enhanced luminol ELISA substrate (Pierce Chemical EMD, Rockford, IL), 
and light emission was measured using a UV Products (Upland, CA) BioChemi digital 
darkroom. Data were graphed as a percent of cells receiving growth factor alone and IC50 
values were determined from two to three separate experiments (n = 8–24) using non-linear 
regression dose–response analysis with Prism 5.0 software (GraphPad, San Diego, CA). In 
each case, the activity of a positive control inhibitor did not deviate more than 10% from 
the IC50 values listed in the text. 
 
Chorioallantoic membrane assay of angiogenesis: The CAM assay is a standard assay 
for testing antiangiogenic agents. Briefly, fertile leghorn chicken eggs (CBT Farms, 
Chestertown, MD) were incubated for 10 days. The proangiogenic factors human VEGF-
165 and bFGF (100 ng each) were then added at saturation to a 6 mm microbial testing 
disk (BBL, Cockeysville, MD) and placed onto the CAM by breaking a small hole in the 
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superior surface of the egg. Antiangiogenic compounds were added 8 h after the 
VEGF/bFGF at saturation to the same microbial testing disk and embryos allowed to 
incubate for an additional 40 h. After 48 h, the CAMs were perfused with 2% 
paraformaldehyde/3% glutaraldehyde containing 0.025% Triton X-100 for 20 s, excised 
around the area of treatment, fixed again in 2% paraformaldehyde/3% glutaraldehyde for 
30 min, placed on Petri dishes, and a digitized image taken using a dissecting microscope 
(Wild M400; Bannockburn, IL) at 7.5X and a SPOT enhanced digital imaging system 
(Diagnostic Instruments, Sterling Heights, MI). A grid was then added to the digital CAM 
images and the average number of vessels within 5–7 grids counted as a measure of 
vascularity. Sunitinib and semaxanib were used as a positive control for antiangiogenic 
activity. Data were graphed as a percent of CAMs receiving bFGF/VEGF only and IC50 
values calculated from two to three separate experiments (n = 5–11) using non-linear 
regression dose-response relation analysis. 
 
DHFR inhibitory assays: For analysis of inhibitor susceptibility, DHFR was assayed 
using a continuous spectrophotometric assay. The assay contains a final concentration of 9 
µM dihydrofolic acid, 117 µM NADPH, and 6–8 IU of enzyme activity (1 IU D0.005 
optical density units/min). The reaction is incubated at 37 °C and change in absorbance at 
340 nM, which is related to oxidation of NADPH, is measured over 3 min. The assay under 
standard conditions is linear over this time span and linear with protein concentration. KCl 
150 mM is included in assays of mammalian DHFR. The standard error of the means for 
these values are 12% or less than the mean value. 
